The longitudinal assessment of clinical features and brain volume in human prion disease. by Macfarlane, R.G.
The longitudinal assessment of 
clinical features and 
brain volume in 
human prion disease
Thesis submitted for the degree of 
Doctor of Philosophy
Rebecca Gillian Macfarlane
University College London 
MRC Prion Unit 
Institute of Neurology 
2007
UMI Number: U591684
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Disscrrlation Publishing
UMI U591684
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
DECLARATION STATEMENT
I Rebecca Macfarlane, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has 
been indicated in the thesis.
Rebecca Macfarlane
ABSTRACT
Crcutzfcldt-Jakob disease (CJD) is a human prion disease found in four forms: sporadic, 
familial, iatrogenic and variant. Clinical and radiological presenting features o f the 
various forms o f prion disease are well documented, but the natural history is less well 
described. Knowledge o f the imaging appearances in human prion diseases is increasing 
and quantitative magnetic resonance imaging (MRI) techniques have been developed to 
analyse progression o f cerebral atrophy.
As part o f a clinical trial, patients with different types o f CJD were assessed regularly 
using a standardised videoed clinical examination (including cognitive and motor tests) 
and MRI including a volumetric sequence. Each clinical video was scored by an 
independent neurologist blinded to the patients’ diagnosis, date o f examination and arm 
o f trial. The corresponding volumetric MRI was also analysed blindly to measure brain 
volume, the brain boundary shift integral (a more accurate means o f assessing volume 
change between scans) and a visual representation o f the sites o f atrophy.
Rates o f brain atrophy were correlated with baseline clinical scores and clinical decline 
in scores. Regional analysis o f cerebellar volume was performed and the changes in the 
different types o f human prion disease were compared.
Greater understanding o f disease course and rates o f brain atrophy will aid clinicians in 
diagnosis and prognosis and provide the basis for surrogate markers o f disease 
progression. Use o f the most appropriate markers will optimise measurement o f 
therapeutic outcomes in clinical trials in human prion disease.
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ADL Activities of Daily Living
ADAS-COG Alzheimer’s Disease Assessment Scale -  Cognitive
ANA Anti-nuclear antibodies
BEHAVE-AD Behavioural Pathology in AD scale
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DTI Diffusion Tensor Imaging
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HSV Herpes Simplex Virus
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LCFS Level of Cognitive Functioning Scale
LMM Linear mixed model
MIMSE Mini Mental State Examination
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IMRI Magnetic Resonance Imaging
MRS Magnetic Resonance Spectra
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OPRI Octapeptide Repeat Insertion
PET Positron Emission Tomography
PRNP Prion protein gene
P rp s c Abnormal Prion Protein
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SAP Severely affected protocol of PRION-1 video
SCAG Sandoz Clinical Assessment Geriatric
sCJD Sporadic Creutzfeldt-Jakob disease
SCP Superior Cerebellar Peduncle
SD Standard deviation from the mean
SE Standard error
SIB Severe Impairment Battery
SKT Syndrom Kurztest
SPECT Single Photon Emission Computerised Tomography
T1/T2WI T1 or T2 weighted MRI sequence
TEC Total Functional Capacity score
TIV Total intracranial volume
vCJD Variant Creutzfeldt-Jakob disease
VBM Voxel Based Morphometry
VDRL Venereal Disease Research Laboratory test (syphilis)
WB Whole brain
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THE LONGITUDINAL ASSESSMENT OF CLINICAL FEATURES AND 
BRAIN VOLUME IN HUMAN PRION DISEASE
Overview
Crcutzfcldt-Jakob disease (CJD) is a human prion disease found in four forms: sporadic, 
familial, iatrogenic and variant. Clinical and radiological presenting features o f the 
various forms o f prion disease are well documented, but the natural history is less well 
described. Knowledge o f the imaging appearances in human prion diseases is increasing 
and quantitative MRI techniques have been developed to analyse progression o f 
cerebral atrophy.
As part o f a clinical trial, patients with different types o f CJD were assessed regularly 
using a standardised videoed clinical examination (including cognitive and motor tests) 
and magnetic resonance imaging (MRI) including a volumetric sequence.
Each clinical video was scored by an independent neurologist blinded to the patients’ 
diagnosis, date o f examination and arm o f trial. The corresponding volumetric MRI was 
also analysed blindly to produce brain volume, the brain boundary shift integral (a more 
accurate means o f assessing volume change between scans) and a visual representation 
o f the sites o f atrophy. Serial brain volumes were correlated with clinical score.
Regional analysis o f cerebellar volume was performed and the changes in the different 
types o f human prion disease were compared. There are currently no reports of 
quantification o f atrophy or rate o f atrophy in human prion disease in the literature.
Greater understanding o f disease course and rates o f brain atrophy will aid clinicians in 
diagnosis and prognosis and provide the basis for measurement o f therapeutic outcomes 
in clinical trials in human prion disease.
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Aim
The aim o f this thesis is to:
a) Determine the range and pattern o f eognitive and motor test performanee in patients 
with CJD and to deseribe how this ehanges with time.
b) Quantify rates o f whole brain and eerebellar atrophy in patients with CJD and a 
normal eontrol group.
e) Assess the assoeiations between rate o f brain atrophy and
(i) baseline elinieal seore and
(ii) rate o f elinieal deeline
in order to evaluate rate o f brain atrophy as a potential outeome measure in treatment 
trials in CJD.
Hypothesis
1) Whole brain atrophy rate is a biomarker o f disease severity in CJD.
2) Cerebellar atrophy is a biomarker o f eerebellar symptoms in CJD.
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HUMAN PRION DISEASE
/. /  Clinical Features o f  Creutzfeldt-Jakob disease 
Human prion diseases are uniformly fatal, transmissible, progressive neurodegenerative 
disorders; sporadie, inherited and acquired forms o f prion disease exist. All are 
associated with an abnormal form o f the human prion protein which differs not in amino 
acid sequence from the normal product o f the prion protein gene but in structural 
conformation and glyeosolation pattern o f the protein. The conformational and 
glyeosolation ehanges o f these proteins confer phenotypic variability.
The most common form o f human prion disease is sporadie CJD (sCJD) with an 
incidence worldwide o f 1-2 per million per annum. Inherited prion diseases are a group 
o f autosomal dominantly inherited conditions with high penetrance. Acquired human 
prion disease includes vCJD seen mainly in the UK associated with exposure to bovine 
spongiform encephalopathy (BSE) prions, iatrogenic CJD caused by infection from 
medical or surgical procedures and Kuru, seen only in Papua New Guinea and caused 
by exposure to human prions via endoeannibalism.
1.1.1 Sporadic CJD
sCJD has an incidence o f 1-2 per million in the worldwide population and its aetiology 
(unlike all other forms o f CJD) is unknown. The median age o f  onset is 65 years, the 
clinical course thereafter being rapid with a median duration o f survival o f four months 
(Will). The elinieal phenotype o f sCJD is typically one o f rapidly progressive dementia 
and multifocal neurological features including myoclonus, ataxia, pyramidal and 
extrapyramidal signs. Atypical eases are a particular feature o f this form o f CJD. The 
host codon 129 genotype and the molecular strain o f the transmissible prion agent affect 
the phenotype (Collinge). Progression o f the disease causes loss o f mobility and 
independence, leading to akinetic mutism and eventually death.
The World Health Organisation has published criteria for the classification o f sporadie 
CJD:
I Rapidly progressive dementia
II A Myoclonus
B Visual or Cerebellar problem
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C Pyramidal or cxtrapyramidal features
D Akinetie mutism
III A Typieal EEG 
B Positive 14-3-3
Possible CJD: 1 and 2 o f 11 and duration less than 2 years
Probable CJD: 1 and 2 o f  II and lllA  or possible CJD and lllB  
Definite CJD: Neuropathologieally eonfirmed diagnosis
The main differential diagnoses inelude paraneoplastie disease, Alzheimer’s disease, 
other forms o f CJD, dementia with Lewy bodies, eneephalitis and vaseular dementia. 
Patients with a rapidly progressive dementia and foeal neurologieal signs should have 
sCJD as their primary differential diagnosis. Presenee o f eerebellar, visual and 
pyramidal signs favours a diagnosis o f sCJD over other dementias and duration of 
symptoms is important (Van Everbroeek). Previous studies have shown that between 
25-40% o f ‘possible’ CJD patients eventually have ‘definite’ CJD (Brown, Poser, Will, 
Tsehampa).
Visual disturbanee, exemplified by the Heidenhain variant o f sCJD (Jaeobs) is more 
eommon than auditory disturbanee. Visual symptoms have been reported as presenting 
symptoms o f sCJD (Jacobs, Cambier), as has abnormality in eye movements (Zarei). An 
isolated field defect or visual loss in the absence o f other MRI, EEG (Electro­
encephalogram) or laboratory abnormalities may occur. In Will et al, o f 137 sCJD eases 
9% presented with visual disturbanee and 13% demonstrated cortical blindness during 
the illness. Cortical deafness has been reported as a presenting feature o f sCJD (Tobias). 
Hearing impairment is however unusual in sCJD; there were no reports o f auditory 
symptoms in the eases reported by Will.
Symptoms may be lateralised to left hemisphere (right sided posturing, sensory 
disturbanee and aphasia) or right hemisphere (left sided neglect and dressing apraxia) or 
occipital lobe (Cambier). These localising symptoms may be matched by EEG and MRI 
ehanges.
There are several distinct elinieal phenotypes o f sCJD probably determined by the 
eharaeteristies o f  the prion protein gene. The eodon 129 genotype (methionine
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homozygous MM, valine homozygous VV or heterozygous MV) and the molecular 
strain (biological properties o f the abnormal prion protein determined by prion protein 
conformation and glyeosolation termed type 1-4) may determine phenotype. Codon 129 
methionine and valine homozygosity have been reported as predisposing factors for 
sCJD (Tranchant, Windl, Laplanche).That different conformations o f the abnormal 
prion protein may determine the biological properties o f strains is supported by 
transmission studies o f different o f prion protein strains in transgenic mice expressing 
human prion protein (Collinge 1996).
Several human prion protein types have been identified that are associated with different 
phenotypes o f CJD (Collinge 1996, Parehi 1996). Collinge showed two strains in sCJD, 
with a predominance o f type 2, Parehi found type 1 only in MM patients, and type 2 in 
MM, MV and VV patients. Three distinct groups are described by Tranchant et al in 
their 14 patients with sCJD. The first group (10 patients) were MM and strain 1; initial 
signs were eognitive or visual, followed by dementia and myoclonus. The second group 
(three patients) were VV and strain 2; clinically they showed eerebellar ataxia and later 
dementia. The third group (one patient) was MV and type 1 ; eerebellar ataxia and 
dementia appeared simultaneously. These findings are similar to that o f Parehi (1996) 
who reported 19 sCJD eases, the 13 MM patients presented with early dementia, the 
three VV patients with ataxia and the MV patients with ataxia and dementia.
In Parehi's 1999 paper there was further delineation o f sCJD types. M M l (67%) 
presented with early eognitive disturbanee, ataxia, myoclonus and a typical EEG. VV2 
(16%) present with ataxia and only occasionally a typical EEG pattern. MV2 (9%) has a 
longer disease duration, extrapyramidal signs and only occasionally a typical EEG 
pattern. In Parehi's 2000 paper V V l was described as occurring in younger patients 
with a longer disease duration and late dementia.
Whether strain and genotype are independent or linked factors in determining clinical 
phenotype is yet to be firmly resolved.
1.1.2 Variant CJD
vCJD was described in 1996, (Will) when a new form o f CJD affecting young patients 
with a psychiatric presentation and a slower rate o f progression was described. It is 
causally linked to bovine spongiform encephalopathy (Collinge 2001). The
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transmissible prion agent has a eharaeteristie strain type on Western blotting termed 
type 4 (Collinge) (see Figure 1.1) which differs from the three types found in other 
types o f human prion disease.
A Brain PrP^ <= type ^  Figure L I Western Blot showing vCJD strain
kOa '  Z 3 4
By December 2006, 165 definite or probable vCJD
H A
30 — cascs had been reported in the UKW
(http://www.cjd.ed.ac.uk/figures.htm), as well as eases 
16— in France (Streiehenberger, Oppenheim), USA (see ref
classical CJD vCJD vCJD Probable variant Creutzfeldt-Jakob disease in a U.S.
resident), Ireland (Molloy), Italy (La) and Canada 
(Jansen) with countries being added to the list at regular intervals. Opinions differ on 
the future course o f the primary vCJD epidemic in the UK (Ghani, MeKintosh). Cases 
caused by exposure to BSE are still occurring currently. Transfusion related vCJD and 
iatrogenic exposure are now recognised risk factors in terms o f future cases and 
potential for transmission (Wroe).
Risk factors for the development o f vCJD inelude age and residence in the UK. By 
December 2006 all reported cases examined had demonstrated methionine 
homozygosity at eodon 129 of the prion protein gene and where molecular typing was 
carried out the same strain (type 4) was demonstrated in all patients.
Department o f Health Diagnostic Criteria for variant CJD are shown below:
DIAGNOSTIC CRITERIA FOR VARIANT CJD
I
A) PROGRESSIVE NEUROPSYCHIATRIC DISORDER
B) DURATION OF ILLNESS > 6 MONTHS
C) ROUTINE INVESTIGATIONS DO NOT SUGGEST AN ALTERNATIVE 
DIAGNOSIS
D) NO HISTORY OF POTENTIAL IATROGENIC EXPOSURE
II
A) EARLY PSYCHIATRIC SYMPTOMS *
B) PERSISTENT PAINFUL SENSORY SYMPTOMS **
C) ATAXIA
D) MYOCLONUS OR CHOREA OR DYSTONIA
E) DEMENTIA
III
A) EEG DOES NOT SHOW THE TYPICAL APPEARANCE OF SPORADIC
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CJD *** (OR NO HKG PKRFORMKD)
B) BILATFRAL PULVINAR HIGH SIGNAL ON MRI SCAN 
IV
A) POSITIVE TONSIL BIOPSY
DHFINITH: lA (PROGRESSIVE NEUROPSYCHIATRIC DISORDER) and 
NEUROPATHOLOGICAL CONFIRMATION OF vCJD ****
PROBABLE: I and 4/5 OF II and III A and III B or I and IV A
* depression, anxiety, apathy, withdrawal, delusions.
** this ineludes both frank pain and/ or unpleasant dysaesthesia
*** generalised triphasie periodie eomplexes at approximately one per seeond
♦ ♦♦♦spongiform ehange and extensive PrP deposition with florid plaques, 
throughout the eerebrum and eerebellum.
The presentation o f vCJD differs from sCJD. Patients tend to be younger (median age of 
onset 26 years) (Henry) and have a longer duration o f illness (median duration o f illness 
is 13 months, eompared to four months) (Speneer). There are early psyehiatrie and 
behavioural symptoms and in half eoneurrent sensory symptoms such as limb pain and 
dysaesthesia oeeur. Difficulty is encountered in initial diagnosis due to the early 
psyehiatrie and behavioural symptoms. In W ill’s description o f the psychiatric features 
o f 33 early vCJD patients (Will 2000), 17 were seen first by a psychiatrist and all but 
one demonstrated psyehiatrie symptoms in the early stages o f the disease. These 
included depression, anxiety, withdrawal, first rank symptoms, aggression and 
hallucinations.
As the disease progresses neurologieal features become more prominent (see Table L I), 
particularly eognitive impairment, sensory symptoms (limb pain, dysaesthesia, 
numbness or tingling) and ataxia. The clinician should be aware o f possible atypical 
presentations, including dystonia.
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Table 1.1 Presentation ofvCJD (adaptedfrom Spencer)
Psychiatric <4 months from 1** 4 - 6  months from 1*‘ >6 months from 1**
features symptom onset symptom onset symptom onset
Dysphoria
Withdrawal
Anxiety
Irritability
Insomnia
Loss o f interest
Poor memory Disorientation
Impaired eoneentration Agitation 
Aggression
Neurological <4 months from 1** 4 - 6  months from 1** >6 months from 1*^
features symptom onset symptom onset symptom onset
None Gait disturbance Hyperreflexia
Slurring o f speech Impaired coordination
Myoclonus 
Incontinence 
Eye features
Sensory symptoms are particularly associated with vCJD and are not commonly seen in 
other CJD types (Macleod). In the first 50 vCJD eases, 10 had had sensory symptoms 
from the outset; 32 had persistent sensory symptoms, nine had possible sensory 
symptoms at some time that did not persist and eight had no sensory symptoms at all. 
Symptoms included limb pain (63% o f patients and usually lower limbs), paraesthesia 
(31%), dysaesthesia (28%), numbness (25%) and cold feelings (25%) (Henry). 
Symptoms were lateralised in 10 (31%) o f patients. Sensory symptoms were treated 
variously with non-steroidal anti-inflammatory drugs, simple analgesics, 
carbamazepine, antidepressants and trans-epidermal neurological stimulation (TENS). 
Few were reported to be effective.
Movement disorders become apparent evolving into chorea, dystonia and myoclonus. 
As deterioration occurs, limb rigidity and primitive reflexes become evident, 
swallowing becomes difficult, the patient becomes fully dependent on carers for
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everyday tasks and is bed bound. The disease has a median duration o f 13 months 
(range 6-39 months) (Speneer).
There is no simple diagnostie blood test for vCJD eurrently. 14-3-3 analysis o f 
eerebrospinal fluid does not differentiate between sCJD and vCJD and the EEG does 
not show the eharaeteristie periodie sharp wave eomplexes o f sCJD. In the appropriate 
elinieal setting, the pulvinar sign on MRI (Zeidler 2000) is an extremely helpful 
radiological sign. Collie et al have reported a retrospective sensitivity o f 100% on 
FLAIR imaging and 90% in prospective study (Collie 2003). Uniquely, in vCJD, the 
prion protein is found in the lymphoretieular system, outside the central nervous system. 
In the clinical setting o f vCJD a tonsil biopsy may therefore be used to achieve a 
definitive diagnosis (eurrently 100% specific at the National Prion Clinic, unpublished 
data) thus avoiding a brain biopsy (Hill). Molecular typing o f the biopsy tissue reveals 
the same strain in all vCJD patients. Differential diagnoses inelude paraneoplastic 
syndrome, familial and early onset dementias and metabolic syndromes.
Initial treatment is tailored to the psychiatric presentation, with anti-depressants, anti­
psychoties and eleetroconvulsive therapy. Symptomatic treatments are used as disease 
progresses. Experimental therapies used by some patients inelude pentosan 
polysulphate, an anticoagulant administered intraventrieularly via a pump and 
quinacrine, an oral tablet.
1.1.3 latrosenic CJD 
Over 260 eases o f iatrogenic prion disease have been reported worldwide (Brown). 
Iatrogenic prion disease is caused largely by infection from cadaveric human growth 
hormone prior to 1985, dura mater grafts manufactured and distributed before the mid- 
1980s or corneal grafts. A new cohort o f patients iatrogenieally infected with vCJD via 
blood transfusion has been discussed previously, and represents a new medium of 
iatrogenic disease.
There is also potential for infection via contaminated neurosurgical instruments. The 
Department o f Health and Health Protection Agency recently reviewed the risks o f this 
occurrence (www.hpa.org.uk/infections/topics_az/cjd/information_documents.htm). The 
infection risk was modelled for those patients coming into contact with surgical 
instruments that were used on a patient with CJD. Risk was deemed highest if  the
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instruments had only been used and decontaminated a small number o f times since 
being used on a patient with CJD. Factors considered in whether to inform exposed 
patients o f the potential risk included the elinieal condition o f the patient with CJD, the 
infeetivity levels o f the tissues the instruments had been used on, the type o f instruments 
used, the decontamination processes in place and whether the instruments could be 
traced. The CJD Incidents panel advised contacting patients who have a risk o f at least 
1% o f being infected with CJD via this route, as determined by the risk model 
described. These patients are advised not to donate blood, organs or tissues, to inform 
practitioners if surgical, dental or endoscopic procedures are planned and to advise next 
o f kin in ease o f emergency medical treatment being required.
Clinical features in iatrogenic CJD depend on the route o f inoculation. In peripherally 
inoculated eases, eerebellar presentation rather than dementia predominates, and 
dementia is not invariably present. Apart from vCJD acquired from blood transfusion, 
cases are otherwise clinically similar to sCJD with ataxia, myoclonus, rigidity and 
akinetie mutism.
Incubation periods range from 18 months to up to 30 years, with a mean period o f three 
years for centrally acquired and 12 years for peripherally acquired disease (Summers 
DM, personal communication).
1.1.4 Inherited prion disease 
Inherited CJD occurs due to mutation o f the prion protein gene (PRNP), and accounts 
for 10-15% o f the incidence o f human prion disease (Masters, Windl). Three types o f 
pathogenic PRNP mutation occur: point mutations leading to either an amino acid 
substitution or a premature stop eodon or insertion o f additional octapeptide repeats (see 
Figure 1.2). WFIO diagnostie criteria exist as in sporadic and variant CJD (WHO 1993).
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Figure 1.2 Pathogenic Mutations and Polymorphic variants in the Prion Protein gene
The clinical phenotype has historically been subdivided into Gerstmann-Straussler- 
Scheinker syndrome (GSS), fatal familial insomnia (FFI) and familial CJD (fCJD). 
Principle clinical features in GSS include slowly progressive ataxia with later onset 
dementia; in FFI insomnia, autonomic dysfunction, motor signs and hallucinations are 
seen, and fCJD has a rapidly progressive dementia, myoclonus and psuedoperiodie 
discharges on EEG (Mead).
These descriptions preceded the advent o f molecular genetic diagnosis and now 
describe the extremes o f phenotype. As clinical experience in different mutations has 
grown, the heterogeneity of clinical phenotypes even between individuals with the same 
mutation has been striking, and in reality, disease types have significant clinical overlap.
There are several hurdles for clinicians in diagnosing inherited CJD. The clinical 
phenotype in inherited CJD often overlaps with the common causes of dementia, and 
other dementias such as Alzheimer’s disease are much more common. Bruton et al 
describe an autopsy study where 40% of neuropathologieally confirmed prion cases 
were undiagnosed while alive. However in younger patients, screening for a mutation in 
early onset dementia (such as in the study o f 36 patients by Finekh et al) found PRNP 
accounted for 4/12 eases.
The most common worldwide PRNP mutations are P102L (proline to leucine mutation 
at codon 102) E200K, D178N and OPRI (Mead). Several European studies have
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reviewed the population incidenee o f inherited CJD. Windl in Germany found 40/578 in 
suspected prion disease referrals to their surveillance unit, (13/40 D178N, 8/40 H200K, 
7/40 P102L, 5/40 OPRI). Laplanche in France found 8/57 (all K200K). Pocehiari in 
Italy found 6/38 D178N, 2/38 P102L and 30/38 with H200K or V210I. Kovanen in 
Finland found 12/44 with D178N. in the UK, the 6-OPRI mutation is the most 
frequently detected (Mead).
Inherited CJD is currently the most easily diagnosed o f all CJD types, as a blood test 
alone is the definitive test, rather than brain biopsy in sCJD or tonsil biopsy in vCJD. 
Most mutations co-segregate with methionine at codon 129. O f 455 cases identified by 
the EUROCJD collaborative surveillance project (including Australia, Austria, Canada, 
France, Germany, Italy, Holland, Slovakia, Spain, Switzerland and the UK), the 
majority of cases were either MM 67.9% (vs 39% in controls) or MV 25.8% (vs 50% in 
controls), with few valine homozygotes 6.3% (vs 11% in controls) (Kovacs 2005).
Mean age o f onset is however, lowest in VV, followed by MV, with MM patients 
having oldest onset (Kovacs 2005).
Kovacs reports an excess o f female to male mortality rates (similar to sCJD in 
Ladogana) in all mutaions except FFI, perhaps due to sex-linked genetic factors or 
differential susceptibility. In inherited CJD as a whole there is a strong negative 
correlation between age o f onset and duration o f disease (Mead), possibly due to 
inability o f the aging brain to degrade pathological prion protein.
The main differential diagnosis once prion disease is suspected in the older patient is 
sporadic CJD, highlighting the importance of genetic screening for mutations in these 
patients. Although the incidence o f sCJD is similar in most countries (Ladogana), 
incidence o f PRNP mutations shows large variability from the 15% seen worldwide. 
53.6% o f all CJD cases in Slovakia (Mitrova and Belay 2002), 25.5% in Israel (Kahana 
et al 1974), 26% of cases in Chile (Galvez 1980) and 1.2% o f cases in Switzerland 
(Kovacs) have inherited prion disease. Interestingly 47% o f inherited CJD patients have 
no reported family history (Kovacs), making differentiation from sCJD difficult. Factors 
such as non-paternity, lack o f knowledge o f family tree and death prior to disease onset 
are potential explanations, but the possibility that some mutations are occurring de novo 
(Dagvadorj) or that the mutations are not fully penetrant (Mitrova and Belay 2002) 
exists.
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L I .4.1 E200K
H200K is the most common inherited prion disease worldwide. Patients with this 
mutation have very similar clinical features to sporadic CJD. There is a rapidly 
progressive dementia with myoclonus and pyramidal, extrapyramidal or cerebellar 
signs. Also, like sCJD, neuropathology shows absence o f PrP plaques. Heterozygous, 
and a small number o f homozygous individuals with an earlier age o f onset occur 
(median age 50 instead o f 58), both having similar phenotypes. Median duration of 
illness is the shortest o f all inherited prion disease at five months. Penetrance is 
incomplete as asymptomatic mutation carriers have been identified in old age, and 
shows variability, e.g. 89% in Israeli carriers and 54-59% in Slovakian and Italian 
carriers (Chapman, D ’Allesandro, Goldfarb, Mitrova and Belay)
Triggers for disease onset have been studied in E200K. Psychological stress (divorce, 
death o f a close relative, retirement, loss o f job), surgery with prolonged anaesthesia, 
serious accidents or current infectious disease have been noted prior to disease onset 
(Brandel and Delasnerie-Laupretre 1997, Mitrova and Belay 2002).
L I .4.2 OPRI
The insertion o f more than three oetapeptide repeats causes inherited CJD. 6-OPRI was 
the first PRNP mutation described in the literature in 1989 (Owen). A pedigree o f over 
80 affected individuals and 100 at risk individuals has been traced from a common 
ancestor in the UK (Mead). Clinical features include a cortical dementia with apraxia, 
cerebellar ataxia and pyramidal and extrapyramidal signs. A premorbid personality 
disorder o f aggression and delinquency has been described (Collinge 1992). Age of 
onset varies from third to sixth decade with a range o f progression speeds. Croes et al 
noted a negative correlation between age o f onset and number o f insertions, fewer 
repeats showing later onset and shorter disease duration.
I.I.4 .3PI02L
This mutation was initially described in 1989 and was the typical example o f GSS 
syndrome. It typically manifests as a slowly progressive ataxia with later dementia, but 
phenotypic variability is common, with a median disease course o f four years (Pieeardo) 
and only limited modifying effect o f codon 129.
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LL4.4D178N
Patients with D178N mutation develop insomnia, autonomie dysfunetion and 
myoelonus at a median age o f 50 with a short median disease eourse of 11 months. This 
elinieal syndrome, eoupled with seleetive degeneration of the anteroventral and 
dorsomedial thalamus is termed FFI. Goldfarb (1990) deseribed the mutation on the 
129M ehromosome leading to FFI and on the 129V leading to familial CJD. This 
differentiation does not hold true in all families, and other PRNP mutations have 
deseribed similar sleep and autonomic disturbance.
Explanations for the variability of phenotype include the eodon 129 genotype of mutant 
and wild type alleles, diversity of PrP conformation (different folding patterns of the 
protein) (Pieeardo, Parehi, Mead) and the variable contribution from the product of the 
wild-type PRNP allele (Chen, Mead).
Future hope for patients with inherited prion disease, and their descendants is that they 
may benefit from future therapies that prevent abnormal prion protein propagation; 
treatment could be instigated prior to elinieal disease.
1.1.5 Kuru
This acquired form of CJD was discovered in the 1950s when an epidemic of a 
neurodegenerative disease characterized by a progressive ataxia was found among the 
Fore linguistic group o f the Eastern Highlands of Papua New Guinea (see Figure 1.3).
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Figure 1.3 Eastern Highlands o f Papua New Guinea showing the kuru affected areas.
(Figure from Collinge 2006)
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Field work by several groups suggested that kuru was transmitted during cannibalistie 
feasts (Alpers, Gajdusek 1977, Glasse, Lindenbaum). The neuropathologieal parallels 
with scrapie (Hadlow) and the experimental transmission of the disease to primates 
(Gajdusek 1966) were key concepts in understanding human prion disease.
Clinical features include a cerebellar syndrome with truncal ataxia and tremor that 
progresses through defined elinieal stages (see Figure 1.4). Cognition can remain 
unaffected initially, but all patients then develop progressive dementia.
I
Figure 1.4 Examples o f patients with kuru; stakes are driven into the ground to provide 
support. (Figure from Prion Diseases o f Humans and Animals. Ed SB Prusiner et al.)
The first eases identified historically occurred in the 1920s and the peak of the epidemic 
was in the 1950s, mostly among women and children who participated in the mortuary 
feasts. Patients with kuru are currently alive (Collinge 2006), being exposed before the 
cessation of cannibalism in the late 1950s. Incubation periods have been estimated 
between five and 56 years; incubation time and resistance to prion disease are increased 
in eodon 129 heterozygotes. Being the only previous example o f dietary exposure to 
prions in humans before variant CJD, this group o f patients has provided useful insights 
into human prion disease.
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1.2 Management o f  Creutzfeldt-Jakob disease
1.2.1 Referral
In the United Kingdom patients eome to the attention o f speeialists in prion disease 
through a ehain o f referral. Patients usually present to their General Praetitioner who 
refers to the loeal neurologist. A national referral agreement is eurrently in plaee so all 
patients with a suspeeted diagnosis o f CJD are referred jointly to the National Prion 
Clinie (NPC) in London and the National CJD Surveillanee Unit (CJDSU) in Edinburgh 
with notifieation to the Health Proteetion Ageney.
1.2.2 Investm ation and  Diagnosis
At first eontaet with a prion disease speeialist the patient will usually have a history 
suggestive o f one o f the four types o f CJD.
Sporadie patients tend to be the oldest patients at the most advaneed stages o f disease, 
due to the rapid progression o f symptoms and the relatively long amount o f time 
required to rule out other diagnoses prior to referral. Patients are often bedbound and 
mute at time o f referral, or may pass away in the few days between referral and first 
patient visit.
Variant patients are usually under 40, residents o f the UK for several years in the 1980s 
and 1990s with subtle psyehiatrie symptoms, a movement disorder (either myoelonie or 
eerebellar) and signs o f early eognitive defieits, partieularly episodie memory problems. 
A new cohort o f patients has been identified recently (Wroe) who were exposed to 
infected blood transfusions donated by a presymptomatie patient who later developed 
prion disease. This cohort present in the same way, but have a wider range o f age of 
onset depending on when the transfusion was received.
Inherited patients sometimes have a family history o f a specific mutation in the prion 
protein gene, or more usually a more vague history o f an early onset Alzheimer’s like 
dementia in first degree relatives. Patients may approach prion disease specialists for 
information on the disease, to help understand the disease and care for ill relatives, for 
information prior to starting a family, for presymptomatie testing and genetic 
counselling, or may present with early symptoms. Depending on the mutation, examples 
include patients with early eognitive defieits with a 6-oetapeptide repeat insertion (6- 
OPRl), or eerebellar symptoms in P102L patients.
30
Iatrogenic patients have a history o f ocular or neurosurgery, growth hormone 
supplementation or infected blood transfusion. In peripherally inoculated eases, 
eerebellar presentation rather than dementia predominates.
As CJD is a rare disease, it is important to rule out other causes o f dementia. Any 
outstanding tests not performed by the referring hospital are completed. These include 
Anti-nuelear antibodies (ANA), syphilis (VDRL), Human Immunodeficiency Virus 
(HIV), Epstein-Barr Virus (EBV) and Herpes Simplex Virus (HSV). If there is any 
suggestion o f a paraneoplastic syndrome a whole body CT or PET is performed, and a 
testicular ultrasound scan in males.
More specific tests to confirm CJD include genetic analysis o f the prion protein gene to 
look for mutations and insertions, and eodon 129 status. Methionine homozygosity has 
been found in all vCJD eases to date and tends to indicate a more rapid progression in 
other types o f CJD. The family history is probed further, and any issues o f non-paternity 
addressed as appropriate. EEG is repeated to look for periodic synchronous discharges 
and lumbar puncture performed to determine CSF 14-3-3 and S-100 levels. MRl using 
all relevant sequences is performed or repeated, looking for a pulvinar sign in vCJD or 
cortical and basal ganglia hyperintensity in sCJD. Neuropsychometry looking for types 
and patterns o f eognitive impairment is often performed in patients who are well enough 
to participate.
In eases where the diagnosis is uncertain and when the patient or relatives are keen to 
pursue a definitive diagnosis, a frontal brain biopsy may be performed in possible sCJD 
eases, or a tonsil biopsy in potential vCJD eases (100% specificity in all NPC eases of 
vCJD tested to date (Wroe)). It is important that disposable instruments are used in 
these procedures, and on all invasive procedures in patients with prion disease as a 
differential diagnosis. If non-disposable instruments have been used the instruments 
should be quarantined until a definitive diagnosis is obtained. The infection control 
team, theatre manager and surgical team should all be aware o f the ease and the relevant 
infection control guidelines should be followed. Department o f Health Guidelines for 
those performing invasive procedures can be found at
www.advisorybodies.doh.gov.uk/aedp/tseguidance/lndex.htm. Advice for clinicians 
earing for those with CJD has been reviewed recently by the Health Proteetion Ageney
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in October 2006 and ^an he found at
www.hpa.org.uk/infcelions/topics az/cjd/information documcnts.htm.
Western blotting is pcrl'orined on the biopsy sample to determine the fragment size of 
the prion protein t'ollowjng treatment with proteinase K (only type 4 is found in vCJD). 
Appearances in brain specimens o f spongiform change, gliosis and neuronal loss are 
sought under microscopy. Inimunohistochemical staining with the antibody ICSM 35 is 
performed on tonsil oi brain to identify a follicular or synaptic pattern o f  staining 
respectively.
Once the diagnosis of ^  JU is confirmed the patient and/or their next of kin are informed 
by a senior member ol the specialist prion team, usually in the quieter clinic setting. At 
the NPC a speeialist nnrsc and a counsellor are usually present. As well as discussing 
the diagnosis, written information is given to the family to take home and a 
management plan instigated-
1.2.3 Muna^^nient
CJD creates its own uttiquc management challenges and diffieulties when keeping up 
with the needs ol a rapidly deteriorating patient. Early involvement from the relevant 
multidisciplinary team is important, usually comprising social worker, community 
psychiatric nurse, home eaters, GP, specialist prion doctors, counsellor, patient’s family 
or friends and speeialist prion nurse. The multidisciplinary team may become very 
large, so eareful case coordination and communication is required to ensure its 
efficiency. Confliet between family members or patient and family can occur, and can 
be one o f the most challenging obstacles.
In terms of strueture ol earc, palliative care models for rapidly degenerative conditions 
should be eonsidcred. The practicalities o f home care versus hospiee care should be 
eonsidered in each individual situation. Timely acquisition of adaptations for the home 
and movement aids is important, particularly as patients are often initially nursed at 
home. The location and proximity o f a suitable hospice placement, available at 
relatively short notice is often challenging. Practical problems o f fmanees, transport and 
eare provision arc conimon.
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All aspects o f patient eare in this multifaeeted disease must be eonsidered. Basie eare o f 
pressure areas, bowels and fall prevention is mandatory. As mobility declines 
appropriate aids should be anticipated. Movement disorders can be helped with sodium 
valproate for myoelonus, baclofen as an antispasmodie or haloperidol, which may help 
with hallucinations or delusions, as well as movement disorder. Chorea can be treated 
with tetrabenazine. Bulbar function often becomes affected, requiring eareful 
swallowing and nutritional assessment. Deciding whether and when to plaee a 
nasogastric tube or gastrostomy tube (radiologieally guided) for feeding is difficult for 
patient, family and clinician.
Pain and sensory symptoms can be relieved with gabapentin or amitriptyline, titrated to 
symptoms and side effects. Anti-depressants or antipsyehoties may be beneficial as 
altered mood and behaviour may be a prominent feature. Benzodiazepines should be 
avoided.
As communication diffieulties increase with disease progression there may be 
frustration on the part o f both patient and family. This creates short term practical 
problems and longer term consent problems. Some patients choose to write a Living 
Will, or other document stating their wishes for the time when they are unable to make 
or communicate decisions. The difficult issue o f consent for post mortem should be 
raised at an appropriate point with the patient and/or family.
Real eoneems are addressed by patients and their partners about the possibility of 
horizontal transmission between sexual partners, or vertical transmission during 
childbirth or breastfeeding. There is little evidence to support transmission via these 
routes and this is referred to in the Health Proteetion Agency’s advice above.
Different problems arise in mutation positive younger patients as the lack o f clarity of 
pathogenicity and penetrance produces uncertainty in those who wish to know how and 
when the disease might affect them. This group o f patients is constrained by being 
unable to donate blood or other tissues such as cornea or dura mater, and having to 
notify dentists and surgeons o f their status to prevent iatrogenic transmission o f disease. 
However, it is this group that may benefit the most from future therapies that prevent 
prion propagation as treatment could be instigated prior to elinieal disease.
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Stigma and ignorance o f CJD is still a problem within the health system and the publie. 
Heightened media interest means patient confidentiality requires particular vigilance. 
The understandable distress caused to patients and families as a consequence o f the 
nature and origin o f the disease should be anticipated and managed well. Misleading or 
conflicting information obtained from the internet or media may cause confusion.
The National Prion Clinie and CJD Surveillance Unit also work in an advisory role 
giving help to patients, carers and families. They, along with the Department o f Health 
provide access to the CJD Care Package, a fund used to assist with the eare o f all CJD 
patients. It meets shortfalls in the cost o f services that cannot be met by loeal health 
authorities. Patient support groups exist, including the CJD Support Network and the 
Human BSE Foundation.
Management o f a rapidly progressive, invariably fatal disease whilst under intense 
media scrutiny is challenging. Effectively managed, appropriate and timely earc is 
required to ensure that each patient’s needs arc met.
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IMAGING TECHNIQUES IN DEMENTIA AND THEIR APPLICATION TO 
CJD
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Figure 2.1 Imaging Techniques in Dementia
2.1 Imaging Techniques in Dementia
The imaging techniques used in dementia are first described in this chapter, followed by 
a summary o f cross sectional imaging and longitudinal imaging techniques and their 
application to CJD.
2.1.1 Magnetic Resonance Ima2 in2 (MR!)
MRI is eurrently the preferred structural method for imaging patients with dementia. It 
excludes structural pathologies which may be treatable (such as tumours or intracranial 
haematoma) as well as aiding the diagnosis of degenerative and vascular causes o f 
dementia.
In MRI, tissues are differentiated by their different T1 and T2 values; for example, 
cerebrospinal fluid (CSF) appears dark on T1 images but bright in T2 images (see figure 
2.5). MRI shows cerebral atrophy well. There is no radiation exposure (unlike CT), and 
resolution is superior with better tissue contrast than CT. It is however, less readily 
available as there are more CT scanners then MRI scanners in the UK. The scan takes 
longer, and is dependent on the patient keeping still. Those with non-MRI compatible 
metal implants (orthopaedic or pacemaker) cannot have MRIs due to the strong 
magnetic currents involved. There are European and American guidelines for the 
investigation of possible dementia which recommend either MRI or CT if possible 
(Knopman, Waldemar).
2.1.2 M RI — Fluid  A ttenuated Inversion Recovery (FLAIR)
On FLAIR images the signal from the cerebrospinal fluid (CSF) is suppressed whilst 
maintaining a heavy T2 weighting. This results in high lesion contrast in areas close to
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CSF, and allows better visualisation o f lesions in these areas than conventional T2 
Weighted Imaging (T2WI). The widespread use o f this modality began in the early 
1990s.
2.1.3 M RI  -  Diffusion W eighted Imci^inf^ (DWI)
DWI assesses the mobility of water molecules in tissue and provides physiological 
information not available on standard MR imaging. Cellular swelling and other 
microstruetural changes lead to an alteration o f the water mobility, which becomes 
apparent on DWI. The spatial resolution o f DWI is not as high as that o f conventional 
MR images but it is a rapid imaging technique which represents an advantage in 
patients with movement disorders. Eehoplanar DWI can be acquired within seconds and 
may be the only sequence yielding diagnostic information in confused and agitated 
patients (Waldman 2003).
The apparent diffusion coefficient (ADC) is calculated from two or more images with 
different degrees of diffusion weighting. It allows quantification o f regional water 
diffusion and is independent o f T2 effects.
2.1.4 Com puterised tomography
CT forms an image using X rays, which reflects absolute tissue density. CT has been 
used historically to exclude a focal lesion in the investigation o f a patient with dementia. 
However, CT images generally have lower resolution than MRI and have the additional 
disadvantage that individuals are subject to a dose o f radiation. CT now has less routine 
use in the elinieal imaging investigation o f dementia, having been largely replaced by 
MRI.
2.1.5 M agnetic resonance spectroscopy (MRS)
Proton magnetic resonance spectroscopy (MRS) assesses the spectra o f specific brain 
metabolites such as A-acetylaspartate (NAA), the decrease o f which can serve as a 
marker of neuronal loss or dysfunction.
2.1.6 Positron Em ission Tomography (PET) and  Single Photon Emission  
Com puted Tomography (SPECT)
PET measures several functions in the brain including oxygen metabolism, glucose 
metabolism or blood flow. Uptake o f labelled glucose can be decreased in dementias
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such as AD. Binding o f specific ligands (such as those binding to amyloid) can be used 
in a disease or pathology specific manner (Agdcppa). SPHCT measures blood perfusion 
within the brain.
2.2 The Alzheimer \s disease template in dementia
The neuroimaging patterns in dementia are increasingly being used as diagnostic tools 
and markers o f disease progression or treatment effect (Miller). O f all the dementias, 
brain atrophy in Alzheimer’s disease (AD) has been studied the most. Alzheimer’s 
disease is the most common cause o f dementia and is eharaeterised by progressive 
cerebral atrophy. In the 1970s the advent o f CT allowed the first studies o f brain 
atrophy in AD to be performed. The first quantitative imaging studies in AD were 
performed in the 1980s (de Leon MJ). Patterns o f atrophy in AD (in the medial 
temporal lobe, partieularly the hippoeampus) have been correlated with eognitive or 
behavioural performanee (Jaek) as have rates of brain atrophy and eognitive decline 
(Fox 1999). Currently, the use o f funetional imaging sueh as SPECT and PET have 
highlighted different areas in AD compared to eontrols (cortical change rather than 
hippocampal change) (Small). Brain volume has been used as an outeome measure in 
therapeutie trials in AD (Fox 2005).
AD is a useful model for studying brain volume ehanges in human prion disease. 
Atrophy may eorrelate with disease progression in both diseases (normal, mild 
eognitive impairment and established AD compared to normal, preelinieal or early 
symptomatic and established human prion disease). This is partieularly true in familial 
eases where the preelinieal phase can be more easily identified in patients with positive 
mutations but no symptoms. This study will eompare patterns o f atrophy with 
performanee on neurological examination using the same method to determine brain 
volume as used in AD.
2.3 Methods o f  assessment in dementia imaging
The two methods o f analysing struetural images are either in a cross sectional or 
longitudinal manner.
2.3.1 Cross sectional ima2 in s  in dem entia  
Cross sectional imaging is the most eommon form o f imaging in dementia, usually by 
visual assessment. Different dementias have different patterns o f atrophy. Alzheimer’s
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disease shows bilateral hippocampal atrophy followed by more generalised atrophy. The 
pattern o f cognitive impairment characteristic o f frontotemporal dementia has been 
described in association with different pathologies including Pick’s Disease, Lewy body 
disease, vascular disease, CJD, progressive supranuclear palsy and eortieobasal 
degeneration (summarised by Neary).
Different MRI sequences help to differentiate dementias on cross sectional assessment, 
for example T2 and FLAIR (fluid attenuated inversion recovery) better visualise 
vascular dementia lesions than TI. Quantification in this method is usually by rating 
scales, rather than any specific scan measurements. Rating may be based on subjective 
assessment, introducing bias unless the radiologist is blinded to disease and stage of 
progression. Most rating scales are usually easily and reproducibly applied by raters, 
and are often well validated. In CJD a visual reference scale o f the signal intensity in the 
pulvinar nucleus has been reported (Collie 2003). In Alzheimer’s disease reduction in 
the size o f the medial temporal lobe is estimated semi-quantitatively using the Scheltens 
scale (Scheltens 1992), and in vascular dementia there are scales o f ischaemic load 
(Scheltens 1998).
Sensitivity of this method may be low due to overlapping appearances with normal 
ageing, wide inter-individual variation in brain volume caused by age and sex 
differences and consequent difficulty in detection o f subtle early changes. Specificity 
may be low as there are overlapping patterns in different dementias. Measures such as 
total intracranial volume (TIV) (Whitwell 2001) can reduce overlap by correcting for 
estimated pre-morbid brain volume.
Figure 2.2 Total intracranial volume. A 
standard threshold o f  3 3% o f  the mean 
intracranial signal intensity is used to outline 
the outer border o f  dura. Every 10 th axial 
section is segm ented with the inferior border 
set as the lowest section in which cerebellar 
tissue is present. Linear interpolation o f  areas 
is used to obtain an estimate o f  the TIV from  
the segm ented sections. The axial sections used to sample the total intracranial volume 
are m arked on the sagittal view in this figure.
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TIV calculates the volume within the skull, and is a more regular shape than the 
gyriform brain surface. Whole brain measurement is usually (as in this thesis) 
performed on every ‘slice’ o f an MRI scan, TIV can be calculated in just as 
reproducible a level (less than 1% mean absolute difference between raters) when 
measured at regular intervals (every 10 slices). TIV correction can be performed for 
both whole brain measurement and for smaller struetures or regions of interest.
Using structural MRI voxel based morphometry (VBM) compares the local 
concentration of brain tissue e.g. grey matter at the voxel level between two groups of 
subjeets and allows assessment of anatomical differences throughout the brain in either 
a cross-sectional manner (e.g. between controls and disease groups) (Ashbumer 2000, 
2001) or with time (e.g. evolution of sites of atrophy). An example of the hippocampal 
and temporal lobe changes in Alzheimer’s disease is shown below.
Figure 2.3 Example o f  cross sectional VBM in A lzheim er’s disease.
2.3.2 Cross sectional im aains in human prion disease 
Cross sectional appearances in the different types of CJD are described, followed by a 
summary of the evidenee for the best application o f each imaging technique in CJD.
39
Table 2.1 Summary o f  imaging appearances in CJD
Type of 
CJD
MRI in
diagnostic
criteria?
Characteristic
appearances
Most useful 
sequence
Key references
Variant Yes Pulvinar or 
hockey stick sign.
FLAIR most 
sensitive 
sequence, DWI 
sensitivity data 
limited
WHO(2004), Zeidler 
2000, Collie 2003
Sporadie No Increased cortical 
and/or basal 
ganglia signal.
DWI is most 
sensitive clinical 
diagnostic test.
Tschampa 2005, 
Shiga
Inherited No Cortical/cerebellar 
atrophy, 
decreased basal 
ganglia signal or 
no change.
Little evidence to 
suggest most 
useful sequences
Wimberger, Aimer, 
Arata
Iatrogenic No Caudate/putamen 
hyperintensity; 
only atrophy in 
durai recipients. 
Pulvinar sign if 
donor had vCJD.
Little evidence to 
suggest most 
useful sequences
Brown 2000, 
Caboclo, Oppenheim 
2004, Martinez-Lage, 
Garcia Santos 1996, 
Wroe, Collie DA 
(pers comm)
2.3.2.1 Variant CJD
Initially the MRI scans o f vCJD were reported as being normal (Zeidler 1997). The first 
two case reports o f pulvinar change were published in 1996 (Chazot, Tabrizi). The 
pulvinar sign is now a part o f the World Health Organisation (WHO) diagnostic criteria 
for vCJD (Will 2000). The current WHO definition o f the pulvinar sign is bilateral 
symmetrical pulvinar high signal relative to the signal intensity o f other deep grey 
matter nuclei and cortical grey matter using T2WI, proton density weighted, FLAIR and 
axial DWI sequences (WHO 2004) (see Figure 2.5 F,G). This, and the ‘hockey stick’ 
sign o f high signal in both pulvinar and dorsomedial thalamic nuclei was described in 
2000 (Zeidler 2000). As yet there is no evidence that the pulvinar sign could be used as
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a presymptomatie test for vCJD prion infeetion as scanning has only been earried out in 
symptomatie patients.
In a study of 36 neuropathologieally eonfirmed vCJD eases eompared to 57 controls 
with suspected CJD, the pulvinar sign had a sensitivity o f 78% and specifieity o f 100% 
(Zeidler 2000). T2W1 and proton density sequenees on the most reeent set o f seans 
available on eaeh patient were used. In a retrospeetive study o f MRI in 86 
neuropathologieally confirmed cases o f vCJD the most sensitive sequenee was FLAIR 
(Collie 2003) where the pulvinar sign was present in 100% o f the 30 FLAIR scans 
performed. In a further study of 27 vCJD eases eonfirmed with tonsil biopsy compared 
to 18 tonsil biopsy negative patients, retrospeetive blinded analysis of T2WI, DWI, 
FLAIR and proton density weighted images was performed on all images solely to 
assess the presence or absence o f the pulvinar sign. A sensitivity o f 81% and a 
speeificity of 94% for the pulvinar sign was found (Siddique). High signal in the 
pulvinar nucleus has been deseribed in sCJD (Martindale, Haik, Rossetti), and in two 
reports (Petzold, Krasnianski) the WHO criteria were fulfilled (WHO 2004) with 
pulvinar intensity being higher than other deep grey matter nuelei. There are two reports 
o f an initially positive pulvinar sign disappearing as disease progresses (Collie 2003, 
Yamada). Other eonditions sueh as paraneoplastic limbic encephalitis may initially 
present in a similar way (Mihara).
Variant CJD has the most consistent changes on MRI of any human prion disease type, 
perhaps representing the fact that only one molecular strain o f human prion disease is 
seen in these patients (Collinge 2001). This consistency is useful as the pulvinar sign 
ean often be identified in scans despite movement artefact. Hyperintensity o f other 
structures in vCJD is seen, whieh varies between patient and sequenee weighting. In 
particular dorsomedial thalamic nuclei, periaqueductal grey matter and caudate 
hyperintensity are seen. Occasionally parietooccipital white matter and asymmetric 
pulvinar hyperintensity is seen, or cerebral and eerebellar atrophy (Collie 2003).
SPECT has been used in two eases. Areas of cortieal hypoperfusion were seen (left 
temporoparietal in one, widespread reduction in cortical perfusion with cerebellar and 
basal ganglia reduction in the second). SPECT changes were seen before ehanges on 
MRI or eleetroencephalogram (EEG) (De Silva). MR spectroseopy may be useful as a
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measure of disease activity, monitoring of treatment effects (Pandya) and a future tool 
in early diagnosis (Cordery).
2.3.2.2 Sporadic CJD
Historically, imaging features were not a part o f the diagnostic criteria for sCJD, which 
relied more on clinical, neurohistopathological, EEG and CSF features. There is, 
however, growing support for MRI, and in particular DWI to be included in the 
diagnostic work up for sCJD (Collie 2001, Tschampa 2005, Shiga) (Figure 2.5 A-C).
Traditionally the recognised features of sCJD on MRI are bilateral high signal in the 
caudate and putamen (Tschampa 2005, Schroter). Recent publications have additionally 
highlighted the importance o f cortieal ribbon hyperintensity (Shiga). Shiga described 26 
cases of sCJD (a mix of definite and probable cases); 41.7% showed only cortical 
lesions, 45.8% showed lesions in both cortex and basal ganglia and 12.5% lesions only 
in the basal ganglia. Sensitivity o f DWI was 92.3%, significantly more than in T2WI 
(40%) or FLAIR (50%).
Patterns emerging from work on sCJD subtype analysis include consistent 
hyperintensity in caudate and putamen in codon 129 heterozygotes using T2WI. All 26 
heterozygotes in Meissner, (Meissner 2004) 90% of 20 MV2 patients in Krasnianski, 
(Krasnianski 2006b) and 10 o f 11 heterozygotes in Zerr (Zerr 2000) showed this 
pattern. Methionine homozygotes form 71% of the sCJD population, (Parehi 1999) 
however patterns of MRI change are less clear. In a study o f MM2 patients, five out of 
eight had no abnormality on any MRI sequence, (Krasnianski 2006a) however newer 
imaging techniques such as SPECT may be useful in identifying patterns in these 
patients (Hamaguchi). In seven VVl patients (a subtype that mimics vCJD with young 
onset, prolonged disease course and psychiatric symptoms) all had cortical high signal, 
atypical o f vCJD (Meissner 2005). (Molecular subtypes quoted refer to the Gambetti 
classification).
2.5.2.3 Inherited CJD
Imaging in inherited prion disease has a role in excluding other diseases (both prion and 
non-prion), but changes are non specific. Imaging appearances in symptomatic patients 
fall broadly into four categories; no change, (Collinge 1998, Zerr 1998) cortical atrophy, 
cerebellar atrophy (Figure 2.5 D-E) or decreased T2 signal in the basal ganglia (Zerr
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1998, Wimberger, Aimer). Atrophie changes can be progressive (Wimberger, Arata). 
Presymptomatie P102L gene carriers have shown early parietal atrophy on MRI (Fox 
1997b) and in symptomatic P102L patients with normal MRI examinations, SPECT 
imaging showed patchy decrease across the whole cerebrum (Arata). In two series of 
patients with familial fatal insomnia (D178N mutation), MRI did not show any specific 
abnormality, (Zerr 1998) or at most mild to moderate atrophy (Aimer).
2.3.2.4 Iatrogenic CJD  
The type o f donor material and route o f inoculation seem to produce different imaging 
patterns in recipients. In the largest and most recent imaging series, an Anglo-French 
cohort o f 27 human growth hormone recipients (and one durai graft recipient) reported 
bilateral symmetrical hyperintensity of the caudate head and putamen in 64% of 
patients, DWI changes occurring before T2WI changes (Collie DA, MRI of iatrogenic 
Creutzfeldt-Jakob disease: appearance in an Anglo-French cohort. Presented at British 
Society o f Neuroradiologists Conference 2003, personal communication). Caboclo and 
Oppenheim (2004) also report caudate and putamen hyperintensity in three growth 
hormone recipients on FLAIR, DWI and T2 imaging, with additional thalamic 
hyperintensity on DWI in two cases. Serial scanning showed progressive atrophy with 
reduction and eventual disappearance o f the FLAIR and DWI changes, a similar finding 
to pulvinar sign disappearance in late stages of vCJD mentioned previously.
Basal ganglia hyperintensity has been reported in case reports of dura mater recipients, 
(Wakisaka, Kretzschmar 2003, Preusser) as well as a case o f thalamic hyperintensity in 
end stage disease (Wakisaka). In 11 cases reported or reviewed by Martinez-Lage and 
Garcia-Santos atrophy was present, which was progressive in some cases.
In the single comeal graft derived case with MRI findings reported, caudate and 
putamen hyperintensity was present, but FLAIR and DWI also showed cortical 
hyperintensity (Rabinstein).
Prion infection has been reported in three patients following blood transfusion from 
asymptomatic donors who later developed vCJD (Llewelyn, Peden, Wroe). In two of 
these cases infection was identified post mortem and one o f these was said to be 
symptomatic with a normal MRI. In a single case diagnosed ante mortem MRI was 
normal during the early symptomatic clinical disease course, the pulvinar sign
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becoming apparent with more advanced elinieal disease and signifieant neurologieal 
disability.
2.3.3 Cross-sectional appearances in different im asins techniques in 
CJD
Different sequences have different applications within CJD; the current literature on the 
application o f each technique in CJD is reviewed.
2.3.3.1 M RI - T2 W eighted Imaging
Standard T2WI can be useful in human prion disease. The reeognised features of both 
sCJD (high signal in the cortex, caudate and putamen) and vCJD (the pulvinar sign) on 
MRI may be demonstrated on T2WI. The basal ganglia, cerebellar and atrophie ehanges 
o f inherited prion disease and the hyperintensity o f the eaudate head and putamen in 
iatrogenie prion disease are also seen in T2WI. Generally other sequences such as DWI 
or FLAIR tend to be more sensitive than T2WI.
The mechanism o f signal change has been investigated by Chung who found T2 
hyperintensity correlated with gliosis and hypointensity with vacuolation in an in vivo 
hamster serapie model.
2.3.3.2 M R I-F L A IR
FLAIR has been successfully applied to all types of human prion disease. It is more 
sensitive than either T2WI or DWI for detection o f the pulvinar sign in vCJD, although 
DWI sensitivity data is limited (Collie 2003) (Figure 2.5 F-H). FLAIR imaging shows 
pathological signal intensity inerease in the cerebral cortex (termed ‘cortical ribboning’) 
and basal ganglia changes more elearly than T2WI (Vrancken, Schwaninger). Inereased 
signal intensity in the cortical ribbon on FLAIR has been co-localised to periodie sharp 
waves on EEG (Cambier). Increased FLAIR signal corresponded to increased DWI 
signal intensity in the basal ganglia (Haik) and cortex (Haik, Young, Mao-Draayer).
The meehanism o f signal change in FLAIR images continues to be debated. Astrogliosis 
has been reported to be the cause o f high FLAIR signal in one paper (Urbach) and 
another demonstrated a strong correlation between FLAIR signal and aecumulation of 
prion protein (PrP^^\ but did not find any correlation between gliosis or spongiform 
change on FLAIR (Haik).
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Work on the quantification o f intensity distributions in basal ganglia using multimodal 
T l, T2 and FLAIR has differentiated between sCJD and vCJD and has potential for 
automatic detection o f CJD on MRI (Linguraru).
2.3.3.3 M RI  -  Diffusion W eighted Imaging (DWI)
DWI abnormalities seen in human prion disease can be striking (Collie 2001). Positive 
scans show ribbon-like abnormalities in the cerebral cortex and/or hyperintensity in the 
caudate and putamen or thalamus. DWI may be the only positive investigation in human 
prion disease, (Shiga, Mittal) may facilitate an early diagnosis as changes have been 
noted as early as three weeks after the onset of symptoms (Shiga) and may be used to 
monitor disease progression (Young, Demaerel, Matoba, Ukisu). Due to the rapid 
acquisition time in eehoplanar DWI this may be the only imaging sequence yielding 
diagnostic information in CJD (Waldman 2003) (Figure 2.5 I-J).
DWI abnormalities have been noted in all types o f human prion disease. DWI may be 
the most sensitive imaging modality for sCJD, (Tschampa 2005, Demaerel, Bahn) Some 
inherited cases show hyperintensity in the basal ganglia and frontoparietal cortices, 
similar to sporadic cases (Nitrini). vCJD shows bilateral hypersignal in the striatum and 
thalami (Oppenhein 2000). Caudate and anterior putamen high signal on DWI in 
iatrogenic CJD is seen before T2 weighted imaging changes. (Collie DA, personal 
communication)
Serial DWI has shown increased intensity and extension o f hyperintense signal with 
disease progression (Ukisu, Russmann). The most likely pathophysiological explanation 
o f the DWI changes is altered molecular motion o f water and restriction of extracellular 
space due to spongiform degeneration (Bahn). Other proposed causes include deposition 
o f prion protein, (Haik, Na) fibrillary gliosis seen in end stage CJD (Masters 1978) and 
progressive neuronal death (Oppenheim 2004). Interestingly, in several studies on serial 
changes in DWI, initial hyperintensity disappeared in the late stages o f disease (Collie 
DA, personal communication, Matoba, Ukisu, Oppenheim 2004).
ADC measurements in human prion disease have been performed by several 
investigators (Waldman, Demaerel, Bahn, Oppenheim 2000, Russmann, Bahn, Lim). In 
sCJD most investigators found ADC values in lesions were lower than in normal brain
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parenchyma (Russmann, Na, Bahn) with the exception of one (Demaerel). No 
correlation has been found between reduction in ADC and semi quantitative 
neuropathologieal change (Russmann). In a recent paper, thalamic ehanges in sCJD 
were only detected by quantitative measurements o f ADCs, and not visible on DWI or 
T2WI (Tschampa 2003). In vCJD early reports on ADC measurement were conflicting 
(Collie 2001, Demaerel).
High intensity areas on DWI have been correlated with low perfusion on SPECT, (Na) 
hypometabolism on positron emission tomography (PET), (Demaerel, Na) clinical 
findings, (Na) disease progression, (Mao-Draayer, Russmann) neuropathology showing 
spongiform change, (Mittal) neuronal loss and gliosis, (Russman) and periodic sharp 
wave activity on EEG (Mao-Draayer, Na, Lim).
23.3.^ CT
The early literature on the imaging of human prion disease revealed that CT showed 
atrophy, with only one report o f focal parenchymal abnormality (Falcone). 33 cases 
were reported up to 1992 and more recent reports have added no further insights into 
CT appearances. In the largest single study of 15 patients, 80% had normal scans and 
20% had atrophy (Galvez).
2.3.3.5 M agnetic resonance spectroscopy (MRS)
Decreases in absolute levels or ratios o f NAA or other metabolites have been seen in 
variant, (Pandya, Cordery) sporadic, (Pandya) iatrogenic (Oppenheim 2004) and 
inherited CJD (Konaka, Waldman 2006). The first report o f MRS dates from 1991 
(Bruhn). Early reports found little change in NAA in the first stages o f disease, but at 
the late stage o f CJD when neuronal loss is more obvious neuropathologieally, 
decreases in grey and white matter were seen (Bruhn, Graham). The pattern o f 
metabolite change matches the findings on T2 and FLAIR imaging, with significant 
reductions in absolute levels or ratios o f NAA in the putamen in sporadic patients and in 
the pulvinar in variant patients (Pandya, Cordery). A presymptomatie inerease in myo­
inositol was seen in two P102L patients, (Waldman 2006), a potential non-invasive 
surrogate marker o f disease onset in this disease type.
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2.33.6 PET
Generally, FDG PET (2-(18F)fluorodeoxyglueose) shows widespread hypometabolism 
in human prion disease, which differentiates it from other dementias such as 
Alzheimer’s disease whieh show speeifie patterns on PET (Henkel 2002, Goldman). 
Hypometabolism on FDG PET has been eorrelated with histopathologieal astrocytosis 
and neuronal death (Goldman, Engler) and spongiform ehange (Goldman).
In a multitracer PET study (Engler) o f 15 patients with probable or definite CJD 
ehanges in regional eerebral blood flow (using oxygen-15 labelled water), regional 
eerebral glucose metabolism (FDG) and astroeytosis (using monoamine oxidase B 
inhibitor 7V-[’’C-methyl]-L-deuterodeprenyl (DED)) were deteeted. Hypometabolism 
was more prominent in the eerebellum, frontal, occipital and parietal lobes than the 
thalamus, pons or putamen, which differs from the distribution pattern seen on MRI 
studies. However, PET seems partieularly good at identifying occipital lobe 
hypometabolism in patients with visual symptoms, including the Heidenhain variant 
(Henkel 2002, Tsuji).
Future advances in PET include creating an in vivo probe to label prion plaques, like 
that successfully developed for amyloid plaques in Alzheimer’s disease (Agdeppa). An 
in vivo method in presymptomatie and symptomatic mice using the ligand methoxy- 
X04 has been successful (Sadowski) as has an in vitro method using fixed sections from 
patients with sCJD, vCJD and GSS (Bresjanac).
23.3.7 SPECT
Regions o f decreased eerebral blood flow have been demonstrated using SPECT in 
variant, iatrogenic, familial and sporadic CJD. In the largest series o f 19 definite or 
probable sporadie CJD patients using 99mTc-HMPAO- or 99mTc-ECD-SPECT, 89% 
showed hypoperfusion on SPECT examination, the majority showing widespread 
reduction in eerebral perfusion including the occipital lobes, the cerebellum or one 
whole hemisphere (Henkel 2004). As in PET, this pattern of change is different from 
other types o f dementia. SPECT has been reported to be useful in a rare subtype of 
sCJD with eodon 129 methionine homozygosity and a thalamic neuropathologieal 
pattern. All four patients showed reduction in cerebral blood flow as well as 
hypometabolism bilaterally in the thalamus, with preservation in the putamen 
(Hamaguchi). Regional changes in blood flow (as seen by decreased uptake o f tracer,
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either 99mTc-HMPAO, 1231-IMP or Xe-133 with and without acetazolamide) are seen 
at earlier stages of disease than MRI changes (De Silva, Arata, Matsuda, Jibiki, 
Mathews). Focal areas o f decreased uptake may be seen in the basal ganglia, (Lim) 
thalamus (Hamaguchi), cerebellum (Henkel 2004) and frontotemporal lobes (Arata, 
atsuda) or occipital lobes in Heidenhain variant patients, (Jibiki, Mathews) and inherited 
patients (Arata). Sometimes changes are seen in an asymmetric pattern (Henkel, 
Matsuda).
At present it remains unclear whether the perfusion changes seen on PET and SPECT 
could also be investigated with MR perfusion imaging. Given the good correlation of 
SPECT data with MR perfusion imaging in neurovascular diseases and tumour imaging 
it appears likely that MR perfusion imaging might also be useful in human prion 
disease.
2.3.4 L om itud ina l im a ^ im  
Methods o f quantifying brain atrophy in dementia range from simple subjective visual 
ratings to highly sophisticated digital 3D Tl MRI acquisition software for computerised 
post-processing o f serial scans. As these methods have evolved over the last 10 years, 
patterns o f atrophy in the different dementias such as AD, Pick’s disease, 
frontotemporal dementia, Lewy body dementia and vascular dementia have been 
identified (Frisoni).
2.3.4.1 Advantages o f  longitudinal imaging in dementia  
The advantage o f longitudinal measurement o f atrophy in individuals is that the first 
scan acts as an internal control for comparison with future scans, thus removing the 
problem of inter-individual variability. A rate o f atrophy can then be calculated which 
improves differentiation between normal ageing and disease processes (Fox 1996, Jack 
1998).
Several groups have designed techniques to match scans spatially (Collins, Woods, 
Freeborough 1996, Jenkinson). They match voxels using an automated system so all 
structures in scan pairs correspond. Brains alone are matched rather than non-brain 
material preventing confounding effects o f changes in relative brain to skull position. 
The simplest form of registration is six degrees-of-freedom or rigid registration which 
involves aligning the scans in the three axes of the image but does not remove
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fluctuations in voxel size (voxel drift). A nine degrees-of-freedom registration is 
commonly used which includes a scaling factor, allowing for compensation o f voxel 
drift (Whitwell 2004).
Change is quantified using a subtraction method (baseline scan minus repeat scan in a 
registered pair) called the boundary shift integral (BSI) which has been validated as a 
robust and accurate measure o f brain loss (Freeborough 1997b). The BSI determines the 
total volume through which the boundaries o f the brain have moved directly from voxel 
intensities and a visual representation o f the site o f boundary change is generated.
2.3.4.2 Rates o f  atrophy in normal ageing  
Normal rates o f brain atrophy have been studied by many groups. Knowledge of the 
distribution and timing of brain volume loss during normal ageing is increasing. This 
knowledge is essential when interpreting imaging changes in dementia. Whether decline 
is due to consistent low level atrophy or whether the rate o f atrophy accelerates after a 
certain age is being answered by longitudinal studies in different age groups (Scahill 
2003, Mueller, Resnick). These longitudinal studies avoid problems o f secular trends 
(e.g. brain volume may be increasing due to better maternal nutrition) and inter-person 
differences as each subject’s first scan becomes their own control. Current research 
suggests age-related decreases in brain volume across the adult age range with evidence 
o f acceleration in rates o f atrophy after the age o f 70 (Scahill 2003).
2.3.5 Alternatives to whole brain resistration
2.3.5.1 Regions o f  interest
Whole brain volume analysis is a general measure o f brain atrophy, but does not 
demonstrate comparative regional changes. Quantification o f atrophy has been 
performed on different structures or ‘regions o f interest’, such as the hippocampus, 
amygdala and cerebellum (Jack 1998). The segmentation and registration of smaller 
brain regions such as the hippocampus introduces a greater degree o f measurement error 
and variability but may demonstrate more disease specific changes. These methods are 
usually manual rather than automatic.
2.3.5.2 Ventricular volume
Another reproducible method for quantifying change over time is to calculate change in 
CSF spaces such as the ventricular volume.
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Figure 2.4 Ventricular Volume calculation example (A) saggital and (B) coronal view.
Ventricular volume increases in normal ageing, mild cognitive impairment and 
Alzheimer’s disease (Scahill 2003, Jack 2004). In normal ageing Resnick et al reported 
that ventrieular volume increases at a rate of 1.5cm cubed per year in individuals with a 
mean age o f 70 (range 59-85 years) (Resnick 2000). A particularly useful aspect of this 
technique is that a time interval o f six months (as opposed to the usual one year) is a 
sufficiently long period over which to calculate ventricular BSI (Schott 2005).
However, all focal information is lost in this method.
23.5.3 KFM
A method whieh combines both regional and quantitative change in groups of patients is 
VBM. Group baseline and repeat images can be compared on a voxel by voxel basis 
cross-sectionally at both time points (Ashbumer) or by importing the deformations from 
non-linear registrations into VBM and assessing statistical differences between groups 
longitudinally (Scahill 2002). Similarity in group disease profile and imaging quality 
are necessary to produce reproducible VBM findings.
2.3.5.4 F lu id  registration  
A further method which demonstrates anatomical longitudinal change is fluid 
registration (as opposed to rigid registration used in this thesis). This method optimises 
the match between the baseline and repeat scan by using the baseline image as a mask 
and warping the repeat image to the baseline image. A fluid registration model has been 
described by Freeborough 1998 and uses parameters outlined by Crum (Crum 2001). A 
viscous fluid model is used to compute a deformational field throughout the image at 
voxel level. This estimates volume change occurring at each voxel (known as the 
Jacobian value). To examine longitudinal scans, logarithms o f the Jacobian values for
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each voxel are analysed. A colour overlay representing voxel expansion and voxel 
contraction is used. A visual representation o f anatomical sites o f atrophy is therefore 
generated. However, this technique is computer intensive and generally not used as a 
quantification tool.
Measurement o f atrophy is therefore an important and developing tool in monitoring 
disease progress, early diagnosis and clinical trial endpoints in dementia.
In the following two sections the existing evidence o f atrophy in human prion disease, 
and atrophy o f the cerebellum are discussed. There are currently no reports o f 
quantification o f atrophy in human prion disease, a situation this thesis aimed to rectify.
2.4 Atrophy in human prion disease 
Brain atrophy has been described in all forms o f human prion disease. The majority of 
evidence is cross sectional in nature, with reports o f atrophy from single scans, in 
comparison to a normal population. Most reports are from visual inspection and 
subjective impression by radiologists who may or may not be blinded to diagnosis. 
However, there are increasing reports o f longitudinal scanning whieh prove atrophy is 
increasing with time, but quantification of the rate o f atrophy has not been performed.
In general, atrophy in vCJD is uncommon, perhaps reflecting the young age group o f 
affected patients. Atrophy in familial disease is heterogeneous ranging from no change 
through to cerebral and cerebellar atrophy. Iatrogenic patients are interesting in that 
signal changes on FLAIR and DWI are similar to sCJD, yet the cerebral and cerebellar 
atrophy is less pronounced. Sporadic CJD has a rapidly progressive atrophy occurring 
over the short time span o f this disease.
In the largest reported series o f vCJD patients Collie reported the MRI scans o f 86 
neuropathologieally proven vCJD patients. Cerebral atrophy (detected visually and 
commented on by presence and degree) was an uncommon feature. Cerebral atrophy 
was judged as moderate or severe for age in 15% o f patients with generalized cerebellar 
atrophy in 9%. In two o f 21 eases with serial imaging, there was a significant subjective 
progression in cerebral atrophy over the intervals o f 67 and 144 days respectively 
(Collie 2003).
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In familial prion disease a speetrum o f atrophy is seen, as patients are seanned at all 
stages from preelinical disease to the terminal stages o f illness. Cerebral and cerebellar 
atrophy has been reported in a presymptomatie familial patient who became 
symptomatic in the interval between scans. There was diffuse rapidly progressive 
atrophy in the brain including caudate, thalamus, cerebellum and pons. In a review o f 
365 familial eases comprising 135 Gerstmann-Straussler-Seheinker, 68 familial fatal 
insomnia, (FFl) 81 base pair insertion and 62 other familial prion disease patients MRI 
usually showed atrophy. Correlation between site o f atrophy and clinical symptoms was 
rarely noted (frontal atrophy and paraspastieity in a P 105 L mutation or hemispheric 
atrophy and contralateral hemiparesis in an A117V patient) (Kovacs). In Gerstmann- 
Straussler-Seheinker disease scans may be normal (Brown), show cerebral or cerebellar 
atrophy (Collins review), have cerebellar volume loss (Farlow,) or progressive atrophy 
(Wimberger).
In FFl both cerebral and cerebellar atrophy and ventricular dilation were seen only in 
patients with a prolonged course (Montagna). Many subjects show non-specific cerebral 
and/or cerebellar atrophy or neuroimaging may be normal (Zerr). In two cases o f P I05L 
mutation frontal atrophy with no cerebellar atrophy was reported (Yamada). A 5-OPRl 
patient showed mild cortical and cerebellar atrophy (Beck).
Iatrogenic prion disease has occurred in recipients o f human growth hormone (hGH), 
recipients o f durai grafting and recipients o f blood transfusions from presymptomatie 
patients with variant CJD. In the largest case series (Summers) o f 27 hGH recipients 
and one durai graft recipient 43% had cerebral atrophy and 32% had cerebellar atrophy. 
Changes in late disease included marked atrophy. In a case report o f a hGH recipient 
progressive basal ganglia and cerebellar atrophy were reported (Oppenheim). In a ease 
series o f four durai graft recipients all had cerebral atrophy on CT and MRI, 
predominantly cortical, also with caudate atrophy and progressive in three. In a ease 
report o f blood transfusion acquired iatrogenic vCJD no atrophy was seen (Wroe).
Atrophy in sporadic CJD tends to be more rapidly progressive than other forms o f CJD, 
but most reports are hindered by failing to confirm the diagnosis histopathologically and 
not excluding genetic mutations in the prion gene. Initial reports using CT in the 1970s 
(Rao) described rapidly progressive atrophic changes on serial CT, however in a series 
o f 15 patients reported in 1984, 12 had no atrophy (Galvez).
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In a case series o f 29 eases o f CJD (14 biopsy eonfirmed, rest probable diagnosis, 
genetie analysis not reported) Finkenstaedt found that the degree o f atrophy in the 
eortex and basal ganglia corresponded to the time between onset o f symptoms and MRI. 
All patients with disease duration o f longer than four months had substantial volume 
loss and sequential studies in four patients demonstrated a rapidly progressing cortical 
and striatal atrophy in patients with disease o f more than six months duration 
(Finkenstaedt). Uchino described two histopathologically eonfirmed eases with 
dramatic progression o f brain atrophy over 14 and 17 month intervals (Uchino).
There are no reports o f quantification o f atrophy or rate o f atrophy in human prion 
disease in the literature.
2.5 Atrophy o f  the cerebellum
Age related loss o f cerebellar tissue was first documented by Ellis in 1920, from a post 
mortem examination (Ellis 1920). Techniques to further quantify this change have 
developed from post mortem histopathology, to pneumoencephalography, CT, MR 
stereologic mapping techniques and in vivo three-dimensional MRI volumetry. Cross 
sectional and longitudinal studies have been performed across age groups. The gold 
standard is now serial MRI with image registration to improve sensitivity to change by 
correcting for differences in patient position and orientation. Differentiating volume loss 
within different cerebellar regions is possible, as well as whole cerebellar change. 
Voxel-based differential image analysis software allows visualisation o f site o f atrophy 
as well as quantification. Techniques developed to study normal aging have been used 
to describe disease specific cerebellar changes.
Changes in cerebellar volume are small, thus methods used to detect significant change 
must be chosen carefully. In the late 1990s eonflieting evidence emerged in the 
literature as to how, where and when the normal cerebellum atrophies with age. In a 
volumetric MRI study (Luft 1997) and a T2 weighted stereologieal study (Esealona) no 
significant atrophy with age was found. However one MRI study did show atrophy with 
age (Sullivan). Raz (1997) pointed out that despite methodological differences all 
showed a negative correlation between age and cerebellar volume. Differences could be 
accounted for in correction for head size and different charaeteristies (variance) in age, 
cerebellar volume and head size among the sample groups. More recent work remains
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conflicting, most articles confirming age related cerebellar atrophy (Luft 1999, Liu 
2001, Raz 1998), but one contradicting (Jemigan), In an exponential model used by 
Luft (1999) cerebellar volume was predicted to remain stable until the age o f 50 before 
declining.
Differential rates o f atrophy between cerebellar regions have been investigated by 
several groups by different methods. Histology and CT studies reported pronounced 
volume loss in the anterior vermis (Roller, Torvik). MRI studies have also attempted 
differential analysis. Raz estimated the volumes o f the cerebellar hemispheres and the 
cross sectional areas o f the vermis and ventral pons in 146 healthy volunteers, aged 18- 
77. The cerebellar hemispheres and the posterior vermis showed significant atrophy 
with age. Luft (1999) seanned 48 healthy volunteers aged 19.8 -73.1 and found the 
vermis affected most, followed by the medial hemisphere.
In neurological disease states other than prion disease, cerebellar volume has been 
assessed in temporal lobe epilepsy, progressive supranuclear palsy (PSP) and cerebellar 
ataxia. Cerebellar atrophy was found in neuropathologieal reports o f institutionalised 
epilepsy patients dating back to 1825 (Honavar). There are seven recent reports o f 
quantitative MRI investigations in cerebellar atrophy in epilepsy summarised in 
Hermann et al (Hermann 2005). All reported smaller cerebellar size in the epilepsy 
groups examined, as compared with controls. Predictors o f cerebellar atrophy included 
neurodevelopmental disorders, duration o f disorder (corrected to allow for normal age 
related atrophy, intracranial volume and gender) but not treatment factors such as 
phenytoin use and duration.
In PSP post-mortem studies have shown atrophy o f the superior cerebellar peduncle 
(SCP). A study using VBM aimed to identify areas of regional atrophy in PSP, 
Parkinson’s disease (PD) and normal controls. The SCP was one subeortieal region 
identified as being relatively atrophic in the PSP group (Price). Quantitative MRI and 
blinded neuroradiologieal rating was performed prospeetively on 53 subjects with PSP, 
multiple system atrophy, PD and normal controls to distinguish PSP from other 
neurodegenerative diseases. Mean SCP volume, correeted for total intracranial volume 
was significantly lower in PSP than controls (Paviour).
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In a study designed to eompare the severity o f pure eerebellar ataxia using the 
International Cooperative Ataxia Rating Seale with the eerebellar volume in ehronic 
cerebellar disease, a significant negative correlation was found.
Similar quantitative MRI techniques to those described in the studies reported above 
will be applied to eerebellar volume measurements in patients with prion disease in this 
study.
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Figure 2.5 Legends
(all images acquired as i f  looking up from fee t e.g. left side o f  image is right hemisphere)
(A-C) 56 year oldfemale patient with sporadic CJD.
(A) Axial T2 weighted image shows a subtle increase in signal intensity o f  the left putamen 
anteriorly. The remainder o f  the basal ganglia and cortex appear normal.
(B) Axial diffusion weighted image (DWI) acquired with a b = WOO shows hyperintense signal 
in the heads o f  both caudate nuclei and in both putamina (on the left more than on the right). In 
addition there are gyriform areas o f  hyperintensity in both insulae and in the frontal temporal 
and occipital cortices.
(C) A map o f  the apparent diffusion coefficient (ADC) shows reduced signal in the areas which 
appear hyperintense on DWI image (B), confirming that the diffusion o f  water is restricted in 
these regions.
(D-E) Coronal TI-weighted images o f  a volumetric MRI study in two cases with inherited CJD.
(D) 39 year old female patient with 6-octapeptide repeat insertion. The MRI shows cerebellar 
atrophy with widening o f  the cerebellar fissures and supratentorial atrophy with enlarged 
lateral ventricles and very prominent Sylvian fissures.
(E) 57year old male patient with PI02L mutation. There is marked cerebellar atrophy with 
pronounced enlargement o f  the horizontal cerebellar fissure andfourth ventricle. There is also 
supratentorial atrophy, mostly o f  the central type with ventricular enlargement.
(F-H) 18 year old patient with variant CJD.
(F) Axial FLAIR image acquired seven months after onset o f  symptoms demonstrates 
hyperintensity in the dorsomedial thalamic nuclei andpulvinar bilaterally ( “hockeystick sign ”).
(G) DWI images (b=IOOO) acquired at the same time as (F) also shows hyperintense signal 
change. It is however less marked than on the FLAIR images, appears more linear and affect 
predominantly the dorsomedial nuclei.
(H) DWI acquired one month after (G) demonstrates progression o f  the signal change in the 
thalami, which now more obviously involves the pulvinar. At this stage o f  the disease both the 
T2 weighted and the FLAIR images were degraded by patient movement.
(I-J) 25 year old patient with variant CJD 7 months after onset o f  symptoms.
(I) The axial T2 weighted image is severely degraded by patient movement and o f  limited 
diagnostic value.
(J) The axial DWI image (b -  1000). The patient managed to keep still during the acquisition o f  
this sequence which is diagnostic and shows hyperintense signal in the dorsomedial thalamic 
nuclei and pulvinar, relative to the signal intensity o f  the putamina.
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CLINICAL ASSESSMENT IN DEMENTIA
3.1 Methods o f  assessment in dementia
3.1.1 Clinical Video
Video has an increasing role to play in clinical medicine with a growing number of 
applications across the specialities. Technology has advanced from shoulder carried 
professional cameras with bulky video tapes, to operator friendly hand held digital 
camcorders with small digital tapes, DVDs or hard drives. It is no longer necessary to 
involve a departmental audiovisual department at the image acquisition stage, and even 
video editing and output to DVD is possible using editing software on personal 
computers.
Within the specialty o f neurology, imaging o f movement disorders has proved a useful 
tool in the diagnosis and analysis o f movement patterns and to track symptom 
progression and treatment. EEG video monitoring is used in diagnosis o f epilepsy and 
sleep studies use video to assess movement during sleep.
Clinical teaching has been augmented with examples o f clinical eases and signs 
demonstrated on video. Surgical training often incorporates use o f video in teaching 
basic surgical skills.
Online video publications are now commonplace as they allow immediate visualisation 
o f clinical signs in patients or, for example, new operative techniques or equipment. 
Video conferencing is becoming more commonplace, allowing multiple audiences to 
see operations or clinical demonstrations.
Modem medicine and surgery is dependent on high quality images for many 
applications such as laparoscopic surgery and endoscopy.
3.1.1.1 Clinical video in neurology  
Assessment o f motor function has leant itself well to the video medium. In this study 
various measures o f motor function were videoed, including walking, heel-toe walking, 
rapidly alternating movements, copying gestures and sequential finger tapping.
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Gait assessment has evolved in the computer age into complex three dimensional 
modelling used in orthopaedies and sports medicine, performed in a ‘gait laboratory’. 
Use o f video in gait analysis in dementias with motor signs such as Huntington disease 
has been reported (Reynolds). The use o f video to assess the effect of a drug 
(Clozapine) within a trial setting (double blind randomised comparative study) to 
improve on the voluntary and involuntary motor signs in Huntington disease has been 
reported (van Vugt). In a monkey model o f Parkinson’s disease video was used, along 
with an image analyser system to produce an ‘activity curve’ correlating to motor 
behaviour (Chassain). The use o f video editing software such as Adobe Premiere 
(Adobe Systems Incorporated, San Jose, California, USA) has been reported in studies 
correlating motor behaviour with firing patterns o f neurons in parietal cortex o f 
monkeys (Gardner).
One o f the eharaeteristic motor signs in CJD is myoclonus. Video has been used to 
characterise myoclonus in other dementias, such as Rett syndrome (Guerrini). Articles 
have been published (e.g. Saari) reporting the satisfactory use o f hand held video 
cameras for imaging the face and anterior eye, a technique similar to this thesis.
The MMSE (Mini Mental State Examination, Folstein 1975) is one o f the non-videoed 
tests in this thesis. Various publications have discussed the use o f ‘remote’ scoring of 
the MMSE (e.g. videoconferencing, fax or telephone consultations) versus face to face 
scoring. Although videoconferencing is different from simple video, as images are 
viewed in real time, the same principles should apply.
Ball et al (1999) assessed the reliability o f scoring written items o f the MMSE (sentence 
and pentagrams). Face to face and fax were the most reliable; videoconferencing scored 
sentences reliably, but not pentagrams. They therefore advised caution in accepting 
video results. In an earlier study Ball (1993) found that written material viewed via 
videoconferencing was difficult to score, but that reseoring the written material ‘in 
person’ did not move any subjects into or out o f the range suggesting cognitive 
impairment.
Montani reported the performance o f 15 hospital inpatients over the age o f 75 with no 
known psychiatric history on MMSE (Montani 1997). They found a small but 
significantly lower performance on MMSE when using a videoconferencing system
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than when face to face. Some patients also felt inhibited by the presence o f the 
equipment, and sound quality was sometimes poor. In one study (Ball 1993) o f MMSE 
in a young adult psychiatric population, some patients showed higher attention levels in 
the video consultation than when face to face but there was good correlation between 
the scores. In one type of cognitive assessment (CAMDEX) (Roth) technical video 
problems meant that written test responses could only be scored in person and not from 
video. Other tests o f cognitive function (CAMCOG in Ball 1995) have been used 
reliably over a videoconferencing system without major modification.
Within the PRION-1 trial a BPRS (Brief Psychiatric Rating Scale) assessment is 
videoed with the patient, to allow later independent scoring by an independent 
psychiatrist. The experience of videotaping the BPRS has been described in two papers 
(Overall and Ball 1998).
Other psychiatric ratings using video have been published. In Teri et al caregivers 
assessed depression in dementia patients using video (Teri 1994). They found that 
caregivers were able to correctly identify depression in patients and that the caregiver’s 
mood did not affect this assessment. Fuehs et al describe a double-blind, plaeebo- 
eontrolled trial o f the antidepressant maprotiline in patients with dementia and 
depression where a videoed rating of global impression was used as well as the Mini- 
Mental State Examination (MMSE) and Geriatric Depression Seale (GDS) (Fuehs 
1993). Here video rating was the main parameter o f the study and interrater reliability 
was high. A review o f the use o f digital video in psychiatry is found in Falzone 2005.
Memory is assessed using video in patients with dementia o f the Alzheimer type in 
Rusted et al 2002. In this longitudinal study performance in tea-making was assessed in 
the home setting, and in unfamiliar surroundings over a six year period. The nature and 
pattern o f errors as disease progresses are described.
3.1.1.2 Methods o f  image capture 
Advice has been published as to the best format o f video acquisition in clinical video as 
applied to movement disorders (Jog) and also how to digitally encode, compress and 
transmit the resultant images (Boudier). Similar methods o f image acquisition and 
editing to those used in this thesis have been reported in use in other areas such as 
videoing o f knee arthroscopy (Johnson).
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Many publications describing analogue to digital conversion arc now out o f date as 
technological advances have rendered their advice obsolete (Berges, Miron, Prasad). 
Even during the period o f this thesis the shift from Mini DV format to DVD or hard 
drive recording has occurred.
A cautionary note is struck by Rothenberg when he calls into question the longevity of 
digital documents such as video. Despite the rapid evolution o f this technology, it is 
only as useful as the software necessary to interpret the data, and only accessible as long 
as the hardware and software necessary to view it do not become obsolete.
3.1.2 Dementia Rating Scales
3.1.2.1 Overview
The increasing understanding o f the causes and mechanisms o f dementia have meant 
that more potential therapeutic agents are entering clinical trial phase in humans than 
ever before. Clinical trials have to be designed carefully in order to detect change and 
efficacy o f new treatments. Where possible randomised controlled trials should be used 
(double blinded and placebo controlled), with patients having fulfilled established 
diagnostic criteria to allow entry; the aims o f the trial should be clear (either halting 
decline or showing improvement). In dementia the choice o f rating scale (the outcome 
measure) is critical.
A problem often encountered is that treatments may only be useful in a subset o f the 
patients with a disease. Understanding the normal progression o f decline with a set o f 
clinical scales is thus paramount, so that any change from the background non-treated 
disease population can be detected. It is important to have the ability to assess a range of 
treatment responses, both in groups and individuals.
The multifaceted nature o f dementia means that many functional areas should be 
assessed such as physical and social ability, behaviour, emotional response and 
relationships, overall function, as well as cognition.
Many dementias have their own disease specific scales, tailored to the disease. There is 
also a group o f  tried and tested rating scales that are used more generally, and this 
allows comparison between the dementias, and between different treatments in the same 
disease.
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Outcome measures ean be organised into six groups:
( i ) Cognitive tests
(2) Clinieians’ global assessments o f severity
(3) Clinieians’ global assessments o f ehange
(4) Behavioural ratings
(5) Funetional assessments
(6) Comprehensive rating seales
3.1.2.2 Cognitive tests 
Cognitive tests are often the primary measure o f effieaey in elinieal trials. Measures 
used inelude the Alzheimer’s Disease Assessment Seale (ADAS) (Rosen), the Syndrom 
Kurztest (SKT) (Erzigkeit, Overall 1992), the Information-Coneentration-Memory 
subtests (ICM) from the Blessed-Roth Dementia Seale (Blessed), the Mattis Dementia 
Rating Seale (DRS) (Mattis), and the MMSE (Folstein).
Most reeent elinieal trials for AD have used the eognitive subseale o f the ADAS 
(ADAS-COG) to measure eognitive ehange. It was designed as a battery o f tests to 
assess impairments seen in AD, and takes around an hour to perform. The ADAS-COG 
has revealed signifieant differenees in randomised eontrolled trials with eholinesterase 
inhibitors and other drugs.
The Syndrom Kurztest (SKT) assesses attention and memory using nine performanee 
subtests, eaeh limited to one minute and has been used particularly in clinical trials in 
German-speaking eountries. The SKT has been used as a eognitive outeome measure in 
elinieal trials o f various drugs aimed at enhaneing eognition.
The MMSE was developed as a eognitive sereening test, but has proven to be useful in 
staging and to be sensitive to change. It takes around 10 minutes to perform.
Other tests used often in dementia inelude the Information-Coneentration-Memory 
(ICM) Test whieh uses eomponents o f the Blessed-Roth Dementia Scale and the 
Cambridge struetured interview to assess orientation, long-term memory, recall, 
concentration and performanee. The Mattis Dementia Rating Seale seore attention, 
perseveration, praxis, abstraetion, verbal and non-verbal reeent memory.
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The Severe Impairment Battery (SIB) (Saxton) was developed for severely impaired 
patients and uses single words or one-step commands combined with gestures. Its use 
would be similar to the Severely Affected Protocol used in this thesis, i.e. those with an 
MMSE score less than 10 who are unable to perform the ADAS-COG.
Problems can be encountered when scores ‘floor out’, thus scales aimed at the later 
stages o f disease have been developed. The Level o f Cognitive Functioning Scale 
(LCFS) is one o f the early scales used to assess eognitive functioning in post-coma 
patients (Hagen 1972). It was developed for use in the planning o f treatment, tracking of 
recovery, and classifying of outcome levels. Eight levels are used to classify patient 
response from 1 -No response to V lll -Purposeful-appropriate. It is also useful in 
tracking the opposite situation of decline.
3.1.2.3 Clinicians ’ global assessments o f  seventy 
Assessing severity helps the clinician to give prognostic information and plan optimal 
care. It can also be used to stage entry into clinical trials. These tests often encompass a 
wider range o f symptoms than cognitive tests and are thus a better way o f tracking 
disease progression.
Examples o f these tests include the Clinician’s Global Impressions -  Severity o f Illness 
scale (CGIS) (Guy), a non specific 7-point scale ranging from 1 (normal) to 4 
(moderately ill) to 7 (among the most extremely ill). The Clinical Dementia Rating 
Scale (CDR) (Morris) is a five point scale determined by struetured interview with 
patient and carer. It either stages dementia, including cognitive, funetional and social 
assessment or measures ehange by summing scores. The Global Deterioration Seale 
(GDS) (Reisberg) is a seven point staging o f dementia (l=norm al, 3=late confusion, 
5=middle dementia, 7=late dementia) that does not require an interview.
3.1.2.4 Clinicians ’ global assessments o f  change
This category o f elinieal assessments measures change from a specified baseline. The 
rationale is that a clinician should be able to see the elinieal effect o f a treatment after a 
short interview. These measures are fairly unstructured whieh limits their sensitivity.
The most commonly used measure is the Clinician’s Global Impression o f Change 
(GIC) whieh has been used in many early clinical trials for anti-dementia drugs. An 
impression o f ehange is scored by the clinician from l=very much improved to 7=very
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much worse. The CIBIC (Clinicians’ Interview-Based Impression o f Change) which 
uses a similar 7 point scale to the GIC, and the CIBIC+ which additionally interviews 
the caregiver as well as the patient are also commonly used, but is a more in depth 
interview than the GIC.
3.1.2.5 Behavioural ratings
Behavioural ratings are not often used in clinical trials as patients are often selected on 
the basis o f those who do not have significant behavioural symptoms such as agitation, 
depression, delusions and hallucinations. The most commonly used scale is the ADAS 
non-cognitive behaviour subscale (Rosen) which assesses tearfulness, depression, 
concentration, uncooperativeness, delusions, hallucinations, pacing, motor activity, 
tremors and appetite on a 6-point (0 to 5) severity scale. The Behavioural Pathology in 
AD seale (BEHAVE-AD) (Reisberg) assesses 25 well-defined behaviours in seven 
areas, rated as mild, moderate, or severe. The Brief Psyehiatrie Rating Scale (BPRS) 
(Overall 1962) uses an interview by an experienced clinieian; 18 items are rated on a 7- 
point severity scale. The Neuropsychiatrie Inventory (NPI) (Cummings) assesses 13 
behaviours on the basis o f frequency and severity.
3.1.2.6 Functional assessments
Activities o f daily life are an important and praetical assessment o f a patient’s ability to 
maintain independent living. Assessments are usually performed with both carer and 
patient present. The Rankin and Barthel scores are most often used currently in clinical 
trials, the former due to its brevity and the latter due to its good assessment o f 
longitudinal function. In the past, the Physical S e lf  Maintenance Scale (PSMS) and the 
Instrumental Activities o f Daily Living (lADL) (Lawton) were used with newer tests 
such as the Progressive Deterioration Scale (DeJong) and the Interview for 
Deterioration in Daily living activities in Dementia (IDDD) (Teunisse) adding to the 
areas tested and the number o f rating points, structuring the interview.
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3.1.2.7 Comprehensive rating scales 
These scales assess patients on a range o f cognitive, behavioural, motor, and daily 
activities. Examples inelude the Gottfries-Brane-Steen (GBS) (Gottfries) and Sandoz 
Clinical Assessment Geriatric (SCAG) seales (Shader). The GBS is a 26-item, 7-point 
seale assessing motor performance, intellectual impairment, emotional impairment, and 
other symptoms. The SCAG includes 18 cardinal signs and symptoms o f dementia rated 
by the clinician.
The Disability Rating Seale (DRS) (Rappaport) was developed for patients with 
moderate and severe traumatic brain injury (TBI) to accurately measure general 
functional changes in an inpatient setting. The DRS ean track an individual from coma 
(seore o f 29 ==extreme vegetative state) to community living (without disability=0). 
Measurement areas include eye opening, communication, motor response feeding, 
toileting grooming and employability. The DRS is insensitive at the low end o f the scale 
and cannot detect subtle changes, but has use in measuring decline once symptoms are 
established.
The heterogeneity o f disease in dementia means that many seales have been devised in 
an attempt to capture the stages o f decline that are clinically useful and that measure 
change in treatment trials. Much can be learnt from the different seales applied to 
dementia and head injury as there is significant crossover. Selection o f an appropriate 
seale is crucial in outcome measurement o f clinical trials.
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CLINICAL TRIALS IN HUMAN PRION DISEASE
4.1 The PRION-1 trial
The PRION-1 trial was a three year partially randomised patient preference trial to 
evaluate quinaerine in all types o f human prion disease in the UK. Patients were placed 
into three groups according to preference and willingness to be randomised, and 
followed the same schedule o f evaluations. The first group included patients who were 
willing to be randomised to immediate open-label quinaerine versus no quinaerine with 
the option o f starting open-label quinaerine after six months.
At the design phase o f the trial it was felt that in a universally fatal and often rapidly 
progressive disease, very few patients would be willing to enter a randomized trial, thus 
two more patient preference groups were created. The second group had a preference 
for receiving quinaerine immediately, and the third had a preference for not receiving 
quinaerine.
Eligible patients were adults or children aged 12 years or over diagnosed with any type 
o f human prion disease, and without elinieal or laboratory abnormalities contra­
indicating use o f quinaerine.
PRION-1 recruitment took place over two years, with follow-up o f one year after the 
last patient had been randomised or enrolled. It aimed to enrol and follow up 160 
patients until the end o f the trial, with 80 patients in the randomised arm.
Lack o f deterioration in the digital visual recording o f the neurological exam was a 
primary effieaey endpoint. Secondary efficacy endpoints were non-videoed neurological 
changes, including changes in markers o f disease activity, MRI, EEG and neurological 
assessments, where appropriate.
PRION-1 was the first UK clinical trial in human prion disease and aimed to establish 
an appropriate framework for the clinical assessment o f therapeutic options for human 
prion disease that could be refined or expanded in the future, as new agents become 
available.
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x t ic r
Quinaerine (Mepacrinc hydrochloride) is known to 
penetrate the CNS and acts as a stimulant. There is no 
basis for assuming that quinaerine would be more or 
less effective for any CJD subtype as no studies with 
human prion strains, human cell lines, or transgenic 
Figure 4.1 Quinaerine structure mice expressing human prion proteins are available. 
Transgenic mice studies with quinaerine to date have failed to show a prolongation of 
incubation time.
PRION-1 is the fifth trial o f quinaerine in human prion disease, and the first attempt at a 
controlled clinical trial in a larger cohort o f CJD patients. Four previous studies had 
between one and four patients (Seoazec, Nakajima, Kobayashi, Benito-Leon); a French 
study o f 32 severely affected CJD patients showed a slight, but non-statistically 
significant increase in survival duration (Haik 2004). A randomised trial comparing 
quinaerine, quinaerine plus chlorpromazine and placebo in human prion disease began 
in the United States in 2001. A randomised, placebo-controlled study from the same 
group investigating the efficacy o f quinaerine in sporadic CJD in over 100 patients 
began in March 2005. Results are awaited.
An open-access programme in France was less encouraging; 14 out o f 20 patients 
receiving quinaerine died between one week and three months after starting treatment. 
O f the four continuing to take quinaerine, three were stable and one had deteriorated 
(Prion Therapeutics Abstract). However, many o f these patients had late stage disease at 
enrolment into the programme.
Previous clinical experience at the National Prion Clinic with quinaerine includes 
several examples where subjective improvement o f elinieal state was noted for a period 
o f time by patients, carers or family members. This has also been reported by other 
investigators. The key objectives o f the PRION-1 trial were to determine whether 
quinaerine has a signifieant effect on cognition or survival duration in all types or 
particular sub-types o f human prion disease.
This thesis has different aims than those o f the PRION-1 trial, but includes data from 
patients taking part in the pilot phase o f the PRION-1 trial and all but the last six 
months o f the full PRION-1 trial. Fewer patients were recruited into PRION-1 than had
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been predicted. The small number o f patients in the trial, and the small numbers taking 
quinaerine mean that no comparisons have been made between quinaerine treated and 
non-treated groups. This limitation has not affected the main aim o f this thesis, to 
demonstrate and quantify associations between elinieal measures and MRI measures in 
human prion disease.
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METHODS
5.1 Subjects
Subjects were participants in the pilot or full phase o f the PRION-1 trial. Only those 
patients with two or more MRI scans were included, and the first clinical assessment 
used in this thesis was that performed at the same time as the first MRI scan. Consent 
for the trial was obtained at enrolment and consent for video and MRI was reconfirmed 
at each time point.
A control group o f 12 age and sex matched normal subjects was identified for 
comparison with the pilot patients. They had been scanned at St Mary’s Hospital, Praed 
Street, London as part o f a group o f 25 controls for a familial Alzheimer’s study using 
the same scanning protocols as this study. These patients were all recruited with 
appropriate consent to this ethically approved study. The principal investigator and 
research governance officer eonfirmed the appropriateness o f inclusion o f these controls 
in this thesis from a consent and ethics point o f view (See Appendix B consent form). 
Table 5.1 Demographics table fo r  Pilot and Control Patients
PILOT CJD type A Sex Symp Quin
30-34 35-39 40-44 45-49 50-54 55-59
I PI02L x (x ) M No No
2 6-OPRI x (x ) M Yes No
3 6-OPRI x (x ) M Yes Yes
4 A II7V
X (x) F Yes Yes
5 6-OPRI
X (x) M Yes Yes
6 6-OPRI x (x ) F Yes Yes
7 6-OPRI
X (x) M Yes Yes
8 6-OPRI
X (x) F Yes Yes
9 6-OPRI x (x ) F Yes Yes
10 6-OPRI
X (x) M Yes Yes
II PI02L
X (x) F Yes No
12 PI02L x (x ) M Yes Yes
Pilot age = X Paired control age = (x)
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All but three control patients were within one year in age from their paired pilot patient. 
These patients had between two and five years difference in age.
Table 5.2 Demographics table fo r Full Trial Patients
FULL CJD type Age Sex Symp Quin
30-34 35-39 40-44 45-49 50-54 55-59 60+
1 sCJD X F Yes Yes
2 A117V X M Yes Yes
3 vCJD X M Yes Yes
4 P102L X M No No
5 P102L X M No No
6 Q212P X F Yes No
7 6-OPRl X M Yes Yes
8 6-OPRI X F Yes No
9 E200K X M No No
10 Y163X X F Yes Yes
11 6-OPRI X M Yes Yes
12 6-OPRI X F Yes No
13 6-OPRI X F Yes Yes
14 P102L X M Yes Yes
15 D178N X M No No
16 sCJD X M Yes No
17 6-OPRI X M Yes Yes
18 6-OPRI X F Yes Yes
19 P102L X M Yes Yes
20 P102L X M Yes No
21 5-OPRI X F Yes No
22 P102L X M Yes Yes
23 A117V X F No No
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5.2 MRI Examination
5.2.1 MRI procedure
The process o f performing an MRI was defined in a standard operating procedure (SOP) 
(Appendix C). Eaeh patient was given a patient information sheet on MRI (Appendix 
A). Pilot patients were scanned at St M ary’s Hospital, Paddington, London and full trial 
patients were scanned at the National Hospital for Neurology and Neurosurgery, Queen 
Square, London.
MRls were performed at 0, 1, 2, 4 and 6 months and thereafter 3 monthly (see Appendix 
D- Schedule for follow up). As patients often had involuntary movements or were in 
relatively late stage human prion disease, sedation with an oral sedative was sometimes 
required. A clinieian monitored each patient throughout the scan. Some patients 
required general anaesthesia (GA), a Standard Operating Procedure was used (see 
Appendix E) and consent was reconfirmed, MRI under GA was carried out at the 
discretion o f the treating clinieian, with priority given to main assessments at months 0, 
2, 6 and 12.
5.2.2 MRI acquisition and preprocessins
Scans were performed by the staff at St M ary’s Hospital, Paddington and the National 
Hospital for Neurology and Neurosurgery MRI department. The scanning protocol used 
for the pilot study was matched in the full study. In the full trial Diffusion/ADC, DTI, 
FLAIR, MT and spectroscopy were also performed, but were not used in volumetric 
analysis.
All volumetric scans were T1 weighted and acquired on a 1.5 Tesla Signa unit (General 
Electric, Waukesha, Wl, USA) as 124 contiguous 1.5mm coronal slices using a standard 
imaging protocol. Images were taken using a 256x128 image matrix with the field o f 
view being 24cm (acquisition parameters: repetition time=35ms; echo time=5ms; flip 
angle=35°).
After each scan the radiographer completed a Prion-1 Trial MRI Proforma (Appendix
F). The volumetric sequences were transferred to a Sun Blade 1500 workstation (Sun 
Microsystems, Mountain View, CA) either via optical disc or image link for analysis.
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5.2.3 Imase process ins 
Image processing was performed using the MIDAS (Medical Image Display and 
Analysis Software) software tool (Freeborough 1997a) according to the SOP for Whole 
Brain Segmentation o f T1-Weighted Volumetric MRI o f the Dementia Research Centre.
5.2.3.1 Bias Correction
Eaeh scan was bias corrected to even out any intensity inhomogeneity (the slowly 
changing and smooth spatial variation in signal intensity that ean occur within a scan). 
Bias ean be caused by inhomogeneity o f the magnetic field o f the MRI system, 
inhomogeneity o f the radiofrequeney pulse or nonuniformity in the sensitivity o f the 
receiver coils used to detect the MR signal. Different techniques have been used to 
remove this bias field on individual scans, such as an intensity histogram sharpening 
technique called N3 (Sled) used in this ease.
Eaeh scan underwent segmentation, registration and brain boundary shift integral (BSI) 
calculation from which rates o f brain atrophy were calculated. Whole brain and 
eerebellar analysis was performed. All image processing was done in a blinded manner, 
using the ‘blind load’ facility, thus the segmenter had no knowledge o f the patient or 
date o f scan.
5.2.3.2 Segmentation
This semi-automated process outlined the brain. A single segmenter (myself) performed 
all analysis. After training at the Dementia Research Centre, intrarater and interrater 
variability was calculated. A value o f <1% intrarater and interrater variability was 
achieved after training (mean intrarater difference 0.32%, SD 0.65%, mean interrater 
difference 0.41% SD 0.28%).
The aim of segmentation was to label all voxels which were predominantly brain while 
excluding non-brain (e.g. CSF, dura and the superior sagittal sinus). Whole brain 
segmentation was accomplished in the following steps:
1. Intensity Thresholding - thresholds are set with the morphological segmentor tool to 
exclude voxels brighter than brain (e.g. scalp) and darker than brain (e.g. CSF) (Figure 
5.1).
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Figure 5.1 (left) The morphological segmentor tool used in segmentation o f MRI scans 
(right) Upper and lower thresholds set to include brain and exclude scalp and CSF
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The axial cut-off level is set to 
remove any structures below 
the inferior edge o f the 
cerebellum (Figure 5.2).
Figure 5.2 The axial cut-off 
(red line) should coincide with 
the bottom o f the cerebellum.
2. Erosion -  this stage removes a layer of edge-voxels from all surfaces to leave the 
largest connected three-dimensional object in the current region. The purpose is to break 
thin connections between brain and non-brain (Figure 5.3). Often the brain remains 
connected to scalp on a few slices, connections can be broken manually using the 
interactive connection breaker (mouse operated).
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mFigure 5.3 An eroded brain region disconnected from surrounding tissue.
3. Dilation - the purpose of this step is to recover the brain voxels that have been 
removed by erosion. Each dilation grows out from the edges o f the current brain region 
but only into voxels within the currently defined range o f intensities which represent 
brain (Figure 5.4).
Figure 5.4 Dilations recover previously eroded brain voxels.
4. Rethresholding -  reclaims any remaining excluded voxels internal to the brain region.
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5. Manual editing - in cases where either some 
non-brain tissue remains in the segmentation, 
or brain tissue has been omitted, manual 
editing may be required using an irregular 
volume window (Figure 5.5). New borders ean 
be redrawn manually and new regions ean be 
ineluded by plaeing a ‘seed’ in the appropriate 
area. Alternatively new upper and lower 
thresholds ean be seleeted to automatieally 
delineate structures.
Figure 5.5 Irregular volume segmentation tool
6. Brain volume -  a whole brain volume in mm eubed is ealculated.
5.2.3.3 Registration
A nine degrees-of-freedom rigid registration was performed to align the repeat seans of 
a patient onto their baseline image (first sean) (Freeborough 1996). A visual 
representation o f the site of boundary change was generated, red for apparent loss 
(atrophy) green for apparent gain (Figure 5.6).
Figure 5.6 Example o f a registered image Red=atrophy Green = apparent gain
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Atrophy was quantified using the brain boundary shift integral (BSI) (Freeborough 
1997b). The BSI determines the total volume through whieh the boundaries o f the brain 
have moved (volume change) directly from voxel intensities. It is robust to 
segmentation errors.
5.2.3.4 Differential bias correction 
Several registered scan pairs still showed intensity inhomogeneity despite N3 bias 
correction (Figure 5.7). All scan pairs therefore underwent differential bias correction 
during registration to eliminate this confounding effect. The more similar the baseline 
and follow up scans in terms of grey matter/white matter contrast and intensity the 
better the quality of quantifications and localisation o f change. The bias field of a scan 
pair may be differentially adjusted (such that the bias field of the difference between the 
images is corrected) to make the bias o f the scan pair similar (Lewis). This form of bias 
correction will not correct for bias that is common to both images. Differential bias 
correction can be applied with or without individual scan bias correction.
Figure 5.7 Coronal MRl showing intensity inhomogeneity, before (A) and disappearing 
after (B) differential bias correction.
5.2.3.5 Independent quality control process 
A person (RS) experienced in performing segmentation, registration and quality control 
o f volumetric MRI scans reviewed the entire database o f scans. They were blinded to all 
patient details.
The following factors were assessed for whole brain segmentation (see Figure 5.8 for 
examples):
1) Scan quality
same imaging protocol appearance between scans
76
no movement artefact, or minor and consistent between scans 
brain/CSF boundary definition adequate on ail slices
all intraeerebral structures included (no sean cut off, particularly posteriorly) 
absence o f confounding structures e.g. post operative changes from brain biopsy, 
new changes affecting volume e.g. large cerebral infarcts
2) Segmentation quality
no omitted slices
no errors o f inclusion o f non-brain material 
no errors o f exclusion o f brain material
good paired segmentation (same/similar thresholds used in pairs)
(where segmentation errors were identified the brain was resegmented)
3) Registration quality
good technical registration 
no image flipping 
no ‘stretch’
no/minimal image intensity gradation difference between scans (bias)
4) Intra-patient review
where baseline scan was o f adequate quality but inferior to the rest o f the seans 
for a patient, the original baseline sean was excluded and a new baseline chosen. 
Registrations were performed with the new baseline scan.
5) Singleton scans
Patients with only one scan were excluded from longitudinal analysis
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Figure 5.8 Examples o f inadequate scans: (A) Movement artefact, mild but distorts the 
brain/CSF boundary, crucial in determining volume. (B) Frontal brain biopsy. (C) 
Anterior and Posterior cut off points overlap with brain. (D) Early protocol used in 
error, image quality different, grainier.
5.2.3.6 Cerebellar segmentations 
Cerebellar segmentation and registration to baseline was performed on the same set of 
patient scans that were deemed of adequate quality in the independent assessment of 
whole brain registrations. The scans had been bias corrected before segmentation, and 
registered with differential bias correction to baseline using a nine degrees-of-freedom 
registration.
Cerebellar segmentation was then performed according to the SOP for cerebellar 
segmentation at the Dementia Research Centre (Figure 5.9). MIDAS software was used, 
as for whole brain segmentation. Intensity thresholds used were the 60% mean values 
from the whole brain segmentations. Segmentation was performed on all slices from 
anterior to posterior, including cerebellar cortex, superior cerebellar peduncle being 
excluded until there was contiguous tissue superiorly. Coronal and sagittal planes were 
checked to ensure all cerebellar tissue was included. Cerebellar volumes were then 
calculated.
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Figure 5.9 Cerebellar segmentation. Segmented coronal view of (A) anterior cerebellum 
(B) superior cerebellar peduncle (C) posterior cerebellum.
Cerebellar BSI calculation was performed for each scan pair in each patient. Cerebellar 
BSI calculation, unlike whole brain BSI calculation has not been previously validated. 
The windows of image intensity specified for cerebellar BSI calculation were modified 
from those used in whole brain BSI calculation, to account for the fact that cerebellar 
mean intensities were approximately 80% of mean whole brain intensity. This method 
improves the accuracy o f cerebellar rates o f atrophy by tailoring the windows of 
intensity used to a cerebellar range o f intensity (Boyes).
All image processing was done in a blinded manner, using the ‘blind load’ facility, thus 
the segmentor had no knowledge o f the patient or date o f scan. Attempts were made to 
register all scans to ‘standard space’, a composite mask o f 125 brain scans, used to 
standardise the position of the brain before segmentation and registration. However, 
technical difficulties could not be overcome, thus scans registered/standardised to the 
baseline image in each patient were used.
5.2.3.7 Independent assessment o f cerebellar segmentation and 
registration
A person (SP) experienced in performing segmentation, registration and quality control 
o f volumetric MRI scans reviewed the entire database o f scans. They were blinded to all 
patient details.
The following factors were assessed for cerebellar segmentation and registration: 
Segmentation quality
no omitted slices
no errors of inclusion of non-cerebellar material
no errors of exclusion o f cerebellar material
good paired segmentation (same/similar thresholds used in pairs)
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Intra-patient review
When one patient had a large set o f cerebellar segmentations the same cut off slice for 
inclusion of cerebellar peduncles was used for all scans in that patient, regardless of 
contiguous tissue superiorly, to avoid the error introduced by the transition from 
inclusion to exclusion of the superior cerebellar peduncle.
Finally a scatterplot of cerebellar volume change against cerebellar BSI was done to 
double check those segmentations in outlying points (highlighted in different colours in 
an example scatterplot shown in Figure 5.10 below).
Figure 5.10 Scatterplot o f cerebellar volume change against cerebellar BSI
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5.2.3.8 Control Group 
The control group comprised twelve normal control patients scanned twice on the St. 
Mary’s scanner, an average o f 650 days between scans (range 385-1128) over a period 
of seven years (1993-1998). The pilot study used the same MRI scanner (2000-2004). 
No scanner upgrades were performed at any time during these periods. Whole brain and 
cerebellar volumes and BSI calculations were performed using the same methods and 
protocols as the other subjects. Segmentations were performed blinded to patient name 
and date of scan, using the blind load facility. The same segmentor (myself) performed 
all analysis.
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5 .23 .9  Change in MRI scanner between pilot and full phase o f  
trial
Longitudinal analysis o f brain atrophy can only be assessed reliably when a single MRI 
scanner is used, and no software upgrade has been performed. As a cohort o f patients 
moved from the pilot phase to the full phase o f the trial, an attempt was made to 
evaluate if  there was any reliable ‘transfer faetor’ whieh would allow longitudinal 
analysis to be performed aeross scanner in these patients. Four sean pairs were 
performed in three patients, one sean at each scanner within 24 hours o f each other. 
Imaging protoeols were matehed in both seanners, but not identieal. No consistent 
‘transfer factor’ in whole brain volume was found when brain volumes were calculated, 
and the sean pairs eould not be registered together due to the slightly differing imaging 
protocols. It was accepted that no ‘transfer factor’ to allow direct longitudinal analysis 
of both pilot and full trial could be applied, eonsequently only repeat within-seanner 
data was used.
5.2.3.10 Rate o f  atrophy
Once whole brain and eerebellar volumes and BSIs had been caleulated, a rate of 
atrophy was determined using the following equation using first and last scans:
Rate (%/yr) = Last BSI x 100 x interval in davs 
initial volume 365
Described in words, the amount o f volume change (Last BSI) was divided by the initial 
volume and deseribed as a percentage (xlOO), this percentage change was then made 
into an annual percentage ehange (Rate) by multiplying by the time interval in years 
(interval in days/365).
5.2.3.11 Statistical analysis
The principles used in the statistical analysis o f longitudinal MRI data are described in 
Frost et al 2004. The BSI is a ‘direet’ measure o f ehange, unlike a ‘subtraeted’ measure 
of ehange sueh as subtracting a repeat brain volume from a baseline brain volume. The 
analysis o f repeated ‘direct’ measures o f change sueh as BSI in longitudinal imaging 
improves the statistieal power and precision in measuring outeomes in a clinical trial. 
Measurement error in a direct measure o f ehange is antieipated to be less than an 
indirect measure made by subtraction o f two measured brain volumes. This analysis is
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more complex as within-person consecutive measures are not independent o f each other 
and therefore the correlation structure is different.
This technique has been used in calculating brain volume changes in Alzheimer’s 
disease when two seans are acquired one year apart (Freeborough 1997b), and rates of 
brain atrophy acquired this way discriminate well between AD and normal ageing (Fox 
1997a). This method has been used as an outcome measure in a trial o f an antibody in 
AD (Fox 2005) and eould be applied to studies attempting to identify predictors of 
disease progression, sueh as this one. Scanning protoeols in trials that involve repeated 
seans (three or more times) increase the statistieal power. The use o f monthly scans for 
the first three months of the sometimes rapidly progressive disease course in CJD, 
followed by a series o f repeat seans is therefore justified in this study.
Linear mixed models are designed for the analysis o f longitudinal data. Frost et al 2003 
describe how a family o f linear mixed models ean deal with the correlation structure 
required by analysis o f ‘d ireef changes. The reduced variability o f these changes means 
that mean atrophy rates ean be estimated more precisely, whieh is particularly important 
in this study where a small dataset is used, and changes (particularly in small local 
structures sueh as the cerebellum) are small. This framework also allows flexibility in 
number o f follow-up visits at different time intervals (a common occurrence even within 
the structure o f the trial). Accelerations in atrophy rates ean be explored by using 
quadratic time terms (see Chan), rather than linear models.
Analysis was performed using the statistieal programme Stata (StataCorp 2005. Stata 
Statistical Software: Release 9. College Station, TX: StataCorp LP.) and Microsoft 
Excel (Microsoft Corporation, One Microsoft Way, Redmond, WA, USA).
82
5.3 Videoed clinical examination
5.3.1 Video in the PRION-1 trial
A digital visual recording o f a standardised neurological examination was performed on 
all trial patients at each trial assessment. Other neurological measures sueh as the 
MMSE, CDR, Rankin test, ADAS-COG, GCS, GIC and Barthel, were also performed 
during the assessment, but not videoed.
5.3.2 Standardised Neurolo2ical examination
Clinical examination consisted o f a formalised examination based on the Queen Square 
format, summarised on a standardised neurological examination form (see Appendix
G). There were three sections, a 15 point cognitive, 11 point motor and an overall 
assessment. (Abbreviations used in the rest o f the thesis are shown in parenthesis.)
The cognitive tests comprised:
1) Memory task -  patients were asked their name, age, and either the month of 
their birthday or if  they were married. (ME)
2) Letter cancelling task -  patients were asked to identify all oeeurrenees o f a 
designated letter in a grid o f different letters. (EC)
3) Line drawing task -  ten drawings o f common objects were printed on a page,
and the patient was asked to name them. (LD)
4) Reading Passage -  one of three paragraphs was placed in front o f the patient 
who was asked to read the passage, and remember as much as they eould. (RP)
5) Spelling task -  the patient was asked to spell six designated simple words. (SP)
6) Fragmented letters task -  the patient was asked to identify three letters that had 
been fragmented. (FL)
7) Fragmented Objects task -  four line drawings o f objects, with some elements o f 
the object removed were asked to be identified. (FO)
8) Calculation task -  four increasingly difficult addition tasks. (CA)
9) Miming task -  patients were asked to show how they would brush their teeth,
comb their hair and use a screwdriver. (Mf)
10) Copying Gestures -  patients were asked to copy three hand gestures. (CG)
11) Frontal lobe sequencing task -  alternating hand movements were copied. (FL)
12) Words beginning with a letter task -  patients were asked to name as many words 
beginning with a particular letter as they could. (WC)
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13) Proverbs -  interpretation o f two eommon proverbs e.g. ‘strike while the iron is 
hot’, ‘too many eooks spoil the broth’. (PV)
14) Digit span -  3 to 7 number digit span was tested e.g. 345, 5284, 39568, 194738, 
7931645. (OS)
15) Reeall -  reeall o f the passage read out previously was tested. (RC)
Examples o f pieture tests are given in Appendix H.
The motor tests eomprised:
1) Eye movements -  full range o f eye movements tested, as well as pursuit. (EM)
2) Finger nose testing -  bilateral finger nose testing. (FN)
3) Rapid alternating task -  patient tapped front and baek o f hand on opposite palm, 
performed bilaterally. (RA)
4) Sequential index finger tapping -  performed bilaterally. (SI)
5) Sequential opposition -  thumb opposed to eaeh finger, repeated bilaterally. (SO)
6) Primitive reflexes -  glabellar tap, pout reflex and palmomental reflex. (PR)
7) One minute observation -  for abnormal movements in all four limbs. (OM)
8) Walking -  asked to walk length o f room. (WA)
9) Heel toe walking -  asked to walk heel to toe for the length o f the room. (HT)
10) Rombergs test -  assess stability standing upright with eyes shut. (RH)
11) Neurologieal examination -  tone, power and reflexes assessed bilaterally. (NE)
The overall assessment seetion asked whether the patient was able to eope with task 
demands, whether the overall level o f attention and eoneentration was satisfaetory and if 
the patient was eooperative. Overall impression o f eognitive, extrapyramidal, pyramidal 
and eerebellar impairment was also assessed.
In order to minimise learning efleet, three versions o f eaeh o f the five pieture tasks test 
were developed and presented at random to the patient. Eaeh test was seored by the trial 
elinician earrying out the assessment. To ensure that the neurologieal rating seales were 
applied consistently, they were always carried out by one o f the two PRION-1 trial 
clinicians, and videoed by one o f the trial nurses.
5.3.3 Severely Affected Protocol (SAP)
A truncated version o f the standardised neurologieal examination was performed for 
severely affected patients, defined as those who seored 10 or less on the MMSE, or had
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a GCS o f less than 15. These tests ineluded the memory test, eye movements, primitive 
reflexes, one minute observation, walking and neurologieal examination, and are starred 
on Appendix G (Neurologieal Examination Form).
5.3.4 Storyboard
Filming o f the examination was performed aceording to a standard storyboard (Figure 
5.11) whieh defined the eamera and shot that should be used to eapture the response in 
eaeh test. Ineluded in the storyboard was a label shot at the beginning o f the 
examination for eaeh eamera giving the patient’s initials, date o f birth and date o f 
assessment.
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story board for Prion-1 Trial videos
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Figure 5.11 Storyboard for PRION-1 Trial Videos
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5.3.5 Equipment
Two digital camcorders were used to film each examination. One was placed on a tripod 
at shoulder height, and the other clamped to the table in front o f the patient to capture 
responses to the tabletop cognitive tests and for better sound recording. Mini-DV format 
cameras were used, each Mini-DV tape was labelled with the trial study number o f the 
patient and week o f assessment.
5.3.6 BPRS (Brief Psychiatric Ratins Scale)
Psychiatric status was assessed by an independent Consultant Psychiatrist using the 
videoed BPRS, providing a final seore ranging from 7 to 168. The BPRS scored 24 
items on a qualitative scale from 1 to 7 (according to whether the symptom was absent, 
very mild, mild, moderate, moderately severe, severe or extremely severe). Components 
included anxiety, depression, hostility, disorientation and blunted affeet. Quinacrine is 
known to have psychotie side efleets in a minority o f patients, and CJD itself can be 
associated with a number o f psyehotic features. Unfortunately independent assessment 
o f the BPRS videos could not be completed in time for this thesis, so no further 
discussion o f BPRS is made.
5.3.7 Post acquisition processins
After each video was recorded the labelled tape was stored in a labelled box in the 
National Prion Clinic (NPC) offices. Each visual recording was then allocated a 
randomised video identifieation number for the purpose o f independent assessment.
Each patient was allocated a number (e.g. 45) and each visual recording o f that patient 
was given a random number (e.g. 5). A "Prion Videos Master List" o f the video 
identifier numbers was kept on a password secured PC.
Digital tapes were edited using Adobe Premiere Pro^^ video editing software (Adobe 
Systems Incorporated, San Jose, California, USA). The original visual recording was 
separated into individual clips for each test o f the examination. These clips were 
converted into .avi files using the video editing software.
Eaeh edited visual recording was then assembled into a set order o f examinations, 
starting with a disclaimer notiee, and with the video identifier number displayed at all 
times. Eaeh clip was labelled and shown in the specified order, separated by five
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seconds o f blank video. A disclaimer notiee was shown at the end. If a severely affected 
protocol was used, this was labelled at the start.
A DVD o f the final sequenee was burned using the video editing software and labelled 
with the video identifier number. A baekup eopy o f the files was burned onto DVD and 
stored separately from the original video. The baekup files were listed using Portfolio^^ 
software v8.0 (Portfolio Extensis Ine. Portland, OR, USA) on a password proteeted PC 
at the MRC Prion Unit for ease o f retrieval. All DVDs were stored in a fireproof safe 
loeated at the NPC.
5.3.8 Independent Assessment 
The purpose o f digitally reeording the neurologieal assessment was to allow subsequent 
blinded seoring by an independent assessor. Independent assessment o f the neurologieal 
examination and the BPRS assessment were carried out by a speeified independent 
neurologist and psyehiatrist.
The independent neurologist or psyehiatrist was given a portable DVD player with a 
yellow filter over the screen to blind them to quinaerine usage (quinaerine is a dye and 
ean turn the skin yellow). For eaeh visual reeording, a seoresheet was filled out (see 
Appendix I), the only identifier being the video identifieation number. A master list of 
eorreet answers for Memory questions was eompiled and updated for use by the 
independent neurologist. Completed forms were stored in a fire safe at the NPC.
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5.4 Neurological Assessment 
Separate non-videoed neurological assessment formed part o f the PRION-1 trial. All 
measures were assumed to be continuous rather than categorical variables. Examples of 
score sheet may be found in Appendices J-O.
-MMSE: used as an overall severity score for eognitive function, ranging from 0 to 30 
incorporating questions on time, place, word registration, attention and calculation, 
word reeall, repetition, comprehension, reading, writing and drawing. A normal score is 
30.
-CDR: a measure widely used in clinical studies o f dementia. Using a semi-structured 
interview with a caregiver, it measures a patient’s function in areas o f memory, 
orientation, judgement and problem solving, community affairs, home and hobbies, and 
personal care, providing a score ranging from 0 to 18. Each component is seored from 0 
to 3 (no impairment, mild, moderate and severe impairment).
-Rankin scale: a simple global assessment o f the impact o f human prion disease on 
activities o f daily living, providing a seore ranging from 0 to 5 (no symptoms, no 
significant disability despite symptoms, slight disability, moderate disability, 
moderately severe disability, severe disability).
-ADAS-COG: performed in those with a MMSE of 10 or greater. A more detailed 
assessment o f cognition, validated in Alzheimer’s disease. Score ranges from 0 to 75. It 
assesses 12 items covering similar orientation, language and comprehension tasks to the 
MMSE but in considerably greater detail.
-GCS: aims to capture disease progression across all ranges o f ability, scores ranging 
from 3 to 15.
-Barthel scale: measures ability to perform activities o f daily living.
-GIC: a scoring system completed by both doctors and nurses on the PRION-1 trial to 
assess ehange from normal, and change from last assessment.
-Patient’s visual analogue seore: assessed using a 10cm line and the patient is asked to 
mark on the line how they feel today, and since their last assessment.
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5.5 Statistical Methods
5.5.1 Analysis approach -  determinin2 atrophy rates 
Four analysis approaches are discussed. Analyses 1-3 use scans registered to the 
baseline scan, giving a ‘direct’ measure of change, the BSI (change in volume).
Analysis 4 uses the raw volumes only and measures change from baseline scan using an 
‘indirect’ method i.e. subtraction. All analyses produce an atrophy rate (%/year) for 
each patient.
Whole brain rates o f atrophy were first calculated using the four analyses, then 
cerebellar rates o f atrophy.
5.5.1.1 Oyeryiew o f Analyses 1-4:
Analysis 1- Use first and last scans only in each patient to determine rate o f atrophy. 
Analysis 2- Perform a linear regression using 0 as intercept to determine rate o f atrophy 
using all available data points.
Analysis 3- Use a random slopes model (Frost) This model gives less weight to 
individuals with fewer measurements (and greater within subject variation).
Analysis 4- Perform a linear regression o f the raw brain and cerebellar volumes, firstly 
to compare to the BSI calculation of atrophy and secondly to assess the variability of the 
intercept (e.g. volume at first scan) used in analysis 1-3.
Analvsis 1 is the simplest method, and 
might have greatest clinical use as it is 
more user-friendly if calculating rates in 
clinic (potentially using automated 
volume measurement). It does however 
lose the information from all interim
0 .5 1 1.5_______Interval years  ^ ’ ® measurements. It is the most open of all
I »  W BBSI/100(ml) Fitted values |
analysis techniques to inaccuracy from 
Figure 5.12 Example o f Analysis 1 errors in measurement of volume change
in one or either scan, as this method assumes that both measurements are performed 
without error.
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Interval years
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Analysis 2 uses all data points for each 
patient. All points have equal weight in 
calculating the patient specific slope, but 
the points at the longest intervals have the 
most influence on the slope estimate. 
Separate regressions are fitted to the data 
for each patient. This method assumes 
that the baseline sean is the ‘gold 
standard’ and is measured without error,Figure 5.13 Example o f Analysis 2 
as the regression uses changes in volume (BSI) from the baseline scan.
?■
interval years
Analysis 3 is a random slopes model 
tailored to longitudinal scanning with 
multiple non-homogenous time intervals. 
Like analyses 1 and 2 it uses direct 
measures o f change (BSI) rather than 
measured volumes and indirect change 
calculated by subtraction (as in Analysis
I •  y ------------  Fitted values I
4). Rates o f atrophy from patients with 
Figure 5.14 Example o f Analysis 3 fewer scans and shorter time intervals
give less weight towards the group mean. Rates o f atrophy from patients with the most 
scans over the longest periods provide the greatest weight to the group mean. The mean 
rates of atrophy generated by this method are thus more precise than those generated by 
indirect methods o f determining rate. However, in small data sets such as this with 
substantial heterogeneity in atrophy rates between subjects, the gain in precision is said 
to be minimal.
The equation used to calculate the % atrophy rate is:
log
M u
=  (y? +  b iy tik  -  tij)+ dijk
, (  Mij 4- Cijk \  .
the outcome variable (atrophy rate) for direct measures o f % ehange
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Mij is the outcome variable (baseline volume) for subject i at visit j
Cijk is the measured difference (BSI) between the jth and kth time points for the ith
person
is the mean rate for all subjects 
hi is the difference in rate of change between the ith person and the mean rate
hk - hj is the length o f time over which the difference is measured
dijk is the variability introduced when measuring a ‘direct’ change in the outcome 
variable between a pair of time points (adapted from Frost).
This method is used in longitudinal analysis of rates o f atrophy in Alzheimer’s Disease.
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Analvsis 4 uses actual 
volumes, rather than BSI as a 
measure of volume change. A 
separate linear regression is 
fitted for each patient. This 
method is the most open to 
errors in segmentation and 
uses an indirect measure ofFigure 5.15 Example o f  Analysis 4 
change (subtraction). The BSI is robust to segmentation errors as it uses voxel 
differences in the scan itself to measure volume, guided by the segmentation.
5.5.7.2 Statistical commands 
For all analyses the statistical commands (Stata) are listed in italics for the sake of 
transparency. On all data, time was transformed to years and BSI to millilitres (mis). An 
outcome variable y was generated for all analyses: 
gen y=log((wholebrainvolscanl-wholebrainbsi)/wholebrainvolscanl)
Log-transforming was used as it was assumed that brains atrophy at a constant % per 
year, as opposed to constant volume loss per year. This also allows direct comparison 
between subjects.
5.5.7.5 Analysis approach 1 
The BSI change over the longest interval for each patient was used: 
sort patientid intervalyears
All BSI changes except the one over the longest interval were dropped.
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drop if  patientid==patientid[_n+IJ
The results were baek-transformed to get % change per year over longest interval. 
gen percent change=100*(I-exp(y/intervalyears))
5.5.1.4 Analysis approach 2 
bysort patientid: regress y  intervalyears, noconstant
y was regressed on the interval in years, but the noconstant option forced the intercept 
o f the regression to be zero. This regression gave the estimated mean 
rate/year (after exponentiating to get the rate in %). It weighted the BSI changes 
according to the interval between scans, weighting appropriately. For patients with only 
one BSI ehange (three in the pilot phase and 14 in the full phase o f the trial), the one 
value o f y was exponentiated to get % atrophy.
Seatterplots o f each patient's BSI changes using analysis 2 were plotted showing the 
corresponding line o f best fit (again forcing it to go through the origin).
twoway (scatter y  intervalyears, xscale(range(0)) yscale(range(0))) (Ifity intervalyears, 
estopts(noconstant) range(0 .)) if  patientid==n
A linear relationship was assumed in all patients. Where a non-linear relationship 
looked possible from seatterplots a simple two slope model or quadratic (see Chan) was 
fitted to see if  there was evidence o f non linearity.
Control patient rates o f atrophy were calculated using analysis 2. As each control patient 
had two seans in total, analysis 1 eould also have been used, and given the same result. 
Seatterplots o f eaeh control patient's BSI changes were plotted showing the 
corresponding line o f best fit (forcing it to go through the origin)
twoway (scatter y  intervalyears, xscale(range(0)) yscale(range(0))) (Ifity intervalyears, 
estopts(noconstant) range(0 .)) ifpatientid==n
5.5.1.5 Analysis approach 3 -  random slopes model 
xtm ixedy intervalyears, noconstant \ \ patientid: intervalyears, noconstant
The following predicts slope in eaeh subject, adds estimated mean slope to subject- 
speeifie slopes and then converts to %.
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predict slope blup, reffects (extracts how much the slope differs from the mean) 
matrix B=e(b) (extracts mean slope o f group)
gen subject_slope_blup=B[l,l]+slope_blup  (generates subjects slope)
gen subject slopej)ercent_blup=100*(l-exp(subject slope blup)) (generates %)
5.5.1.6 Analysis approach 4 — using baseline volumes not BSI 
Past work in volumetric MRI has shown that the BSI is a more robust measure of 
ehange in brain volume than actual brain volumes as there is less segmentation error 
(Freeborough 1997b). For completeness and the sake o f eomparison, rates of atrophy 
were derived for eaeh patient using the actual whole brain and cerebellar volumes. 
bysort patientid: regress cerebvol intervalyears
5.5.1.7 Analysis approach -  Neurological and Video scores 
The same analysis approach was used for tests performed in the video and non-videoed 
neurological examinations.
1 ) Baseline clinieal measure- Does initial elinical score predict those who will atrophy 
at a faster rate?
The baseline elinical measure at first assessment in eaeh patient (which matches the first 
volumetric scan) was used as a elinieal predietor.
2) Rate of change of elinical measure
The rate o f change/decline in each clinical score is calculated firstly by linear regression 
and seeondly within the linear mixed model and compared to rates o f atrophy in each 
patient to determine whether brain atrophy is a surrogate marker o f disease progression.
Correlations using atrophy rates generated from analyses 1-3 are ealeulated
5.5.1.8 Linear mixed models
Linear mixed models refer to the general elass o f models whieh may contain both fixed 
effects (used in standard linear regression e.g. analysis 4 or analysis 2 but setting the 
intercept to 0) and random effeets (e.g. random slopes model/Analysis 3).
As BSI ehange does not have an intereept (BSI at time 0 is always 0 as it is a measure 
o f change), the model used in analysis 3 is a random slopes model (no random 
intereepts model required).
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In analysis 3,
xtmixedy intervalyears, noconstant \ \ patientid: intervalyears, noconstant 
the first intervalyears allows an effect o f intervalyears which is the same for each 
subject (fixed). The second intervalyears term (afterpatientid:) additionally allows a 
random effect o f intervalyears, on top o f the fixed effect.
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RESULTS - OVERVIEW  OF DATABASES
6,1 Description o f PRION-1 MRI database 
The entire database of scans from both pilot and hill phase o f the PRION-1 trial is first 
considered, prior to quality assessment. Two hundred and seventeen MRI scans were 
performed in 44 patients with any form of CJD. Each patient had between one and 
nineteen scans eaeh (mean 4.50, median 3). The earliest scan was in February 2000, the 
latest in October 2006. All subjects with four or more scans were patients with inherited 
prion disease.
Ideally the number o f neurological assessments and number of MRIs performed should 
have been very similar, however fewer MRIs were performed for a variety of reasons. 
The most common was that when assessments were in a patient’s own home or a local 
hospice/hospital no MRI scan was performed, as this would have involved a special trip 
to the National Hospital. Other reasons included patient preference, all allocated 
PRION-1 scanning slots for the week being filled and MRI service days.
Number of MRI scans performed 
in each PRION-1 trial patient 
(pilot and full trial prior to quality 
assessment)
12
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Number of MRI scan s  per patient
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Figure 6.1 Number o f  MRI scans performed in each patient pre quality assessment
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The profile o f  CJD types within the full scan database is shown below:
D isease types - all patients 
(prior to quality a ssessm en t)
■ inherited CJD
■ variant CJD
□ sporadic CJD
□ iatrogenic CJD
33
Figure 6.2 Pie chart showing CJD types in all patients pre quality assessment
Inherited CJD types - all patients 
5-OPRi, 2 1 (prior to quality assessm ent)
D178N, 1 1 I
Y163X, 1 (1  I 
E200K, 1 
Q212P, 1 
A117V, 4
P102L, 10
6-OPRI, 13
■  P102L
■  6-OPRI
■  A117V
□  Q212P
■  E2G0K
□  Y163X
□  D178N
□  5-OPRI
Figure 6.3 Pie chart showing inherited CJD types in all patients pre quality assessment
6.1.1 Pilot phase patients 
One hundred and six MRI scans were performed in 26 patients. Each patient had 
between one and eleven scans during the pilot phase (mean 6.00, median 4). The earliest 
scan was in February 2000, the latest in August 2004.
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Total num ber of MRI sc an s  performed in pilot 
ph ase  participants
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Figure 6.4 Total number o f MRI scans performed in pilot patients
6.1.2 Full trial patients 
One hundred and eleven MRI scans were performed in 30 patients. Each patient had 
between one and nine scans during the full phase (mean 3.42, median 3). The earliest 
scan was in August 2004, the latest in October 2006.
Total num ber of MRI sc a n s  perform ed in fuil 
phase  participants
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Figure 6.5 Total number o f  MRI scans performed in full phase patients
6.1.3 Crossover patients 
Eight patients were scanned in both the pilot and the full phase o f the trial. Their scans 
are included separately in the two phases, as pilot and full phase scans were performed 
on different seanners. All crossover patients had inherited prion disease (3 P102L, 5 6- 
OPRI).
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6.1.4 Se2mentation and resistration
Segmentation o f all scans was performed, regardless o f quality o f images. All 
segmented scans in each patient were registered to the first scan in each phase o f the 
trial.
6.1.5 Quality control process
During the quality control process 79 scans were discarded, the majority due to 
inadequate scan quality due to movement artefact (see Table 6.1). Ten singleton scans 
were discarded. In early pilot phase scans in 2000 some were affected by an apparent 
change in scan protocol. Problems in registering scans could not be overcome in eight 
patients, and non-movement scan quality problems (such as anterior or posterior slice 
omission) in seven patients. Where an initial scan was o f adequate quality but the later 
set o f scans were o f better quality, the initial baseline scan was discarded in favour o f a 
better quality new baseline. One scan was excluded as a patient had a brain biopsy 
between baseline and last scan, and non-resolvable image bias (gradient in voxel 
intensity across scan) caused a single scan exclusion.
Table 6.1 Reasons fo r  discarding scans
R eason  for discarding scan Number
scan  quality - m ovem ent 37
singleton scan 10
protocol change 9
technical registration problem 8
scan  quality - non m ovem ent 7
new baseline 6
post brain biopsy 1
bias 1
total 79
After quality control most patients still had at least two scans to perform longitudinal 
volume analysis. However, 17 patients were left with one or no scans so therefore had 
to be excluded from further analysis.
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Disease types in patients exciuded 
due to poor quaiity scans
■  inherited CJD
■  variant CJD
□  sporadic CJD
□  iatrogenic CJD
Figure 6.6 Pie chart showing CJD types in patients excluded due to poor quality scans
Unfortunately four of the original five variant patients and three of the five sporadic 
patients had to be excluded due to excessive movement artefact (see Figure 6.6).
6.2 Description o f final MRI database
After quality assessment, 138 scans remained, 59 scans in 12 patients in the pilot phase 
and 79 scans in 23 patients in the full phase. Eight patients were scanned in both the 
pilot and full phase.
6.2.1 Pilot phase patients 
Fifty nine MRI scans were performed in 12 patients. Each patient had between two and 
nine scans (mean 4.92, median 3.5). The mean interval between first and last scans in 
each patient was 1.24 years (range 0.35-1.98).
Number of MRI sc a n s  performed in pilot phase  
participants - post quaiity control
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Figure 6.7 Number o f  MRI scans performed in pilot patients post quality control
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The profile o f  CJD types in the pilot phase is shown below:
Disease types - pilot phase
■  inherited CJD
■  variant CJD 
□  sporadic CJD
Figure 6.8 Pie chart showing disease types in pilot phase post quality control
All 12 pilot phase participants had inherited CJD.
Inherited CJD types - pilot phase
□  P102L
■  6-OPRI
■  A117V
Figure 6.9 Pie chart showing inherited CJD types in pilot phase post quality control
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6.2.2 Full phase patients 
Seventy nine MRI scans were performed in 23 patients. Each patient had between two 
and nine scans (mean 3.43, median 2). The mean interval between first and last scans in 
each patient was 0.79 years (range 0.07-1.69). The variant case and one o f the sporadic 
cases were confirmed with tonsil and brain biopsy respectively. The second sporadic 
case was not confirmed by brain biopsy but fulfilled the WHO criteria for a probable 
case.
Number of MRI sc a n s  performed in full trial 
participants - post quality control
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Figure 6.10 Number o f MRI scans performed in full trial patients post quality control 
The profile of CJD types in the full phase is shown below:
D isease types - full phase
□  inherited CJD 
■  variant CJD
□  sporadic CJD
Figure 6.11 Pie chart showing CJD types in full phase patients post quality control
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Inherited CJD types - full phase
5-OPRI, 1
D178N,1 
Y163X, 
E200K, 1 
Q212P, 1
A117V.2
P102L.6
6-OPRI, 7
□  P102L
■  6-OPRI
■  A117V
□  Q212P
■  E200K
□  Y163X
□  D178N
□  5-OPRI
Figure 6.12 Pie chart showing inherited CJD types in full phase patients post quality control
6.2.3 Control patients 
Twelve age and sex matched normal control patients were identified from a familial 
Alzheimer’s trial to match the pilot patients. They had been scanned on the same 
scanner, with the same protocol as the pilot patients. They each had two scans only, an 
average o f 1.78 years apart (range 1.05-3.15).
103
6.3. Description o f Video database 
A total o f 103 patients had videoed assessments as part o f the pilot and full phase o f the 
PRION-1 trial (mean 5.15, median 3, range 1-20). All videos were assessed by the 
independent neurologist.
Number of videos per patient during pilot and full 
trial (to November 2006)
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Figure 6.13 Number o f  videos per patient during pilot andfull trial
However, video data was only used from those patients who had at least two good 
quality MRIs in either the pilot or full phase o f the trial. The first videoed assessment 
used in each person was the one closest to the first MRI scan in each patient.
6.3.1 Pilot video data
The pilot phase of the PRION-1 trial was one of evolution for the videoed examination; 
the protocols were being developed and improvements implemented at various times 
during the pilot phase. As a result, the data from the pilot phase had many missing 
values.
The technical quality of the videos also evolved. The pilot videos were taken using a 
single tripod mounted video camera; a frequent criticism from the independent 
neurologist was that responses were inaudible. For the full trial two cameras were used, 
both with wide angle lenses and directional microphones, and a table clamp was used 
with the second camera.
There was often mismatch between first MRI and first video date, as scanning often 
happened before the video protocol had been started. Only four o f the twelve pilot
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patients had a clinical examination within 10 days o f their MRI, the rest had their first 
clinical examination a mean time of 1.63 years after the first MRI scan (range 0.30-4.67 
years).
Therefore video data was only used in full trial patients, where it was available in its 
most complete and consistent form.
6.3.2 Full video data
Nineteen out o f the 23 full trial participants had MRI scans and first videoed assessment 
on the same day, or one day before or after. Four patients had longer intervals, a 
sporadic patient with a 42 day interval, a variant patient with a 48 day interval, a 
symptomatic inherited patient with a 23 day interval and an asymptomatic inherited 
patient with a 62 day interval. The mean interval in the whole group was eight days 
(range 0-62, median 1). These ‘baseline’ video assessments were used as the first 
assessment in all further analysis.
One hundred and six videoed assessments were made on the 23 full trial participants. 
Each participant had a mean o f 4.61 assessments (median 5, range 2-9) over a mean 
time period o f 0.97 years (median 0.98, range 0.16-1.92).
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6.4 Overview o f structure ofpilot and fu ll phase data 
In summary, this figure shows that the 12 pilot phase patients have 12 matehed eontrol 
patients with whom to eompare MRI data. The 23 full phase patients have time matched 
MRI and video/neurological data to monitor longitudinal changes and allow 
associations between them to be measured. There are no controls for the full phase 
patients.
PILOT PHASE FULL PHASE
1cla
Ss
Vi-O0
1
' V '
12 pilot phase 
patients with M RIs
23 full phase 
patients with  
M RIs and 
clinical data
12 matched controls  
with M RIs
No controls
1993 1998 2000
Time (year)
2004 2006
Figure 6.14 Overview o f  structure ofpilot andfull phase data
6.4 Description o f Quinacrine profile in trial patients
A description o f the profile of the quinacrine profile in trial patients is given below. One 
patient chose to be randomised to immediate or delayed quinacrine, the rest chose 
immediate quinacrine.
Sixteen PRION-1 trial patients took quinacrine. Seven were 6-OPRI patients, three 
P102L, two AI 17V, one D178N, one Y163X, one sCJD and one vCJD. Nine patients 
started quinacrine during the pilot phase, six of whom crossed over from pilot to full 
phase on quinacrine; seven started in the full phase o f the trial. All started on a dose of 
300mg/day and all had time matched MRI scans.
Two patients stayed on 300mg/day throughout the trial or until death. Fourteen had a 
dose reduction, of these eleven eventually stopped and three continued on reduced dose 
until the end of the trial. Dose reductions were due in seven patients to liver function
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test abnormalities, in five to skin rashes, in four to nausea, in one to an abnormal EEG, 
in one to diarrhoea and one deeided voluntarily to reduce the dose. O f the eleven who 
stopped quinacrine completely during the trial four deeided voluntarily, three due to 
skin rashes, two due to nausea, one due to liver function test abnormality and one due 
to prion disease progression. The mean length o f treatment was 209 days (range 16- 
553).
The aim o f this thesis is not to determine the effects, if any, o f quinacrine on human 
prion disease, either clinically or on atrophy rates. This thesis would however not be 
complete without a description o f the profile o f those who were on quinacrine. The 
effect o f quinacrine is not known. There are many reasons for heterogeneity in the 
clinical function o f these patients, quinacrine usage is a small additional factor which is 
unlikely to affect the relationship between brain atrophy and clinical function.
Quinacrine (Mepaerine hydrochloride) is known to penetrate the CNS and acts as a 
stimulant. There is no basis for assuming that quinacrine would be more or less 
effective for any CJD subtype as no studies with human prion strains, human cell lines, 
or transgenic mice expressing human prion proteins are available. Transgenic mice 
studies with quinacrine to date using RML (Rocky Mountain Laboratory (RML) prions, 
a strain derived from a sheep with scrapie) have failed to show a prolongation of 
incubation time.
Various attempts have been made to see if  clinical function is changed with quinacrine. 
PRION-1 is the fifth trial o f quinacrine in human prion disease, and the first attempt at a 
controlled clinical trial in a larger cohort o f CJD patients. Three previous studies had 
only between one and four patients; a French study o f 32 severely affected CJD patients 
showed a slight, but non statistically significant increase in survival duration (Haik, 
Seoazec, Nakajima, Kobayashi, Benito-Leon). A randomised trial comparing 
quinacrine, quinacrine plus ehlorpromazine and placebo in human prion disease was 
carried out in the United States in 2001. Results are awaited. A randomised, placebo- 
controlled study from the same group investigating the efficacy o f quinacrine in 
sporadic CJD in over 100 patients began in March 2005.
An open-aceess programme in France showed that 14 out o f 20 patients receiving 
quinacrine died between one week and three months after starting treatment. O f the four
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continuing to take quinacrine, three were stable and one had deteriorated (Prion 
Therapeuties Abstraet). Many o f these patients had late stage disease at enrolment into 
the programme.
Previous clinieal experience at the National Prion Clinic with quinacrine includes 
several examples where subjeetive improvement o f elinical state is noted for a period of 
time by patients, carers or family members. This has also been reported by other 
investigators.
The only factor common to the eohort taking quinacrine in the PRION-1 trial is the 
starting dose. The disease types, number in eaeh disease type, length o f quinaerine 
usage, dosage profile and reasons for stopping were all different. The best evidence to 
date (before publieation o f the PRION-1 trial results) is that there may be a transient 
increase in cognitive funetion after starting quinacrine. No adjustments will be made to 
the data to allow for any potential quinacrine effects.
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RESULTS -  VIDEOED EXAMINATIONS
7.1 Cognitive section
7.1.1 Completeness o f cognitive section 
The cognitive section of the video comprised 15 separate tests. Four of the patients were 
either entirely tested using, or it became necessary to use the severely affected protocol. 
In the severely affected protocol only one of the 15 cognitive tests, memory (ME) is 
used. When this was taken into account, 40/1590 (2.52%) test scores were missing.
Num ber of missing values for each  cognitive te s t
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Figure 7.1 Number o f missing values for each cognitive test
The reading passage (RP) and recall o f passage (RC) tests had the most missing values. 
Reasons why data was missing (if severely affected protocol was not used) were either 
that the test was omitted accidentally, or the independent neurologist could not assess 
the response (either due to video quality e.g. sound or visual obstruction). Occasionally 
very dysphasic patients were not asked to read the passage (but there was no way of 
recording this apart from a missing score). If  the performance in the reading passage test 
was poor enough to make the registrar feel there was little point in asking recall o f it, 
then this test was not performed.
Where test scores were missing, no statistical methods were used to estimate response 
(e.g. last observation carried forward or miss=fail).
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7.L2 Lonsitudinal cosnitive assessment sraphs in each full trial patient 
Each patient had longitudinal measurement o f clinieal function. Graphs o f all cognitive 
tests in eaeh patient over time, grouped by disease type and symptoms are shown below.
The maximum possible scores are different in each test - this graphical demonstration of 
longitudinal measurement gives an indieation of which tests reflect change. The same 
time and seore axes are used in each patient to aid easy comparison.
7.1.2.1 Sporadic and variant patients 
Sporadic and variant patients were assessed over a relatively short time period, usually 
the 0, 4 and 8 week assessments. The fast elinical decline in these patients usually 
meant that seores declined sharply or assessment was only possible with the severely 
affeeted protocol. The two sporadic patients (1 and 16) had different profiles, patient 1 
being initially stable in all tests, then declining in five tests by the last assessment, over 
the period of two months. Patient 16 showed marked decline over the first month of 
assessment, and then eould only be assessed with the severely affected protocol. Several 
tests showed decline in function over the short intervals between assessments, 
particularly WC (words beginning with...), SP (spelling) and CA (calculation).
Figure 7.2 Videoed cognitive assessments in all patients
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7.1.2.2 Asymptomatic inherited 
Asymptomatic inherited patients showed consistent high scoring across large time 
intervals. They tended to have the fewest (two) assessments as these patients are only 
assessed yearly. The test with the greatest variability was WC.
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(WC test scored 17 on both assessments)
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(WC test scored 80 and 84 respectively on the two assessments)
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Patient 23
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(WC test scored 19 on both assessments)
7.1.2.3 Symptomatic inherited patients 
Symptomatic inherited patients showed the greatest variability as a group in speed or 
presence of decline. These patients had the most assessments, over the longest time 
periods as they followed the trial protocol of assessments at 0, 4, 8, 12 weeks, 6 months 
9 months, 12 months etc, and though symptomatic, did not decline at a fast rate so 
multiple assessments were possible.
Fluctuation in function seems more common in this group than the others; this either 
represents a confounding effect o f multiple assessments, or a genuine fluctuation in 
ability, either in comprehension or performance.
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Graphs are grouped into those who were:
a) alive throughout the trial and did not require the severely affected protocol (SAP)
b) alive throughout the trial who did require the SAP
c) died during the trial
a) Patients alive throughout the trial who did not require the severely affected protocol
This group o f patients mainly comprises the symptomatic P102L and 6-OPRI patients, 
with one 5-OPRI patient. Those with PI02L symptomatic disease usually had little or 
no cognitive decline (patients 14, 19, 20) (early disease in these patients is typically 
reported as showing cerebellar dysfunction with later cognitive decline). Patients with 
6-OPRI tended to have a more fluctuating test scores, or for cognitive test scores to be 
declining (particularly patient 17).
This group also show the most evidence of learning effects with multiple testing (LC in 
patient 12, WC in patient 19).
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b) Patients alive throughout the trial who did require the SAP 
Three symptomatic inherited patients required the use of the SAP assessment. ME 
(memory) is the only cognitive test used in the SAP. Little useful cognitive assessment 
is possible with the ME scale as patients were already scoring 0 or 1 at the start of the 
SAP.
Patient 8
15
12
9
6
3
0
Longitudinal cognitive a sse ssm en t - 
sym ptom atic inherited 6-OPRI- 
severely affected protocol
M E
"4- in in m in in in CO COo o o o o o o o o o oo o o o o o o o o o o
cy cy cy cy cy cy
00 o C\J <N
1
CO 00 o (N
1g O O o oT— t— —^
o o o o o o o O o o o
d a te
o  o  oo  o  o
CO 0 0  o
O O 1—
117
Patient 10
15
12
9
6
3
0
Longitudinal cognitive assessm ent - 
symptomatic inherited Y163X- 
(final assessm ent severely affected protocol)
o o o o o o o o o o o o o oo o o o o o o o o o o o o o
O O O C N C N J ' ^ C O O O O C ^ C N ' ^ C D O O O
o o o o o o o o o o o o o o
d a te
- ME
-L C
LD
- R P
- S P
-F L
- F O
-C A
- Ml
CG
- F S
W C
-P V
-D S
- R C
Patient 18
9
6
3
0
Longitudinal cognitive assessm ent - 
symptomatic inherited 6-OPRI- 
severely affected protocol
•ME
o o o o o o o o o o o o o oo o o o o o o o o o o o o o
O O O C N C M T f O O O O W C N ^ O O O O
o o o o o o o o o o o o o o
d a te
c) Symptomatic inherited patients who died during the trial
It is notable that none of the patients in this group required the SAP. This was mainly 
due to the fact that final illnesses in these patients tended to be short e.g. pneumonia, 
and faster than the three month interval o f assessments most patients had reached in the 
later stages of the trial.
There is suggestion o f terminal decline in patients 2, 11 and 22 i.e. new decline between 
the penultimate and last test not seen between previous tests. This is arguable in patient 
6. Tests showing terminal decline included LD (line drawing), LC (letter cancelling) 
and WC (words beginning with...).
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7.1.3 Summary o f cosnitive assessments 
The cognitive sections of the assessments were completed well, with 2.5% of test scores 
missing.
Sporadic and variant patients were assessed over a short time period, and declined 
rapidly.
Asymptomatic inherited patients had fewest assessments and showed consistent high 
scoring across large time intervals.
Symptomatic inherited patients alive throughout the trial mainly comprised the P102L 
and 6-OPRI patients. Those with P102L symptomatic disease usually had little or no 
cognitive decline, patients with 6-OPRI tended to have a more fluctuating test scores, or 
to be declining. Once patients required the severely affected protocol, little further 
cognitive assessment was possible. Patients who died during the trial showed terminal 
decline in test scores, particularly LD (line drawing) , LC (letter cancelling) and WC 
(words beginning w ith...).
7.2 Motor section
7.2.1 Completeness o f motor section 
The motor section of the video comprised 11 separate tests, the walking assessment 
having three components (gait, overall and scale). The SAP did not affect the motor 
section as much as the cognitive section as the SAP tested eye movement (EM),
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primitive reflexes (PR), one minute observation (OM) and neurological examination 
(NE).
Overall 176/1378 (12.8%) of motor tests had missing values.
N um ber o f m issing  va iu es  for each  m otor te s t
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Figure 7.3 Number o f missing values fo r  each motor test
The walking tests (WA), heel toe test (HT) and Rombergs test (RH) had the highest 
number of missing tests. This was mostly due to there being no method of recording 
‘unable to walk/perform heel toe/Rombergs’ on the video. Unless this was explained on 
film, these assessments were deemed missing. The walking scale was only implemented 
after early 2005, thus earlier assessments have this score missing.
Complete data sets were obtained for the finger nose test (FN), rapidly alternating 
movements (RA), sequential index finger tapping (SI), sequential opposition (SO), 
primitive reflexes (PR), one minute observation (OM) and neurological examination 
(NE).
7.2.2 Loneitudinal motor assessment sraphs in each full trial patient 
NB the same time and score axes are used in each patient to aid easy comparison, as for 
the cognitive assessments, and grouped in the same way.
The marking scheme in the PRION-1 trial was more categorical, however, the analyses 
later performed on this data required continuous variables (measurement of change over 
time rather than absolute recording of presence or absence). All tests were converted to
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a continuous scale as detailed below. All tests were scored as l=normal test, importantly 
scores higher than 1 represented decline in function.
1. EM (eye movements)
In the PRION-1 trial tests were scored as:
1 (normal)
2 (nystagmus)
3 (failure o f upgaze)
4 (other)
but for the purposes o f the graph below, 1 (normal) and 2 (abnormal) were used. (Only 
one abnormal type o f EM, if  any was reported at each assessment).
11 patients had abnormal eye movements at some point in the trial, one showed 
nystagmus, three had failure o f upgaze, seven had ‘other’ abnormal eye movements, one 
patient had both failure o f upgaze and ‘other’ on separate assessments.
2. FN (Finger nose test)
In the PRION-1 trial tests were scored as:
Two digits composed of:
Right (l=normal, 2=mild, 3=mod, 4=severe, 9=not recorded)
Left (l=normal, 2=mild, 3=mod, 4=severe, 9=not recorded)
For the purposes o f the graph the worst score for either hand 1-4 was used. Five patients 
had normal finger nose tests throughout their assessments.
3. RA (Rapidly alternating movements)
Scored as per FN, nine patients had normal scores throughout.
4. SI (Sequential index finger tapping)
Scored as per FN, sixteen patients had normal scores throughout.
5. SO (Sequential opposition)
Scored as per FN, twelve patients had normal scores throughout.
6. PR (Primitive reflexes)
In the PRION-1 trial tests were seored as:
1 (normal)
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2 (glabellar)
3 (pout)
4 (palmomental)
5 (grasp present)
For the purposes o f the graph:
1 (normal)
2 (one primitive reflex present)
3 (two primitive reflexes present)
4 (three primitive reflexes present)
5 (four primitive reflexes present)
Thirteen patients showed primitive reflexes, often more than one in each examination. 
Ten patients showed glabellar reflexes, six patients showed pout reflexes, no patients 
showed palmomental reflexes and three showed grasp reflexes at some point during 
their assessments.
7. OM (one minute observation)
In the PRION-1 trial tests were scored as:
1 (normal)
2 (myoclonus)
3 (chorea)
4 (tremor)
5 (other)
For the purposes o f the graph
1 (normal)
2 (one abnormal movement detected)
3 (two abnormal movements detected)
4 (three abnormal movements detected)
5 (four abnormal movements detected)
Eight patients overall had abnormal movements; three had myoclonus, two had chorea, 
four had tremor and four had other abnormal movements.
8. WA (walking) gait
In the PRION-1 trial tests were scored as:
1 (gait normal)
2 (ataxic)
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3 (apraxic)
4 (cerebellar)
For the purposes o f the graph
1 (normal)
2 (abnormal)
Ten patients had abnormal gaits; all were ataxic with no apraxic or cerebellar gaits.
9. WA (walking) overall
In the PRION-1 trial tests were scored as
1 (normal)
2 (mild)
3 (moderate)
4 (severe)
5 (wheelchair)
6 (bedbound)
and kept the same for the purposes o f the graph.
Eleven patients had impaired walking, one went from normal to mild, four were mildly 
impaired (three progressed), three were moderately impaired (all progressed), no 
patients started in the severe category and three started in the wheelehair category. No 
patients started in the bedbound category or became bedbound.
10. HT (heel toe walking)
Tests were scored as for the previous test WA. Seventeen patients were able to attempt 
the test; six had a normal test throughout, one progressed from normal to mild 
impairment, two had mild impairment, with one progressing to moderate, six were 
moderately impaired, three progressing and one improving, no patients started in the 
severe category, two were wheelehair bound and none bedbound.
11. RH (Rombergs)
This was scored as:
1 (normal)
2 (abnormal)
for both the trial and the graph. Twelve had normal examinations and six abnormal.
124
12. NE (Neurological examination)
This was scored as:
6 digits composed of O=normal; l=abnormal; 9=not recorded for each of:
Right tone 
Right power 
Right reflex 
Left tone 
Left power 
Left reflex 
For the purposes of the graph:
1 (normal) -  all 6 measures normal
2 (abnormal) -  at least one measure abnormal
was used. Sixteen had normal examinations at the start of the trial. Eight patients had 
normal examinations throughout. Eight started with normal examinations which became 
abnormal. Seven had abnormalities throughout. Eleven had abnormalities in tone, five 
in power and ten in reflexes.
7.2.2.1 Sporadic and variant patients 
Tests in these patients showed different patterns:
Figure 7.4 Videoed motor assessments in all patients
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All tests apart from the third assessment of PR (primitive reflexes) are normal.
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Several tests are declining between assessments over a short period, particularly WA 
(overall) and HT (heel toe). Finger nose assessment has also declined along with RA 
(rapidly alternating movements).
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This sporadic patient, in contrast to the previous sporadic case has almost no normal 
examinations (score=l), and is declining in all tests over the six months o f assessment.
7.2.22 Asymptomatic inherited 
This asymptomatic group, tested over long periods of time show consistently normal 
motor test results. Only two tests have abnormal results, two patients with scores o f 2 on 
finger nose testing and one patient with scores o f 2 on heel toe testing. Possible 
explanations include normal variation in function being marked as abnormal, or early 
motor signs being elicited.
126
Patient 4
Longitudinal m otor a s se s sm e n t 
asym ptom atic inherited P102L
■ ^ ■ ^ ' ^ m i n i n m m m c o c o c D c o c oo o o o o o o o o o o o o oo o o o o o o o o o o o o o
o o o c N W ^ o o o o N N T f t o o o oe s : i : o o o o r r o o o o r
o o o o o o o o o o o o o o
date
W A gait
W A overall
Patient 5
Longitudinai m otor a sse ssm en t 
asym ptom atic inherited P102L
Tf Tf Tf in If)o  o  o  o  oo  o  o  o  o
00  o  o  T- CM ego
m in in in CO CO CO CO COo o o o o o o o oo o o o o o o o oCN eg eg eg eg eg eg eg eg
<o 00 o CO 00 oo o o o o o %—
^—
o o o o o o o o o
date
W A gait
WA overall
Patient 9
Longitudinai m otor a s se s sm e n t 
asym ptom atic inherited E200K
r t ' ^ ' ^ i n i n i n i o i n i o i o c o c D c o c Do o o o o o o o o o o o o oo o o o o o o o o o o o o oc g ç N Ç N C ^ e g c g c ^ e g c ^ c g ç N Ç N C N ç ^
o o o N e g T f o o o o e g e ^ T f o o o o
o o o o o o o o o o o o o o
date
W A _gait
W A overall
127
Patient 15
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7.2.2.3 Symptomatic inherited patients 
Graphs are grouped into those who were:
a) alive throughout the trial and did not require the cognitive SAP
b) alive throughout the trial who did require the cognitive SAP
c) died during the trial
a) alive throughout the trial and did not require the cognitive SAP 
As in the cognitive assessments, there was a lot o f fluctuation in function in this group 
of patients. All patients showed some abnormality in at least five tests during the trial. 
Walking tests in the P102L patients were particularly impaired (perhaps due to the 
combination o f cerebellar signs and proximal leg weakness with loss o f leg reflexes).
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s o  (sequential opposition) and RA (rapidly alternating movements) showed impairment 
in the 6-OPRI patients (representing the apraxia often seen in these patients).
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b) alive throughout the trial who did require the cognitive SAP
The SAP includes the EM, PR, OM, WA and NE tests. There is little difference 
between the patterns o f impairment in these patients and the symptomatic inherited 
patients who did not require the cognitive severely affected protocol. All have 
abnormalities in at least three o f the five tests, which can fluctuate.
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c) died during the trial
Unlike the cognitive assessments there is little suggestion of pre-terminal decline in 
motor function. Fluctuation within tests is still a feature, as is fluctuation between 
patients e.g. in WA overall, one patient is walking normally, two with mild to moderate 
impairment and two with severe impairment or wheelchair bound.
The pattern o f impairment in FN and WA in the P102L patient, and in SO and RA in the 
6-OPRI patient continues in this group. The Q212P patient had few signs, with poor 
walking, the A117V patient abnormalities in all tests except PR. PR (primitive reflexes) 
is the test most likely to be normal in all patients in this group.
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7.2.3 Summary o f  lonsitudinal motor assessments
Tests in sporadic patients showed different patterns; in the first patient all tests apart 
from the final assessment o f PR (primitive reflexes) were normal. The second had 
almost no normal examinations and declined in all tests over the six months o f 
assessment. Tests that declined the most in the variant patient included WA (overall), 
HT (heel toe), FN (finger nose assessment) and RA (rapidly alternating movements).
The asymptomatic inherited group showed consistently normal motor test results.
In symptomatic inherited patients there was a lot o f fluctuation in function. All patients 
show some abnormality in at least three tests during the trial. Walking tests and FN 
testing in the P102L patients are particularly impaired and 6-OPRI patients were 
impaired in SO (sequential opposition) and RA (rapidly alternating movements). There 
is little evidence o f pre-terminal decline in motor function.
The Q212P patient had few signs, with poor walking, the A117V patient abnormalities 
in all tests except PR. PR is the test most likely to be normal in inherited patients.
7.2.4 Further description o f  Neurolosical Examination (NE) fmdinss 
The asymptomatic patients had no abnormalities on neurological examination. Both 
sporadic patients had normal neurological examinations over the first two months o f 
assessments. One sporadic patient then went on to develop progressive neurological 
impairment, with tone and reflex abnormalities, followed by loss o f power over the next 
two months.
Symptomatic PI02L patients all had loss o f reflexes, particularly leg reflexes during 
their assessments, with varying tone and power changes.
6-OPRI patients sometimes had normal examinations initially, with tone, power or 
reflex signs developing, or began the trial with signs at the start.
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7.3 Overall Assessment Section
7.3.1 Completeness o f  overall section
There were seven overall assessment tests; all had full data sets, with no values missing.
The first three assessments, coping with tasks, attention and concentration and 
cooperative were scored:
0 (yes)
1 (fluctuates)
2 (no)
The last four, cognitive, extrapyramidal, pyramidal and cerebellar impairment were 
scored:
0 (none)
1 (mild )
2 (moderate)
3 (severe)
7.3.2 Lonsitudinal overall assessment sravhs in each full trial patient 
NB the same time and score axes are used in each patient to aid easy comparison, as for 
the cognitive assessments, and grouped in the same way. Note that scores higher than 0 
represent decline in function.
7.3.2.1 Sporadic and variant patients 
Again, the two sporadic patients show very different patterns o f impairment. Patient 1 
only had mild to moderate cognitive impairment, and in the last assessment fluctuated 
in coping with the tasks, all other measures were normal. In contrast patient 16 had 
progressive and severe cognitive and extrapyramidal impairment, losing attention and 
concentration and cooperativeness as assessments progressed.
The pattern o f the variant patient’s measures was one o f normal cooperativeness and 
attention and concentration throughout, but progressive severe cerebellar impairment 
and impaired cognition and pyramidal function.
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Figure 7.5 Videoed overall assessments in all patients
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7.3.2.2 Asymptomatic inherited 
The most striking result from the asymptomatic group is how many measures are 
deemed as impaired in this apparently symptom free group. Three out o f five had mild 
cognitive impairment in at least one assessment, three had mild cerebellar impairment, 
one had mild pyramidal impairment and one developed fluctuating cooperation and 
attention. This highlights the difficulty in determining when clinical disease onset 
occurs.
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7.3.2.3 Symptomatic inherited patients 
Graphs are grouped into those who were:
a) alive throughout the trial and did not require the cognitive SAP
b) alive throughout the trial who did require the cognitive SAP
c) died during the trial
a) alive throughout the trial and did not require the cognitive SAP 
Patients in this group fall into the 6-OPRI group with moderate or severe cognitive 
impairment in all assessments and less severe cerebellar impairment, or the P102L 
group with moderate or severe cerebellar impairment and less severe cognitive 
impairment. P102L patients also have little or no impairment in coping with tasks, 
attention and concentration or cooperation. Pyramidal function is normal or at most 
mildly impaired in all patients. The 5-OPRI patient has more severe cognitive than 
cerebellar impairment.
Patient 7
Longitudinal overall assessm ent 
symptomatic Inherited 6-OPRI
m
■ copestasks 
• attent_conc 
cooperative 
•cogjm pair 
•extrapyrjmpair 
•pyrjmpair 
•cerebelijmpair
140
Patient 12
Longitudinal overall a s se s sm e n t - 
sym ptom atic Inherited 6-OPRI
CO CO CO COo  o  o  oTf -4- lO If) lO lO
o O ' f - c N i n o o T - c v j i o c o
O t- O O O t- O O O
o o o o o o o o o o
date
•copestasks
•attent_conc
cooperative
•co g jm p a ir
•ex trapyrjm pair
•pyrjm pair
•cerebelijm pair
Patient 13
Longitudinal overall a s se ssm e n t - 
sym ptom atic Inherited 6-OPRI
in in CO CO
p  p o p00 X- OJ in
p p P
o  o o o
date
■ copestasks 
•a tte n tc o n c  
cooperative 
•co g jm p a ir 
■extrapyrjm pair 
•pyrjm pair 
•cerebelijm pair
Patient 14
Longitudinal overall a s se s sm e n t - 
sym ptom atic Inherited P102L
3
2
1
0
P P lOo ino I COo COi COo
o  o  
date
• copestasks 
•attent_conc 
cooperative 
•co g jm p a ir 
•ex trapyrjm pair 
•pyrjm pair 
•cerebelijm pair
141
Patient 17
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b) alive throughout the trial who did require the cognitive SAP
The pattern o f cognitive impairment in 6-OPRI patients with less cerebellar impairment 
continues in this section. The Y163X patient had a mixed cognitive and cerebellar 
pattern o f impairment, other measures were normal.
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c) died during the trial
The 6-OPRI and P102L patients had the same pattern as described previously with 
cognitive and cerebellar impairment respectively. The A117V patient was severely 
cognitively impaired, and fluctuated between assessments in the other measures, but 
with increasing inability to cope with the tasks. The Q212P patient had a mixed 
cognitive and cerebellar impairment pattern, with mild pyramidal impairment. There 
was little suggestion for pre-terminal decline in these patients.
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7.3.3 Summary o f lonsitiidinal overall assessments 
The two sporadic patients showed very different patterns o f impairment, one with mild 
to moderate cognitive impairment, and the second progressive and severe cognitive and 
extrapyramidal impairment. The variant patient had normal cooperativeness and 
attention and concentration throughout, but progressive severe cerebellar impairment 
and impaired cognition and pyramidal function.
The most striking result from the asymptomatic group was how many measures were 
deemed as impaired; mild cognitive, cerebellar and pyramidal impairment were seen.
In the symptomatic inherited patients the 6-OPRI group had moderate or severe 
cognitive impairment and less severe cerebellar impairment, and the P102L group had 
moderate or severe cerebellar impairment and less severe cognitive impairment. 
Pyramidal function was normal or at most mildly impaired in all patients.
Other inherited patients such as the 5-OPRI patient and A117V patient were severely 
cognitively impaired. The Y163X patient and the Q212P patient had a mixed cognitive 
and cerebellar pattern o f impairment. There was little firm evidence for pre-terminal 
decline in patient scores.
7.4 The Severely Affected Protocol
The SAP was developed as a means of assessing patients in the PRION-1 trial with a 
GCS less than 15 and an MMSE of less than 10. These patients were usually unable to 
perform any videoed cognitive tests and few motor tests, thus a subset o f easier tests
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was selected for this cohort. Four o f the ftili trial patients required the SAP during the 
trial.
There was a large group o f patients in the PRION-1 trial who were assessed using the 
SAP, but not included in this analysis as they did not have MRI scans. Analysis o f the 
use o f SAP in the patients in the full phase discussed here are therefore not necessarily 
representative o f the group requiring the SAP as a whole. The group described here are 
the ‘high performers’ who were either initially well enough to have an MRI scan or 
remained well enough to continue having MRI scans. In general, those not discussed 
here started at the lowest scores in the SAP, and further decline could not be measured 
due to the flooring effect o f the scale.
Two 6-OPRI inherited patients required the SAP from first assessment and were 
followed up five times each over 0.9 and 1.3 year periods respectively. Memory scores 
were mostly 0/3, eye movements could not be assessed due to lack o f following and the 
finger nose, rapid alternating movements, sequential index finger tapping and 
opposition could not be scored. Primitive reflexes were present in all assessments and 
there were no abnormal movements on observation. One patient was walking and the 
other bedbound, neurological examination was abnormal in tone, power and reflexes in 
both patients.
The other two patients were initially scored with a full videoed neurological assessment 
but became severely affected enough to require the SAP after two months in a sporadic 
patient and nine months in a Y163X inherited patient. Their memory assessments had 
declined from 3 and 2 in the full assessment to 1 or 0 in the SAP. The sporadic patient 
had primitive reflexes and myoclonus with abnormalities in tone and power on 
examination. All other tests could not be performed. The Y163X patient had normal 
motor scores in all tests except heel toe test.
The SAP was thus a useful indicator o f patients who had declined cognitively to the 
point where simple tests o f cognition could not be attempted or completed. Beyond this 
there was a mixture o f abilities, but a large amount o f flooring effects, even in this 
‘highly performing’ group.
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A potential source o f bias in using the SAP was that tests previously used in the full 
video but not used in the SAP showed missing values. Any further decline in these tests 
was missed and the linear regressions over the whole trial period represented an 
overestimate in ability. In general however, it was the cognitive tests that were removed 
in the SAP. No cognitive tests tended to show conservation o f function when other tests 
had declined. If  the SAP had not been used, these cognitive test results would still have 
been missing as the patient would have been unable to perform them.
7.5 Summary o f  video recording examinations
The cognitive and overall assessment sections o f the assessments were completed more 
fully than the motor section (2.5, 0 and 12.8% missing respectively).
Sporadic and variant patients were assessed over a short time period, and declined fast 
cognitively, particularly in WC, SP and CA. The two sporadic patients had different 
profiles. Patient 1 was initially stable in all cognitive and motor tests, then declined in 
the last assessment. Patient 16 showed marked cognitive and motor decline 
necessitating the use o f the severely affected protocol.
The variant patient declined most on the cognitive WC task and problems with 
cerebellar function and apraxia were apparent on the motor WA (overall), HT, FN and 
RA. This was on a background o f normal cooperativeness and attention and 
concentration throughout.
Asymptomatic inherited patients had fewest assessments over large time intervals. 
Individual cognitive and motor scores were consistently normal. However, when overall 
assessments were analysed mild cognitive, cerebellar and pyramidal impairment was 
seen.
Symptomatic inherited patients alive throughout the trial mainly comprised the P 102L 
and 6-OPRI patients. Those with PI02L symptomatic disease usually had impaired 
walking and FN testing, but little or no cognitive decline, confirmed by the moderate or 
severe cerebellar impairment and less severe cognitive impairment found on overall 
assessment.
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Patients with 6-OPRI tended to have a more fluctuating, but also declining cognitive 
course. Motor tests showed impairment in SO and RA, overall assessments showed the 
group had moderate or severe cognitive impairment and less severe cerebellar 
impairment.
Once patients required the severely affected protocol, little further cognitive assessment 
was possible.
Patients who died during the trial showed a suggestion o f terminal decline in cognitive 
scores, particularly LD, LC and WC, but this was not obvious in motor assessment or 
overall scoring.
The test that appears to be most helpful in mirroring decline is WC in the cognitive 
section. Those least helpful are the primitive reflexes (PR) in the motor section and 
pyramidal function in the overall section (although the single variant case did have 
pyramidal impairment).
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RESULTS - NON VIDEOED NEUROLOGICAL ASSESSMENT
To complete each trial assessment further tests was performed (Appendices J-O): 
-MMSE (Mini Mental State Examination)
-CDR (Clinieian’s Dementia Rating Scale)
-Rankin scale 
-ADAS-COG
-GCS (Glasgow Coma Score)
-Barthel scale
-GIG (Global Impression of Change)
-Patient’s visual analogue score (today and since last assessment)
8.1 Completeness o f data 
66.9% of all possible data was present (816/1220). The bar chart below shows % 
completeness for each test.
Bar chart showing % completeness of neurological 
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Figure 8.1 Bar chart showing % completeness o f  non-videoed neurological score data
Tests that were more than 80% complete included MMSE, Barthel, CDR, GIC and 
Rankin. ADAS-COG had missing values due to the complexity o f  the test - in a 
proportion o f patients it was deemed too difficult, so was not performed. GCS was 
poorly completed as if MMSE was performed then GCS was not recorded. Although the 
assumption was that patients had a GCS of 14 or 15 if MMSE is performed, the aetual 
value was not recorded. Much valuable information was lost due to this oversight in 
protocol as this is a simple and quick assessment to make.
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The patient visual assessments were the most incomplete tests due to a variety of factors 
including patient ability, understanding, coordination and willingness. These 
assessments were excluded from further group analysis.
8.2 Longitudinal assessment o f non-videoed neurological assessments 
Firstly the two most complex cognitive tests are compared, MMSE and ADAS-COG.
8.2.1 MMSE 
A normal MMSE score is 30.
Firstly a composite graph of MMSE scores in each full trial participant is shown:
MMSE scores in each full trial participant
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Figure 8.2 Composite graph o f  MMSE scores in each patient
MMSE fluctuates but tends to decline in these patients. Graphs for the patients in each 
group are shown below for ease of comparison.
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Figure 8.3 MMSE scores
MMSE sc o re s  in sporad ic  and variant patients
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Ali patients declined over the assessment period. In sporadic patients, Patient 1 ’s 
decline was slower and fluctuated, whereas patient 16 had a rapid decline over the two 
assessments; in this patient four further assessments were performed, but MMSE could 
not be determined due to severity o f disease. The variant patient also declined.
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All inherited asymptomatic patients scored full, or near full marks on MMSE. Patients 5 
and 9 dropped one point (allowable in the normal population) however, patient 4 
dropped either one or two marks on assessments. This may be a sign o f early disease.
MMSE sco res in Inherited sym ptom atic patients 
not requiring the severely affected protocol
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This group o f patients either remained stable, losing less than two points overall 
(Patients 12, 14, 19 and 20) or declined, losing two or more points overall (Patients 7, 
13, 17 and 21). P102L patients were all in the more stable group and had the three 
highest MMSE scores. Apart from patient 12, all 6-OPRI patients had lower scores and 
declined faster. (Gaps in patient lines indicate a missing assessment).
153
MMSE scores in inherited symptomatic patients 
requiring the severely affected protocol
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Patient 8 and 18 had no MMSE examinations as they were too severely affected to 
perform the test. Patient 10 had fluctuating MMSE scores (and one missing value).
MMSE scores in inherited symptomatic patients who died 
during the trial
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This group had no clear pre-terminal decline and patients 6 and 22 had high MMSE 
scores with little decline. Patient 2 had rapid decline in MMSE score. Patient 11 started 
at an MMSE of 12 and only declined a little.
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8.2.2 ADAS-COG
An increasing score on the ADAS-COG examination indicates worsening function. A 
normal score is 0.
A summary o f ADAS-COG assessments in all full trial participants is first shown: 
ADAS-COG sc o re s  in each  full trial partic ipant
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Figure 8.4 Composite graph o f  ADAS-COG scores in each patient
Only three patients in the full trial were unable to attempt the ADAS-COG, they were 
all 6-OPRI patients.
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Figure 8.5 ADAS-COG scores
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The least severely affected sporadic patient actually improved with practise on the 
ADAS-COG. The variant patient declined over a short time period.
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Asymptomatic patients scored consistently well, but patient 5 with P102L had mild 
impairment with scores of 8 and 9.
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ADAS-COG sco res  in Inherited sym ptom atic patients 
not requiring the severely affected protocol
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This group had a large range of scores, each patient scoring consistently with a slow 
decline. The P102L group had the best scores, mirroring MMSE findings. 6-OPRI 
patients started with worse scores than P102L patients. The single assessment in the 5- 
OPRI patient was at the worst possible score, whereas their MMSE scores were in the 
middle range. If more ADAS-COG assessments had been performed this level of 
functioning could have been confirmed.
ADAS-COG scores in inherited symptomatic patients 
requiring the severely affected protocol
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Only one patient performed the assessment, the same Y163X patient who was the only 
one in this group to complete the MMSE task, although more assessments o f MMSE 
were completed (five) than ADAS-COG (two).
ADAS-COG sco res  in Inherited sym ptom atic patients 
who died during the trial
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A mixed picture is seen, the 6-OPRI patient not being able to complete the assessment, 
the P102L patient having stable scores and the A117V and Q212P patients declining 
rapidly.
8.2.2.1 Summary o f ADAS-COG and MMSE 
Patterns of assessments were similar to that of MMSE with two exceptions. More 
MMSE assessments were performed on the same set o f patients than ADAS-COGs (as 
the ADAS-COG is more complex and MMSE easier and quicker to complete). Deficits 
in the asymptomatic group were identified on ADAS-COG that were not found on 
MMSE, as ADAS-COG is a more comprehensive and sensitive test of cognitive deficit 
than MMSE.
8.2.3 Barthel 
The maximum normal Barthel score is 20.
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Barthel scores in each full trial participant
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Figure 8.6 Composite graph o f Barthel scores in each patient
As a group there is a wide range o f Barthel scores at first assessment. Most patients 
show decline.
Figure 8.7 Barthel scores
Barthel scores in sporadic and variant patients
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All patients showed decline, most marked in the variant patient. Like many o f the 
previous assessments patient 1 had normal scores until the last assessment.
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Barthel scores In inherited asymptomatic patients
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All asymptomatic patients had normal scores throughout.
Barthel scores in inherited symptomatic patients not requiring 
the severely affected protocol
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This group had wide ranging and fluctuating Barthel scores. 6-OPRI patients had the 
highest (most normal) scores.
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Barthel sco res In Inherited sym ptom atic patients requiring the 
severely affected protocol
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In contrast, 6-OPRI patients in this group had low scores. These patients therefore had 
both severe cognitive dysfunction as they needed the severely affected protocol, as well 
as severely affected ADLs, suggesting a global deeline in these patients.
Barthel sco res In Inherited sym ptom atic patients who died during
the trial
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These patients show progressive decline, although most function at quite a high level at 
baseline (scores 16, 17 and 18).
8.2.4 Rankin
Activities o f daily living were assessed in a more basic way than Barthel using the 
Rankin scale, a normal score being 0. Unlike Barthel, scores increase with deeline. 
Rankin scores did not improve overall in any trial patient.
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Rankin scores in each fuii trial participant
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Figure 8.8 Composite graph o f Rankin scores in each patient
A very similar profile o f change is achieved to Barthel, but in a less detailed form 
(graphs are mirror images o f each other due to increases in score with decline in Rankin 
and the opposite in Barthel).
There is a notable absence of scores of 1 in this test (no significant disability despite 
symptoms); implying that once you have symptomatic CJD, disability is always present. 
Only two patients scored maximum 5. An already limited number of outcome scores in 
this test were therefore reduced even more. All asymptomatic patients scored 0 
throughout. Eleven out of 18 symptomatic patients declined, the rest had stable scores. 
Sporadic patient 16 had the greatest decline o f 2 points between assessments.
8.2.5 CDR
Six domains of personal life are scored according to whether cognitive impairment 
affects their function. The domains are: Memory, Orientation, Judgement, Community 
affairs. Home and hobbies and Personal care.
CDR scores 0 in the normal patient and increases as dementia worsens, maximum score 
is 18.
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CDR scores in each full trial participant
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Figure 8.9 Composite graph o f  CDR scores in each patient
The pattern here across all patients is similar to ADAS-COG, MMSE and Barthel. The 
asymptomatic patients had normal scores throughout. Other patients declined to varying 
degrees except one symptomatic P102L patient (light orange squares, patient 20). This 
patient had a degree o f functional overlay to their symptoms, making function hard to 
assess, and making the rater more inclined to think function was not declining than in 
other patients.
8.2.6 QIC
Global impression of change assessed by the doctor is shown here (nurse data is 
identical, but slightly less complete). Scores are 1-7, increasing with increasing severity: 
1 Normal, not ill at all, 2 Borderline mentally ill, 3 Mildly ill, 4 Moderately ill, 5 
Markedly ill, 6 Severely ill, 7 Amongst the most ill. This is the most subjective test of 
all discussed in this section.
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GIC scores in each full trial participant
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Figure 8.10 Composite graph o f GIC scores in each patient
Patterns are most similar to Rankin scores as the scoring structure is almost identical 
and on a similar six point scale. Score 2 is little used as ‘Borderline mentally ill’ is 
perhaps too narrow a description for the multifaceted neurological degeneration seen in 
these patients. No patients achieved the maximum (worst) possible score, probably due 
to the poor definition ‘Amongst the most ill’. The variant patient was the only one to 
score the next worst score at 6. Like the Rankin score this is a simple test, but outcome 
scores are closely bunched. Patient 20 is the only one showing an overall improvement.
Figure 8.11 GIC scores
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An interesting difference is that the sporadic patient 1 which normally shows less 
impairment drops 2 points on GIC, the other sporadic patient remains on 4 for both 
assessments (there are missing data points). The variant patient has a sudden decline in 
the last assessment.
8.2.7 Patient Visual Analogue scores 
Only around 12% of the visual analogue scale tests were performed. Data from 
available scores is shown below:
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Figure 8.12 Composite graph o f  patient visual analogue score-today in each patient
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Figure 8.13 Composite graph of patient visual analogue score-since last visit in each patient
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Compared to previous graphs, the patient visual analogue scales showed much more 
variation in apparent improvement or deeline, and in no particular disease pattern. 
Unlike most other tests, only one asymptomatic patient scored themselves at maximum 
score (‘excellent, very well’). This population are understandably vigilant about 
symptom onset and are therefore a group more likely to interpret any symptoms 
(tiredness, mild forgetfulness) as being due to prion disease.
The variant patient closely matched their objective cognitive performance with their 
subjective visual assessment score, showing a high degree o f insight to their rapidly 
declining condition. The single assessment in sporadic patient 1 showed a good degree 
o f insight into their condition.
There are various reasons why a patient may report a decline or improvement. Often 
factors not measured in the trial such as a change in medication (e.g. baclofen) might 
give the patient a large improvement in their movement ability. Factors such as 
depression are important as well as a sufficient degree o f insight and the ability to 
understand how to respond in the test. This test is perhaps a better measure o f symptom 
control and insight than a measure o f disease progression.
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Figure 8.14 Composite graph o f GCS sores in all patients
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GCS is a measure o f level o f eonsciousness, scored between 15 (maximum) and 3 
(minimum). The majority o f patients did not have a GCS score recorded, either because 
one was not done by error o f omission, or a MMSE assessment was done instead, but no 
GCS recorded. Reasons for omission are therefore varied.
All patients in whom GCS was recorded had a GCS o f 10 or more. Six patients had 
GCS below 15, these included four symptomatic 6-OPRI patients, a sporadic patient 
and a variant patient. Patients with declining GCS scores included the sporadic and 
variant cases (the latter having the most rapid deeline) and one o f the 6-OPRI cases. No 
patient improved their GCS during the trial.
GCS is a useful clinical measure in CJD, demonstrating decline in variant, sporadic and 
6-OPRI disease.
8.3 Summary o f  findings in non-videoed neurological assessments 
The non-videoed assessments such as MMSE, ADAS-COG, Rankin, Barthel, CDR and 
GIC all produced similar profiles o f results in the disease and severity groups described.
In the complex cognitive tests MMSE had the advantage o f a more complete data set 
than ADAS-COG, as it is easier to do. Although scores fluctuated in patients, MMSE 
captured useful information on a larger subset o f trial patients. The ADAS-COG was 
best used when trying to identify the point at which a patient changes from 
asymptomatic to symptomatic status. P102L patients scored consistently better on both 
MMSE and ADAS-COG than 6-OPRI patients.
Activities o f daily life were measured with the more complex Barthel and simpler 
Rankin. Patterns o f deeline were the same in both tests but Barthel was more 
comprehensive due to the larger range o f activities considered and greater range of 
outcome scores, more closely mirroring decline. The range o f scores in Rankin was low, 
but it is a quicker and easier test to perform. The more detailed assessment used in the 
Barthel index could be more useful in the least affected or asymptomatic patients. 
Barthel scores in 6-OPRI patients declined once the SAP was required, demonstrating 
global deficits in these patients.
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CDR scores different functions to the tests o f activities o f daily life above and is a 
useful comparison. One patient showed improvement in this scale, the effect o f 
functional overlay in this patient was able to be introduced, that was not possible with 
Barthel or Rankin.
GIC is the most subjeetive o f the tests, as it is dependent on the rater’s opinion which 
may be affected by knowledge o f disease type and length o f symptoms. However, it is 
also free o f the restraints o f fixed determined outcome scores that the other tests have. 
Results mirrored those o f the Rankin score, possibly due to the similar scoring system.
Patient visual analogue scores are useful measures o f symptom control and patient 
insight, but little consistent information is gained about disease progression.
GCS is a very useful tool in assessment across all CJD types. Its utility was 
compromised by a high rate o f missing values due to poor trial design. This test should 
certainly be performed and due to its simplicity could be reliably completed in all 
patients at all stages o f disease (an uncommon virtue amongst tests).
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RESULTS - WHOLE BRAIN AND CEREBELLAR ATROPHY RATES
9.1 Overview o f  Chapter
Rates o f whole brain atrophy calculated using analyses 1-4 are first described (first and 
last scans, linear regression, linear mixed model and raw volumes) and compared. 
Scatterplots o f BSI against time in patients and controls are then compared and 
histograms (to demonstrate that atrophy rates are normally distributed) are shown. T 
tests comparing rates o f atrophy in different groups are presented.
The same analysis is then performed for cerebellar atrophy rates. Whole brain and 
cerebellar rates are compared within patients, and the effect o f symptom profile on this 
relationship is considered. The next chapter considers which factors were predictors of 
rate of atrophy.
9.2 Whole brain atrophy results
In every patient whole brain segmentation was performed and follow-up scans 
registered to baseline scan. Examples o f registrations o f scan pairs in patients with 
different types o f CJD are shown in Figures 9.1 and 9.2. Red represents areas o f atrophy 
and green areas o f apparent gain in the right hand image o f each patient. Different 
patterns and degrees o f atrophy can be seen from these example patients. Generally it 
demonstrates the range o f baseline atrophy, the small percentage changes in atrophy 
being measured and the paucity o f areas showing any apparent gain in green
Examples o f a control patient and an asymptomatic P102L inherited patient are shown 
first, over 15 and 18 month intervals respectively showing no areas o f red or green, 
indicating no volume loss.
A sporadic patient over a shorter 70 day interval showed red areas o f atrophy at the 
edges o f the cortex, ventricles and cerebellum. A similar global pattern was seen in a 
variant patient over a similar 85 day interval.
Figure 9.2 shows inherited CJD patients. First a symptomatic A117V patient with a 10 
month interval and dramatic global atrophy is shown. Secondly two symptomatic 6- 
OPRl patients with two and nine month intervals are shown. The first had atrophied
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significantly in the past, but there was little change over the two months, the second had 
less background atrophy and ventricular change.
Two symptomatie P102L patients are shown finally over 17 and 20 month intervals.
The first had significant cerebellar atrophy with ventrieular change. The second had 
little change.
The volumes o f the red areas (minus the green areas) represent the BSI, an overall 
measure o f ehange in volume from baseline to follow up scan.
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Figure 9.1 R egistered  whole brain images. F or a ll im ages (left) baseline (m iddle) fo llo w  up (right) 
reg istered  image. R ed  =  atrophy Green =  apparent gain.
A - C -  C ontrol patient, 15 month interval
D -F  -  A sym ptom atic P102L inherited patient, 18 month interval
G-1 -  Sporadic patient, 70 day interval
J-L -  Variant patient, 85 day  interval
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Figure 9.2 R egistered  whole brain im ages - inherited patients. F or a ll im ages (left) baseline (middle) 
fo llo w  up (right) reg istered  image. R ed  = atrophy Green =  apparent gain.
A -C  — Sym ptom atic Inherited A 117 Vpatient, 10 month interval 
D -F  — Sym ptom atic Inherited 6-O P R lpatien t, 2 month interval 
G-1 — Sym ptom atic Inherited 6-O P R lpatien t, 9  month interval 
J-L  — Sym ptom atic Inherited P102L patient, 17 month interval 
M -O  -  Sym ptom atic Inherited P102L patient, 20  month interval
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The change in volume between registered scan pairs was calculated (the BSI). 
Percentage rates of whole brain atrophy were determined in pilot and full trial patients 
using Analyses 1-4. This allowed comparison o f rates of atrophy generated by the 
different analyses.
9.2.1 Pilot patients
Rates of whole brain atrophy In pilot patients 
using Analyses 1-4
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Figure 9.2 Rates o f  whole brain atrophy in pilot patients
9.2.2 Full phase patients
Rates of whole brain atrophy in full trial patients 
using Analyses 1-4
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Figure 9.4 Rates o f  whole brain atrophy in full trial patients
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Analysis 4 showed the greatest variability in atrophy rates, whereas those derived from 
analyses 1-3 were more similar. Table 9.1 demonstrates the differing means and 
standard deviations (SD) from the four methods.
Table 9.1 Pilot whole brain atrophy rates (Vo/year) using Analyses 1-4 and matched 
control rates.
patient Analysis 1 Analysis 2 Analysis 3 Analysis 4 Controls
1 -0.01 -0.01 0.08 -3.03 0.23
2 0.91 0.91 0.94 3.48 0.38
3 0.90 0.62 0.63 4.29 0.29
4 7.13 7.58 7.08 16.16 -0.05
5 3.79 3.23 2.28 1.13 0.14
6 0.06 -0.35 0.02 -12.15 0.40
7 0.85 0.73 0.75 -0.15 0.14
8 1.11 1.11 1.23 -0.40 0.31
9 1.08 1.15 1.15 1.77 0.22
10 2.63 2.64 2.51 7.38 -0.09
11 0.11 0.17 0.21 4.82 0.20
12 0.73 0.79 0.80 3.49 -0.06
mean 1.61 1.55 1.47 2.23 0.17
SD 2.05 2.16 1.93 6.35 0.17
NB Patients 1, 2 and 8 had only 2 scans, thus atrophy 
2 were identical. Matched control rates are shown for
rates generated by analyses 1 and 
comparison.
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Table 9.2 Full trial whole brain atrophy rates (%/year) using Analyses 1-4
patient Analysis 1 Analysis 2 Analysis 3 Analysis 4
1 2.36 2.36 1.49 -2.17
2 6.12 6.12 3.59 7.74
3 5.02 5.02 2.26 6.20
4 -0.12 -0.12 -0.02 0.99
5 -0.27 -0.27 -0.15 0.06
6 2.49 2.49 1.79 -5.57
7 2.18 2.29 2.15 0.65
8 14.21 14.21 3.23 -1.21
9 0.70 0.70 0.79 1.89
10 -1.55 -1.55 0.24 9.40
11 0.29 0.76 0.81 2.70
12 3.24 3.24 2.08 7.93
13 -2.52 -2.52 -0.90 -4.09
14 2.13 2.86 2.80 2.61
15 0.37 0.38 0.41 -1.02
16 10.70 10.70 3.33 14.55
17 0.33 0.41 0.43 1.46
18 2.24 2.96 2.73 6.05
19 2.65 0.19 1.45 52.11
20 -0.78 -0.48 -0.44 -1.02
21 3.02 1.63 1.62 -1.56
22 0.52 0.45 0.48 1.42
23 0.99 0.99 1.05 1.17
mean 2.36 2.30 1.36 4.36
SD 3.78 3.79 1.27 11.15
NB patients 3-18, 20-22, 24, 25, 28 and 35 had only 2 scans, thus atrophy rates
generated by analyses 1 and 2 were identical.
9.2.2.1 Means and Standard deviations in the 4 
analysis methods
Mean estimated slope varied across the four analyses, the highest mean rate being in 
analysis 4, followed by analysis 1. The lowest mean slopes were from analysis 3.
The Standard Deviation (SD) measured the variability o f the estimated slopes. SO was 
high in analysis 4 and 1, and most similar in analyses 1-3 in the pilot phase (2.05, 2.16, 
1.93). SD in analysis 3 o f the full trial patients was however, much lower (1.27) than the
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other analyses (3.78, 3.79, 1 1.15). Analysis 3 therefore produced the least variability in 
slopes.
The most similar analyses were 1 and 2, firstly because the same rates were generated in 
patients with 2 scans and secondly as these methods were the most similar and made 
similar assumptions.
NB the mixed model in analysis 3 was fitted across pilot and full phase patients 
together, rather than separately in the two phases. This model pools information across 
patients. Seven patients were common to both pilot and full phase o f the trial, but as 
different scanners were used, separate rates on the two scanners were calculated. An 
alternative method would have been to perform the linear mixed model separately on 
pilot and full trial patients. However, due to the small numbers o f patients involved and 
the crossover o f patients, pooling information across both phases o f  the trial was 
deemed to be justified.
Analysis 4 was included to demonstrate why BSIs rather than raw volumes are used to 
determine rates o f atrophy, as there is much less variability. In further analysis only 
methods 1 -3 were used.
9.2.3 Control patients 
Control patients had only two scans thus Analysis 1/2 was used to calculate rate of 
atrophy in each patient.
A seatterplot o f  rates o f atrophy in the 12 control patients and 12 pilot patients 
(calculated with analyses 1-3) is shown below. (Yellow points show group means).
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Rates of whole brain atrophy 
In controls and pilot patients (An 1-3)
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Figure 9.5 Rates o f  whole brain atrophy in controls and pilot patients
The contrast between the spread o f values in the controls and pilot patients is obvious. 
However, it is important to consider both the interval between scans and the number of 
scans on which the rate o f atrophy was calculated. This issue is addressed in the 
following sections.
9.3 Scatterplots o f  atrophy rates in trial patients generated by Analysis 2 
(linear regression)
Demonstrated in this section (Appendix P) are scatterplots o f every patient’s BSI 
measurements with time, and on each seatterplot the linear regression slope estimate of 
rate of atrophy calculated using Analysis 2 (intercept always = 0, as BSIs in each patient 
are direct measures o f change between follow-up scan and the same baseline scan).
All scatterplots used the same axes, (time 0-2 years, BSI -20 to 80) for ease of 
comparison. A positive slope indicated atrophy, a negative slope apparent gain in 
volume. Most patients had positive slopes, indicating atrophy. Some had a negative 
slope, but these tended to be marginally negative, within the negative values that could 
be explained by segmentation error alone, rather than real gain in volume.
The variety o f BSI values, number of BSIs and variability in time interval in each 
patient can be visualised. It can be seen that BSIs close in time to the baseline that differ 
greatly in value from the regression line, have less impact on the regression line than if 
that same BSI value is further in time from baseline. This has the effect o f weighting the 
slope to BSIs furthest in time from the baseline scan in analysis 2.
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9.4 Scatterplots o f  atrophy rates in control patients generated by Analysis 2
(linear regression)
Comparison between trial and eontrol rates o f atrophy can be made using Appendix Q. 
A set o f scatterplots with regressions for the eontrol patients is shown using the same 
axes. NB time axis differed in three o f these patients as second scan was over two years 
from baseline scan. This is a more homogenous group o f scatterplots than the previous 
trial patient set, with much lower rates o f atrophy. A comparison of eontrol and pilot 
rates is presented below.
9.5 Rates o f  atrophy in different CJD disease types
Atrophy rates in pilot and full phase patients by disease type are shown below.
Bar chart show ing whole brain atrophy rates(An3) 
in pilot patients by d isease  type
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Figure 9.6 Bar chart showing whole brain atrophy rates in pilot patients by CJD type
Bar chart show ing w hole brain atrophy rates(AnS) 
in full trial patients by d isease  type
Patients (n=23)
■ P102L
■ 6-OPRI
□ A117V
□ Q212P
■ E200K
□ Y163X 
a D178N
□ 5-OPRI
■ variant CJD
■ sporadic CJD
Figure 9.7 Bar chart showing whole brain atrophy rates in fu ll trial patients by CJD type
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There was a large range o f atrophy rates aeross all patients and within disease type, 
demonstrating the heterogeneity o f atrophy in these patients and the mix o f disease 
severity, from presymptomatic to severe disease. P102L and 6-OPRI patients (the two 
largest eohorts) had similar ranges o f atrophy rates. An A117V patient had the highest 
rate. Variant and sporadie patients had high rates o f atrophy.
9.6 Assessing normal distribution o f  atrophy rates 
All statistieal tests used sueh as t tests, linear regressions and linear mixed models 
assumed that atrophy rate was normally distributed. It was difficult to assess the 
assumption o f normality in sueh a small dataset, however histograms o f whole brain and 
cerebellar atrophy rates were plotted to assess distribution in Appendix R. Whole brain 
atrophy rates were plotted for analyses 1-3 firstly in the pilot patients and secondly in 
the full trial patients. Generally, the histograms showed a normal distribution but with 
one atrophy rate above the 95% eentile. This is known as a ‘fat tail’. For analysis 1 and 
2 this outlier presented less o f a difficulty as T tests are fairly robust to non-normality 
and small samples (see White and Thompson).
Non-normality presents more o f a problem for the multilevel modelling and multivariate 
analysis, but with the small numbers o f  patients assessed, and the absence o f any 
obvious method to correct this, further analysis proceeds with the understanding o f the 
limitations o f the distributions o f the data set. With small numbers a single large value 
may have a big influence on overall group results.
9.6.1 Robustness o f  baseline whole brain volume 
The baseline scan volume in each patient, determined by the intercept o f the regression 
o f the raw volumes (Analysis 4) was compared with the actual baseline volume in those 
patients with more than two scans. In analyses 1-3 it was assumed that the baseline scan 
volume was measured without error, and this section tested this assumption.
In whole brain volumes there was a mean difference o f 0.78% between actual baseline 
volume and regressed volume at time 0 (range 0.07-5.00). Differences between actual 
and regressed baseline volumes were therefore small and there was no evidence that the 
assumptions were violated.
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9.7 Is estimated variability o f  estimated slope lower i f  a patient has multiple 
scans and a long maximum time interval?
Standard errors o f slopes were calculated in each patient with more than two scans in 
Analysis 2. A Spearman’s rank correlation was performed with the number o f scans in 
each patient and the maximum time interval. (n=18 patients with more than two scans 
including both pilot and full trial patients).
Table showing Standard Error in each patient with more than two scans in Analysis 2 
and ranked by number o f scans. Maximum time interval between scans is also shown. 
Table 9 3  Data table fo r  Spearman's rank correlation with standard error o f slopes
SE
No.
scan s intervalyears
2.05801 3 0.35
0.80096 3 0.15
0.53593 3 0.95
0.11693 3 1.98
1.53225 4 0.07
1.27395 4 1.4
0 .63828 4 0.5
0.53913 4 0.29
0.67481 5 1.29
0.48127 7 0.75
0.30883 7 0.75
0.23764 7 1.05
0.11349 7 1
0.09185 7 1.84
0.09565 8 1.69
0.1524 9 1.53
0.12109 9 0.19
0.11397 9 1.88
The Spearman’s rank coefficient was 0.65 when SE and number o f scans were 
compared.
The Spearman’s rank coefficient was 0.63 when SE and maximum time interval were 
compared.
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Thus, precision o f the estimate o f the slope increases as number o f scans increases and 
as the maximum time interval increases. Both tests were done as a higher total number 
of seans did not necessarily that the mean time interval increased. E.g. a patient with 
three seans could have had a maximum time interval o f 2 months (0, 4 and 8 weeks) or 
2 years (0, 1 year, 2 years).
However, finding an assoeiation between number o f scans and SB might have been 
wholly due to the fact that there was at least some relationship between number o f scans 
and maximum time interval. To conclude that the number o f scans had an independent 
effect, controlling for the confounding effect o f time interval in a regression would be 
required.
The relationship between maximum time interval and SE aecords with the established 
result from regression that estimates are more precise when there is larger variability in 
the independent variable.
9.8 Patients with non-linear rates o f atrophy
When all the scatterplots in Appendix P were viewed, only one patient (no. 3) showed 
any evidence o f non linearity. There seemed to be acceleration in atrophy rate with time, 
starting at 1.25 years from baseline scan.
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Figure 9.8 Seatterplot showing BSI against time fo r  patient 3.
(Linear regression line to 0 plotted and cut off point at 1.25 years in hatched line)
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The following two methods could be used to assess whether relationships other than 
linear better fit the data:
a) A simple two slope model was fitted with a change point o f 1.25 years. (Text in 
italics refers to the Stata statistical package command).
gen extraslope = (intervalyears-1.25)*(intervalyears> 1.25) 
regress y  intervalyears if  patientid==3, noconstant
There was significant statistical evidence for a change in slope after 1.25 years (P=0.02, 
SE .006, 95% Cl -0.03, 0.004). Slope before 1.25 years was 0.46%/year, and 
0.66%/year after, the original overall rate using analysis 2 was 0.62%/year.
b) a quadratic relationship
gen intervalyears_sq= intervalyears^2
regress y  intervalyears intervalyears_sq, noconstant
Using this regression to see if a quadratic relationship fitted the data better than a linear 
relationship, a P value o f 0.08 was calculated. Therefore in this patient there was a trend 
towards a quadratic relationship, but it was not significantly better fitting than a linear 
relationship. The quadratic relationship was not significantly better than a linear 
relationship in any other patient.
9.9 Comparing whole brain atrophy rates in different groups
9.9.1 Comparison o f rates o f atrophy in controls and pilot patients 
The 12 pilot patients had 12 age and sex matched controls. A comparison o f their rates 
o f atrophy is shown below.
Bar chart showing pilot and matched control patient 
whole brain atrophy rates (using Analysis 2)
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Figure 9.9 Bar chart showing pilot and matched control patient whole brain atrophy 
rates (using Analysis 2).
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9.9.2 Are the rates o f  brain atrophy in pilot patients si2mficantlv 
different from their a2e and sex matched controls?
T tests to compare pilot and control rates were performed.
ttest percent_change, by(varl) unequal (The unequal option relaxed the assumption that 
the SD of rates is equal in the two groups)
Table 9.4 T test o f  whole brain atrophy rate in controls and pilot patients 
NB orange colour indicates p<0.05
Analysis 1 Analysis 2 Analysis 3
Mean atrophy rate (%/yr) in pilot patients 1.61 1.55 1.47
Mean atrophy rate in controls 0.17
All patients (n=24, 12 controls, 12 pilot) P=0.03 P=0.05 P=0.04
Symptomatic (n=23, 12 controls, 11 pilot) P=0.03 P=0.05 P=0.04
O f the 12 pilot patients, 11 were symptomatic and one was asymptomatic.
Whole brain atrophy rates were significantly greater in pilot patients than in controls, 
whether the asymptomatic patient was included in the T test or not. In this group 
patients with CJD had a mean rate o f atrophy at least 1.3% / year greater than controls 
This was calculated by the difference in mean rate o f pilot patients and controls.
This is the first time to my knowledge that the rates o f atrophy in patients with CJD 
have been compared to a control population, and quantified.
The mean rate o f atrophy in this control group was less than that reported in the 
literature using the same methods for quantification o f atrophy e.g. Scahill 2003 0.32% 
(0.10-0.54) but within the range seen and in a small and relatively young age group.
9.9.3 T test within the linear mixed model 
An attempt was made to compare slopes between groups within the linear mixed model, 
rather than by doing a T test on the slopes generated. However, it was difficult to extend 
the T test ‘unequal’ option (allowing variability to differ between groups) to the linear 
mixed model. It was not possible to estimate the variability o f the slopes in the controls 
as they only had two seans each.
The number o f scans in each patient became a major source o f bias in the linear mixed 
model (analysis 3). In the trial patients, those with two scans tended to either be very
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severely a fleeted (and were unable to tolerate a third sean) or were asymptomatic 
patients scanned yearly. All control patients had two seans.
The effect o f the model was to downweight the effect on the group mean o f slopes from 
patients with fewer seans, drawing towards the mean rate o f those patients at rate 
extremes (low in asymptomatic patients and high in variant and sporadie disease). The 
model therefore reduced the variability from the mean (SD), the more so the more 
patients with only two seans.
The combination o f this effect, along with the small numbers involved meant that 
figures generated from a comparison within the model were uninterpretable.
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CEREBELLAR ATROPHY
10,1 An example o f  cerebellar atrophy 
An example o f cerebellar registrations in a P102L patient is shown in Figure 10.1. This 
patient had severe progressive cerebellar symptoms.
A
Figure 10.1 Serial cerebellar change from baseline. Red = atrophy, green = apparent gain. 
(A) Baseline (B) 6 months (C) 9 months (D) 12 months(E) 14 months(F) 18 months.
10.2 Cerebellar atrophy rates
10.2.1 Pilot patients
Rates of cerebellar atrophy in pilot patients 
using Analyses 1-4
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Figure 10.2 Rates o f  cerebellar atrophy in pilot patients
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10.2.2 Full trial patients
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Rates of cerebellar atrophy in full trial patients 
using Analyses 1-4
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Figure 10.3 Rates o f  cerebellar atrophy in full trial patients
As seen in whole brain atrophy, analysis 4, using raw volumes only was a much more 
variable measure o f atrophy, and is excluded from further analysis. Analyses 1 and 2 
were similar, but most analysis 3 atrophy rates (in yellow) were smaller than the 
corresponding rates froml and 2.
Table 10.1 Pilot cerebellar atrophy rates (%/year) using Analyses 1-4 and control rates 
o f atrophy
Patient Analysis 1 Analysis 2 Analysis 3 Analysis 4 Controls
1 -0.10 -0.10 0.51 -0.18 0.16
2 0.76 0.76 0.91 -0.24 -0.05
3 -0.71 -0.20 -0.03 0.15 0.33
4 4.68 5.23 2.71 12.40 0.22
5 7.60 7.22 1.36 8.89 0.38
6 -1.00 -0.90 0.69 2.63 0.37
7 1.46 1.30 1.23 1.47 0.36
8 -1.69 -1.69 0.81 -3.00 0.41
9 0.32 0.35 0.47 0.65 0.83
10 1.45 1.04 1.04 3.34 0.19
11 0.01 0.06 0.39 -0.16 0.44
12 1.65 0.79 0.84 2.15 0.26
mean 1.20 1.16 0.91 2.34 0.33
SD 2.49 2.44 0.66 4.10 0.20
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Table 10.2 Full trial cerebellar atrophy rates (%/year) using Analyses 1-4
Patient
Analysis
1
Analysis
2
Analysis
3
Analysis
4
1 -0.58 -0.49 0.89 -0.59
2 6.95 6.95 1.32 10.83
3 12.67 12.67 1.25 15.37
4 0.23 0.23 0.68 0.99
5 -0.29 -0.29 0.43 -1.18
6 2.73 2.73 1.09 5.81
7 2.19 -0.76 0.62 2.70
8 18.50 18.50 1.21 -39.24
9 0.92 0.92 1.00 1.23
10 -3.02 -3.02 0.89 -3.41
11 1.50 3.55 2.07 6.61
12 2.21 2.21 1.07 0.41
13 -3.31 -3.31 0.70 -4.76
14 2.63 2.41 1.83 2.46
15 0.96 0.45 0.67 1.00
16 13.22 13.22 1.22 10.18
17 0.71 1.81 1.58 1.03
18 6.60 8.55 3.00 3.07
19 1.68 1.68 1.03 -37.18
20 -0.89 -0.86 -0.40 -0.09
21 1.84 -1.38 0.03 2.43
22 4.75 2.97 2.33 8.76
23 -0.15 -0.15 0.69 -1.97
mean 3.13 2.98 1.09 -0.68
SD 5.20 5.38 0.72 12.50
10.2.2.1 Means and Standard deviations in the 4 analysis 
methods
In the pilot patients the mean estimated slope varied across the four analyses, the 
highest mean rate being in analysis 4, followed by analysis 1, as in whole brain 
measurements. The lowest mean slope and SD was from analysis 3 (0.91 and 0.66).
In the full trial the presence o f two patients with high negative rates in analysis 4 
(apparent gain -39.24 and -37.18) meant that the group mean was -0.68. There was a 
corresponding very high SD o f 12.5 in analysis 4. O f analysis 1-3 the lowest mean slope 
and lowest SD were from analysis 3, as in whole brain measurements.
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Cerebellar means and SDs in analyses 1 and 2 were generally higher than for whole 
brains, but the opposite was true in analysis 3 where means and SDs were closer to 
controls.
10.2.3 Control patients 
Control patients had only two scans thus Analysis 1/2 was used to calculate rate of 
cerebellar atrophy in each patient.
A seatterplot o f rates o f cerebellar atrophy in the 12 control patients and 12 pilot 
patients (calculated with analyses 1-3) is shown below. (Yellow points show group 
means).
Rates of cerebellar atrophy 
in controls and pilot patients (An 1-3)
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Figure 10.4 Rates o f  cerebellar atrophy in controls and pilot patients
A similar profile o f atrophy rates as in whole brains was seen, although cerebellar 
Analysis 3 generated a much less variable data set than analysis 1 or 2, and a less 
variable data set compared to whole brain analysis 3.
10.3 Assessing normal distribution o f  cerebellar atrophy rates 
Histograms o f cerebellar atrophy rates were plotted to assess distribution (see Appendix 
R). Cerebellar atrophy rates were plotted for analyses 1-3 firstly in the pilot patients and 
secondly in the full trial patients. As in whole brains, the histograms showed more 
patients with atrophy rates above the 95% eentile than a standard normal distribution, 
particularly in the pilot phase. This is known as a ‘fat tail’. Limitations were the same as 
those discussed in the whole brain analysis.
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10.3.1 Robustness o f  baseline cerebellar volume
The baseline cerebellar volume in each patient, determined by the intercept o f the 
regression o f the raw cerebellar volumes (Analysis 4) was compared with the actual 
baseline cerebellar volume in those patients with more than 2 scans. In all o f analyses 1- 
3 it was assumed that the baseline scan volume was measured without error, and this 
method checked this assumption.
In cerebellar volumes there was a mean difference o f 0.48% between actual baseline 
volume and regressed volume at time 0 (range 0.04-2.46%). Differences between actual 
and regressed baseline volumes were therefore small (and smaller than whole brain 
difference at 0.78%) so the assumptions used in analyses 1-3 were not violated.
10.4 Comparing cerebellar atrophy rates in different groups
10.4.1 Comparison o f rates o f  cerebellar atrophy in controls and pilot 
patients
Bar chart showing pilot and matched control 
cerebellar atrophy rates (using Analysis 2)
i l '
II =
-2
1 1 cA 1
1 2 3 4
" f r f  ' ^
5 6 7 l i  9 10 11 12
□  pilot trial patients 
D control patients
patient num ber
Figure 10.5 Bar chart showing pilot and matched control cerebellar atrophy rates
Pilot trial patients had much more variable atrophy rates than control patients, with two 
patients showing relatively large apparent % gains in volume. Measurement of 
cerebellar atrophy may have been more variable than whole brain as the cerebellum is a 
small structure, so smaller errors had larger effects. Whether control and pilot rates were 
significantly different was calculated below.
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10.4.2 Are the rates o f  cerebellar atrophy in pilot patients sisnificantlv 
different from their a^e and sex matched controls?
T tests were performed to determine whether the rates o f eerebellar atrophy were 
significantly different from matched controls. 
ttest percent change, by(varl) unequal
The unequal option relaxed the assumption that the SD o f rates is equal in the two 
groups.
Table 10.3 T test o f  cerebellar atrophy rate in controls vs pilot patients
Analysis 1 Analysis 2 Analysis 3
All patients P=0.26 P=G.28 P=0.014
Symptomatic P=0.25 P=0.26 P=0.016
Cerebellar atrophy rates were significantly greater in pilot patients than controls when 
analysis method 3 was used to determine rate of cerebellar atrophy. The rates in the bar 
chart shown in the previous section for analysis 2 were not significantly different, in 
part due to the negative rates discussed. The difference between analysis 3 and analyses 
1 and 2 was the decreased variability o f analysis 3 - the Standard Deviation was lower 
(0.66 V 2.49 and 2.36) meaning it was easier to detect any difference.
It is interesting to compare these cerebellar results to whole brain results. Whole brain 
atrophy rates from all 3 analyses were significantly different from controls, unlike only 
analysis 3 here. Whole brain analysis 3 had a similar mean and SD to analysis 1 and 2. 
Cerebellar analysis 3 SD was four times lower (0.66) than the SDs o f analysis 1 and 2 
(2.49, 2.44). It may be that cerebellar differences between the controls and trial groups 
were only unmasked when the lower variability in rates in analysis 3 meant that the 
difference became detectable.
10,5 BSI underestimates actual volume loss 
Scatterplots o f BSI against corresponding volume change were performed and a line of 
best fit plotted, and slope calculated. Whole brain and cerebellar plots are shown below:
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Whole brain volum e change  against whole brain 
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Figure 10.6 Seatterplot o f  whole brain volume change against whole brain BSI
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Figure 10.7 Seatterplot o f  eerebellar volume change against eerebellar BSI
A comparison o f these two measures showed that BSI underestimated volume ehange 
over time, which is in agreement with previously published data (Freeborough 1997b). 
This is due to the fact that it is not possible to select parameters for the BSI calculation 
which entirely encompass all boundary transitions, and consequently some loss will not 
be taken into account. In this cohort the underestimate was substantially larger than 
previously reported. This may be due to the increased variability in these scans pairs. 
The scan interval ranged from 0.07-1.98 years, whereas the previous study used scans 
separated by approximately a year. In addition, although all scans were reviewed for 
quality, it is possible that due to the nature o f the disease there was more movement on 
the scans from this cohort. Likewise, the cerebellar BSI underestimates volume change 
in this region, although the problem is not as severe as in the whole brain analysis. It is
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possible that the BSI parameters perform slightly better on this strueture as the 
boundaries are more distinet.
10.6 Comparing whole brain and cerebellar atrophy rates
The whole brain and eerebellar rates o f atrophy in eaeh pilot patient and their age and 
sex matehed eontrol were compared using a paired T test. 
ttest wbrate=cerebrate
Table 10.4 Whole brain and cerebellar atrophy rates fo r  Pilot and control patients with 
paired T test results
Patient
WB
Ani
Cereb
Ani
WB
An2
Cereb
An2
WB
An3
Cereb
An3
WB
controls
Cereb
controls
1 -0.01 -0.101 -0.01 -0.10 0.08 0.51 0.23 0.16
2 0.91 0.76 0.91 0.76 0.94 0.91 0.38 -0.05
3 0.90 -0.71 0.62 -0.20 0.63 -0.03 0.29 0.33
4 7.13 4.68 7.58 5.23 7.08 2.71 -0.05 0.22
5 3.79 7.60 3.23 7.22 2.28 1.36 0.14 0.38
6 0.06 -1.00 -0.35 -0.90 0.02 0.69 0.40 0.37
7 0.85 1.46 0.73 1.30 0.75 1.23 0.14 0.36
8 1.11 -1.69 1.11 -1.69 1.23 0.81 0.31 0.41
9 1.08 0.32 1.15 0.35 1.15 0.47 0.22 0.83
10 2.63 1.45 2.64 1.04 2.51 1.04 -0.09 0.19
11 0.11 0.01 0.17 0.06 0.21 0.39 0.20 0.44
12 0.73 1.65 0.79 0.79 0.80 0.84 -0.06 0.26
T test P=0.4 P=0.4 P=0.2 P=0.07
Mean diff 0.41 0.28 0.56 -0.15
Cl mean -0.70, 1.51 -0.71, 1.27 -0.30, 1.42 -0.31, 0.012
Whole brains did not atrophy at a significantly different rate than eerebelli in pilot and 
eontrol patients. However, not finding a significant difference did not mean that the 
brains and cerebellums atrophied at the same rate necessarily. The lack o f a significant 
difference might have been due to the small sample size.
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The same analysis was performed in full trial patients (full data not shown).
Table 10.5 Paired T test results fo r  Whole brain and cerebellar atrophy rates in full 
trial and control patients
Analysis 1 Analysis 2 Analysis 3
T T est P=0.1 P=0.5 P=0.3
Mean diff -0.77 -0.28 0.26
Cl mean -1.80, 0.26 -1.06, 0.50 -0.25, 0.78
The same result was found, with no significant difference between whole brain and 
cerebellar rates.
10.6.1 Do whole brains atrophy at the same rate as eerebelli in 
symptomatic patients?
The same analysis as the previous paragraph was performed.
(NB symptomatic here indicates any symptoms, not just cerebellar symptoms.)
Table 10.6 Paired T test results fo r  Whole brain and cerebellar atrophy rates in 
symptomatic and asymptomatic patients
Analysis 1 Analysis 2 Analysis 3
^ 0 .0 4 P=0.3 P=0.2
When only the eight full trial patients who were symptomatic at their first assessment 
were included, symptomatic patients had greater mean cerebellar atrophy rates than 
mean whole brain rates using analysis 1. However, this was not true for analysis 2 or 3, 
thus this can probably be assumed to be a spurious result (particularly as fewer numbers 
were used).
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10,7  A sym ptom atic p a tien ts
Finally, the rates o f atrophy in the five asymptomatic patients are summarised 
below.
Table 10.7 Rate o f  whole brain and cerebellar atrophy in asymptomatic patients 
(Analysis 3, full trial)
D isease type WB rate Cerebellar rate
P102L -0.02 0.68
P102L -0.15 0.43
E200K 0.79 1.00
D178N 0.41 0.67
A117V 1.05 0.69
It is interesting to note the wide range o f  rates o f atrophy in a population who on 
average should have an atrophy rate o f around 0.32%/year. The two P102L patients had 
whole brain atrophy rates near zero, yet their cerebellar atrophy rates were higher in 
comparison (this disease type manifests first with cerebellar symptoms). The other three 
disease types represented had whole brain and cerebellar rates that almost all exceeded 
the normal rate and range (0.10-0.54), well into the ranges seen in symptomatic patients. 
This suggests evidence for acceleration in atrophy rates in presymptomatic patients 
prior to measurable deficits being detected.
194
IDENTIFYING PREDICTORS OF RATE OF ATROPHY
The clinical data and atrophy rates from MRI were compared in this section to 
determine which clinical measures predicted rates o f atrophy.
I L I Which baseline characteristics predict rate o f  atrophy?
Baseline characteristics with categorical (rather than continuous) variables such as sex, 
disease type and presence or absence o f symptoms were first considered, to determine 
whether any groups had significantly different rates o f atrophy in each category. 
xi: regress an3 yr i.x (same as T test)
Table 1 L I P  values o fT  tests between baseline characteristics and atrophy rate in 
whole brains and eerebelli
WB Ani An2 An3
symptoms Asymp V symp 0.16 0.19 0.059
sex Male V Female 0.94 0.74 0.93
disease type Inherited v variant 0.40 0.86 0.43
Inherited v sporadic 0.10 0.69 0.21
Inherited CJD 
type P102LV 6-OPRI 0.35 0.29 0.31
P102LV A117V 0.40 0.29 0.18
Coeff (Cl)
1.2 (-0.05, 2.5)
Cerebellum Ani An2 An3
symptomatic Asymp V symp 0.19 0.29 0.17
sex Male V Female 0.63 0.60 0.69
disease type Inherited v variant 0.057 0.48 0.84
Inherited v sporadic 0.30 0.99 0.95
Inherited CJD 
type P102LV 6-OPRI 0.38 0.35 0.35
P102LvA 117V 0.65 0.85 0.97
P102L V all inher 0.55 0.68 0.70
Key
10.3 (-0 .3 ,21 .0)
symptomatic sex disease
Inherited
type
1 asymptomatic 1 male 1 inheritedCJD 1 P102L
2 symptomatic 2 female 2 vCJD 2 6-OPRI
3sC JD 3A 117V
195
Full trial patients were used in this analysis. Atrophy rates were not significantly 
different according to presence o f symptoms, sex, disease type or inherited disease type. 
There was borderline significant difference between the means o f the whole brain 
atrophy rates in asymptomatic and symptomatic patients using Analysis 3 (P=0.059). 
The mean rate o f eerebellar atrophy was borderline significantly different in inherited 
cases than the rate o f the single vCJD patient (P=0.057). These trends were marginal 
and no broad conclusions could be made from them.
The fact that presence o f symptoms did not predict high rates o f atrophy may be due to 
the fact that some severely affected patients survived for a long time, and may not have 
atrophied at a high rate for this whole period.
Although A117V patients had high rates o f atrophy, as numbers are so small, group 
comparisons were not significant.
In light o f the knowledge o f the eerebellar disability in P102L patients, it was perhaps 
surprising that no group differences in cerebellar rate were seen. The range o f severity 
in this group was however large, thus reducing the likelihood o f seeing any significant 
difference.
As variant and sporadic patients had much shorter disease spans than inherited patients, 
one theory might be that these patients had higher rates o f atrophy compared to 
inherited patients. That may be true, but there were insufficient numbers here to prove 
it.
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11.2 Which clinical scores at baseline predict atrophy rate? -Univariate linear
regressions
From a clinical point o f view it would be useful to know which clinical score measures 
predict atrophy rate, for prognostic purposes. Non-vidcoed tests were first considered, 
followed by the cognitive, motor and the overall impression scores from the video. In 
each set o f tests the baseline values for each test were assessed as predictors o f atrophy 
rate i.e. the baseline clinical scores in which tests will predict the atrophy rate 
thereafter? Secondly the rate o f  ehange o f longitudinal scores in eaeh test was used as 
predictors i.e. the rate o f change in which tests most closely mirror the rate o f change in 
brain volume?
11.2.1 Non- Videoed Neurological Assessments
11.2.1.1 Linearity assessment - scatterplots 
Assessments o f linearity were performed with scatterplots o f baseline clinical score in 
eaeh patient against atrophy rate (Appendix S). Rates o f atrophy generated with analysis 
3 were used for the purposes o f  the seatterplot.
On reviewing the scatterplots assumptions o f linearity were justified. There was one 
outlying point in the Barthel plot (bottom left) which may have had a large effect on 
significance o f Barthel as a predictor o f atrophy rate. There was also an outlier in the 
ADAS-COG seatterplot (far right)
Only two GCS results aeross all patients were less than full marks (GCS=15), with 
several missing values, thus any further analyses with GCS was unlikely to represent 
true effects. The same was true for eooperativeness, with only two patients having 
baseline values o f 0, all other patients had values o f 1. SI and OM tests again had only 
two abnormal baseline results. Individual scatterplots are discussed more fully in the 
context o f the regressions below.
It was assumed that all variables described here were continuous, rather than 
categorical. The scatterplots o f  variables with a low number o f possible scores (e.g. GIG 
possible scores 1-5 and Rankin possible scores 0-4) demonstrated that this assumption 
was stretched a little due to bunching o f scores, however, the effect was not so 
detrimental to require assumption o f non-continuity.
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11.2 .1.2 Univariate linear regressions o f  baseline clinical score 
against rate o f  whole brain atrophy using analyses 1-3 
and the linear mixed model.
A linear regression where atrophy rate (analyses 1-3) was the outeome and baseline 
elinieal seore was the predietor was performed (see Tablet 1.2). 
regress an 1-3 baseclinicalscore
The last eolumn in Table 11.2 shows the regression within the linear mixed model. This 
allowed slope to vary with the baseline variable, so a new variable was ereated sueh as: 
gen intervalyears_mmse~intervalyears *mmse_scan 1
xtmixed y  intervalyears intervalyears mmse, noconstant || pa t lent id: intervalyears, 
noconstant
In Table 11.2 univariate linear regression results are shown for eaeh baseline variable 
predietor. P values were eoloured orange if p<0.05 (signifieant) and yellow if p>0.05 
and <0.1 (suggesting a trend). If P values were < 0 .1 then the eoeffieient and the 95% 
eonfidence interval were also reeorded.
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Table 11.2 Univariate linear regressions o f baseline scores V5 rate o f whole brain atrophy using analyses 1-2 and the LMM
predictor
An1 
P value An 1 coeff (Cl)
An2 
P value An 2 coeff (Cl)
An3 
P value An 3 coeff (Cl)
Linmix 
P value Linmix coeff (Cl)
MMSE 0.25 0.24 0.16 0.26
Barthel 0.01 -0.47 (-0.83.-0.11) 0.01 -0.50 (-0.86, -0.15) 0.03 -0.14 (-0.27, -0.19) 0.08 -0.17(0.02, -0.35)
GIC Dr 0.06 1.07(-0.03. 2.18) 0.07 1.03(-0.09, 2.14) 0.03 0.41 (0.05. 0.77) 0.09 0.35 (-0.06, 0.76)
GIC nurse 0.06 1.12 (-0.05. 2.30) 0.06 1.13 (-0.04, 2.31) 0.03 0.43 ( 0.04. 0.81) 0.09 0.41 (-0.06, 0.87)
CDR 0.01 0.52 (0.15. 0.89) 0.01 0.53 (0.16, 0.90) 0.02 0.15(0.02. 0.28) 0.10
Rankin 0.02 1.33 (0.22, 2.44) 0.03 1.29 (0.16, 2.42) 0.02 0.47 (0.10, 0.84) 0.10 0.36 (-0.06, 0.77)
ADAS-COG 0.24 0.37 0.21 0.28
GCS 0.40 0.34 0.19 0.06 -1.41, (-2.87, 0.03)
Age at visit 0.81 0.78 0.58 0.30
Duration sympt 0.48 0.47 0.76 0.97
Baseline vol 0.28 0.21 0.39 0.97
(b)Baseline videoed cognitive score against rate o f atrophy
predictor
Ani
P value An 1 coeff (Cl)
An2 
P value An 2 coeff (Cl)
An3 
P value An 3 coeff (Cl)
Linmix 
P value Linmix coeff (Cl)
Memory 0.03 -1.58 (-3.01,-0.16) 0.04 -1.55 (-2.99, -0.11) 0.05 -0.49 (-0.98, -0.004) 0.09 -0.50 (0.08, 1.09)
Letter cancel 0.23 0.27 0.11 0.07 -0.38 (0.03, 0.79)
Line drawing 0.75 0.76 0.49 0.37
Reading 0.69 0.60 0.95 0.68
Spelling 0.85 0.82 0.81 0.84
Frag letters 0.82 0.75 0.94 0.54
Frag Objects 0.69 0.61 0.44 0.39
Calculation 0.69 0.69 0.92 0.89
Miming 0.52 0.49 0.35 0.29
CopyGestures 0.79 0.76 0.39 0.32
Frontal LSegu 0.25 0.26 0.24 0.22
Words begin 0.64 0.84 0.72 0.09 0.0002 (0.0004, 0.003)
Proverbs 0.53 0.50 0.59 0.54
Digit Span 0.89 0.91 0.90 0.93
Recall 0.28 0.45 0.31 0.62
199
(c) Baseline videoed motor score against rate of atrophy
predictor
An1 
P value An 1 coeff (Cl)
An2 
P value An 2 coeff (Cl)
An3 
P value An 3 coeff (Cl)
Linmix 
P Value Linmix Coeff (Cl)
Eye mvmts 0.32 0.35 0.25 0.16
Finger nose 0.17 0.18 0.06 0.84 (-0.05, 1.72) 0.09 0.89 (0.14, 1.90)
Rapid alternate 0.59 0.66 0.30 0.11
Sequ Index <0.001 2.99(1.88.4.09) <0.001 3.03(1.97,4.10) 0.004 0.94(0.33, 1.56) <0.001 3.16(1.37,4.73)
Sequ Opposit 0.27 0.20 0.11 0.14
Prim Reflexes 0.09 2.13 (-0.32, 4.61) 0.12 0.30 0.26
One Min Obs 0.001 8.54(4.02, 13.07) 0.001 8.62 (4.10, 13.13) 0.01 2.24 (0.52, 3.97) 0.004 6.7 (-12.42, 20.16)
Walk-gait 0.10 2.04 (-0.40, 4.49) 0.13 0.16 0.39
Walk-overall 0.02 1.31 (0.23, 2.38) 0.03 1.27 (0.18, 2.36) 0.08 0.34 (-0.17, 0.85) 0.35
Heel toe 0.28 0.27 0.17 0.19
Rombergs 0.07 -2.86 (-6.02, 0.30) 0.12 0.23 0.74
Neuro exam 0.13 0.16 0.02 1.22 (0.20,2.25) 0.69
(d) Baseline videoed overall score against rate o f  atrophy
predictor
Ani 
P value An 1 coeff (Cl)
An2 
P value An 2 coeff (Cl)
An3 
P value An 3 coeff (Cl)
Linmix 
P value Linmix coeff (Cl)
Copes tasks 0.36 0.31 0.57 0.73
Attention Cone 0.06 -3.49 (-7.19,0.21) 0.06 -3.53 (-7.23, 0.18) 0.25 0.47
Cooperative 0.02 -6.42 (-11.6, -1.22) 0.01 -6.89 (-12.0,-1.79) 0.06 -1.77 (-3.61, 0.06) 0.04 0.03(0.001,0.05)
Cog impair 0.11 0.11 0.10 0.41 (-0.08, 0.89) 0.23
Extrapyramidal 0.69 0.73 0.58 0.52
Pyramidal 0.24 0.22 0.21 0.49
Cerebellar 0.12 0.09 1.05 (-0.18, 2.29) 0.10 0.34 (-0.07, 0.76) 0.17
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11.2.1.3 Non-videoed baseline predictors 
These results showed that simple tests sueh as Barthel, GIC, Rankin and CDR were 
predictors o f atrophy, whereas the more complex longer tests such as MMSE and 
ADAS-COG were not predictors. Significant P values were obtained in Analysis 3 for 
Barthel, GIC, Rankin and CDR, and were either significant or suggested a trend in 
analyses 1 and 2. The same tests all suggested trends in the linear mixed model. A few 
other tests showed trends, but bearing in mind the multiple testing being performed, an 
approximate rate o f at least 1 in 20 random false positive results should be expected. 
GCS analysis was discarded due to the spread o f data on scatterplot.
Interpretation o f the coefficients was important to ensure that the results fitted with the 
clinical context. Some tests had high scores in normal patients (e.g. Barthel, GCS, 
MMSE) and others had low scores (e.g. ADAS-COG, Rankin). In a test such as Barthel, 
if  a low baseline score predicted a high atrophy rate, a negative coefficient would be 
expected. In a test such as ADAS-COG, if  a high score predicted a high atrophy rate a 
positive coefficient would be expected.
All coefficients were o f the appropriate expected sign, i.e. that a worse baseline score 
predicted a high atrophy rate. One exception was that coefficients for cooperativeness 
were negative for analyses 1-3, but just positive (0.03) for the linear mixed model. The 
scatterplot for cooperativeness showed that only two patients were not fully cooperative 
at baseline thus little can be concluded from this result.
Coefficient values in Analyses 1 and 2 were similar, and in Analyses 3 and the linear 
mixed model: Barthel (-0.47 and -0.50, -0.14 and-0.17) GIC (1.07 and 1.03, 0.41 and 
0.35) and Rankin (1.33 and 1.29, 0.47 and 0.36). These coefficients could be explained 
as follows: every baseline point change due to worsening function predicted a 0.5% 
increase in atrophy with the Barthel score, a 1% increase in atrophy with the GIC score 
and a 1.3% increase in atrophy with the Rankin score.
Analysis 1 and 2 used very similar data (identical in those patients with 2 scans) and 
analysis 3 and the linear mixed model had the same atrophy rates but used either a 
simple linear regression or a model to perform regressions. All methods, despite 
different coefficients showed a very similar pattern o f significance o f predictors.
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reinforcing the point that even though different methods o f analysis are used, all showed 
the same effect.
Important negative results included age at visit, duration o f symptoms and baseline 
volume. It might have been expeeted that those most severely affected at the start o f the 
trial might have had the smallest brain volume (due to previous atrophy) and that this 
may predict those with highest rates of atrophy. However, when the scatterplot o f 
baseline volume with rate o f atrophy was eonsidered, the spread o f plots was wide, 
probably due to baseline eharacteristics of age and gender. The effects of potential 
previous atrophy may be outweighed by the effect o f differences in baseline 
characteristics, or that patients who have already atrophied significantly may not be able 
to sustain high rates of atrophy over long periods o f time.
11.2.2 Videoed cognitive score baseline predictors 
Memory was the only baseline test predictive of rate of atrophy in all four analyses. 
Coefficients were appropriate, showing that every memory point lost predicted an 
increase in atrophy of between 0.49%/yr and 1.58%/yr. The scatterplot below shows 
that only seven patients scored less than full marks (3) on this test. There was a broad 
range of atrophy rates in patients who scored full marks.
Figure 11.1 Memory scatterplot (baseline)
Letter cancelling showed a trend with the LMM, with each loss o f letter cancelling point 
predicting an increase in atrophy of 0.38%/yr. Only five patients had deficits on letter 
cancelling, again there was a broad range of atrophy rates in patients scoring full marks, 
which reduced the significance to a trend value.
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Figure 11.2 Letter cancelling scatterplot (baseline)
‘Words beginning with’, although having a trend for significance had a positive 
coefficient (suggesting increasing number o f words predicted increase in atrophy). This 
trend result was therefore ignored as the coefficient was too small to be clinically 
relevant (0.0002), analyses 1-3 were non significant and the scatterplot showed two 
outliers and a broad spread of other points.
Figure 11.3 Words beginning scatterplot (baseline)
11.2.3 Videoed motor score baseline predictors 
Baseline sequential index finger tapping and one minute observation were the best, most 
consistent predictors of atrophy rate with highly significant P values (all 0.01 or less) in 
all 4 analyses. The presence of myoclonus or other movement disorders often occurs at 
a late stage in disease where atrophy rates may be high, so this is understandable. It was 
interesting to note that the ‘sister’ test o f sequential opposition was not a significant 
predictor, perhaps as this is a harder test. Scatterplots of these scores however showed 
only two patients with abnormal scores.
I r
Figure 11.4 SI and OM scatterplots (baseline)
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Walking overall assessment showed promise as a predictor, although not significant in 
the LMM. The scatterplot is shown below.
Figure 11.5 Walking overall scatterplot (baseline)
Walking gait assessment was non-significant along with eye movements, finger-nose 
testing, rapid alternating movements, primitive reflexes and the neurological 
examination.
Heel toe and Rombergs had many missing values; if  scores had been recorded in all 
patients these measures may have been more useful.
11.2.4 Videoed overall score baseline predictors
A notable negative was the overall impression of cognitive impairment not being a 
significant predictor o f atrophy rate. Scatterplots of the cooperative scores showed that 
little inference could be made from the pattern of data previously discussed.
Tests that were significant predictors would be best utilised as a snapshot of severity at 
first contact with a patient. What these predictors did not anticipate was whether change 
in these predictors was also predictive o f atrophy rate. This question is answered in the 
section below ‘Does rate of change in clinical score correlate with rate o f atrophy?’.
11.2.5 Multivariate regression
It was important to determine whether any variables were confounding the associations 
between predictor and rate of atrophy. This was determined by performing a 
multivariate regression using variables with significant P values and removing them 
sequentially by least significant variable in an elimination process. If  factors A and B 
both had ?<0.05, but on multivariate regression A stayed <0.05 but B was >0.05 then 
the univariate effect of B was only because B was associated with A and not with the 
outcome (atrophy rate).
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When sequential multivariate regressions were performed, CDR was the most important 
unconfounded predictor, but no predictor remained significant (P<0.05) in any 
combination o f predictors. The interpretation o f this was that all significant tests were 
essentially capturing the same effects (for example global severity) and measuring 
roughly the same underlying factor and that no test had confounding associations.
11.2.6 R squared values 
Finally, it was possible to look at the R squared values for the linear regressions in 
Analysis 2 and Analysis 3. This quantified how much o f the variation in the slopes was 
captured by variation in baseline clinical score (but did not adjust for confounding). All 
scores which predicted univariably to a significance of P<0.05 were included.
R squared value can be used to roughly rank predictors:
The non-videoed tests were used as an example:
Analysis 2
Clinical score predictor ranking: CDR>Barthel >Cooperative>Rankin>GIC(n) 
Corresponding R squared value: 0.31>0.29>0.27>0.21>0.17
Analysis 3
Clinical score predictor ranking: Rankin>CDR>Barthel>GIC(n)>GIC(dr)
Corresponding R squared value: 0.25>0.23>0.21 >0.21 >0.21
CDR, Barthel and Rankin were the most consistent best predictors overall for non- 
videoed tests.
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11.2.7 Does baseline cerebellar impairment predict rate o f cerebellar 
atrophy?
The same univariate regression was performed as above with cerebellar impairment 
from the video tests against cerebellar atrophy rate as outcome.
Table 11.3 Univariate linear regressions o f baseline cerebellar impairment vs rate o f  
cerebellar atrophy using analyses 1-3 and the LMM
predictor An 1
An 1 
Coeff 
(01) An 2
An 2
Coeff
(Cl) An 3
An 3
Coeff
(Cl)
Linmix
uni
Linmix
uni
Coeff
(Cl)
cerebellar
impairment 0.02
0.92
(0.27,
1.59) 0.02
2.01
(0.43.
3.76) 0.06
0.23
(-0.009,
0.46) 0.06
0.8
(-0.04,
1.7)
Cerebellar impairment at baseline does predict cerebellar atrophy, significantly in 
analysis 1 and 2 and a non significant trend in Analysis 3 and within the linear mixed 
model. All coefficients were positive which fits in with the clinical scenario of 
cerebellar impairment score increase predicting a cerebellar atrophy rate increase.
The relationship between cerebellar function and cerebellar atrophy rates in CJD has not 
been reported in the literature to date.
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11.3 Does rate o f  change in clinical score correlate with rate o f  atrophy?
It would be useful to know whieh longitudinal test ehanges prediet atrophy rate, for 
prognostie purposes. Linear regressions o f the longitudinal measures o f elinieal seores 
in eaeh patient were measured.
Assessments o f linearity were performed with seatterplots o f rate o f elinieal ehange for 
eaeh test against atrophy rate. Rates of atrophy generated within the linear mixed model 
were used for the purposes o f the seatterplot (differenees with Analysis 3 are discussed 
below). See Appendix T.
The seatterplots highlighted some patterns of data that were relevant to interpretation of 
results. The scatterplots could reasonably be fitted to a linear regression.
11.3.1 Determinins rates o f change in clinical scores 
Firstly rates o f ehange in elinieal seores were calculated and recorded in Tables 11.4-
11.7 below:
a) by linear regression (Analyses 1-3) e.g.
bysort patientid: regress m m se jo t intervalyears (gave MMSE rate o f decline in eaeh 
patient)
b) within the linear mixed model e.g.
xtmixed m m sejo t intervalyears \\ patientid: intervalyears, cov(un)
The correlation eoeffieient column described the correlation between the SD o f the 
slope and the SD o f the intercept. Thus in a positive correlation, a positive initial score 
(intercept) was associated with a positive (high) rate o f ehange (slope). This was useful 
as all scores described here had different scales, and this allowed a comparison between 
seores. If  a correlation eoeffieient = 1 or -1 (depending on the test scale) it meant that 
those with the highest seores declined clinically at the fastest rates (slope A below) and 
those with the lowest scores declined clinically at the slowest rates (slope B below).
207
Q.
Change in clinical score
Figure 11.6 Explanation o f  the correlation coefficient
11.3.1.1 Non-videoed neurological tests 
The rates o f change in each predictor are tabulated below.
Table 11.4 Mean rates o f  change per year in each predictor using average rates from  
linear regression, and rates within the linear mixed model.
Test/
predictor
Linear 
regression 
rate (An3)
Linear mixed model 
rate (95% 01)
Correlation
coefficient
MMSE -9.24 -2.48 (-3.90, -1.07) 0.71
Barthel -8.21 -5.95 (-9.93, -1.97) 0.14
GIC Dr 0.96 0.41 (0.08, 0.73) 0.45
GIC nurse 0.95 0.45 (0.10, 0.79) 0.46
CDR 3.30 1.79 (0.69, 2.89) 0.38
Rankin 0.72 0.46 (0.14, 0.78) 0.43
ADAS-COG 6.60 7.65 (2.93, 12.38) 1
GCS -2.88 -0.90 (-2.10, 0.30) 1
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11.3.1.2 Videoed cognitive tests 
Table 11.5 Videoed cognitive tests
Test/
predictor
Linear 
regression 
rate (An3)
linear mixed model 
rate (95% Cl)
Correlation
coefficient
Memory -0.88 -0.04 (-0.35, 0.26) -0.99
Letter cancelling -3.54 -0.85 (-2.51, 0.86) -0.26
Line drawing -5.28 -1.15 (-2.09, -0.21) 0.24
Reading Passage 2.21 0.42 (-0,12, 0.96) 0.04
Spelling -0.38 -0.46 (-0.86, -0.05) 0.26
Fragmented letters -1.44 -0.34 (-0.63, -0.06) 0.70
Fragmented Objects -0.59 -0.53 (-0.96, -0.09) 0.13
Calculation -2.45 -0.21 (-0.54, 0.11) 0.99
Miming -0.54 -0.35 (-0.55, -0.15) 0.99
Copying Gestures -0.89 -0.27 (-0,60, 0.06) 0.99
Frontal L Sequencing 1.30 0.26 (0.016, 0.50) 0.99
Words beginning with -5.06 -2.91 (-9.77, 3.94) -0.99
Proverbs 0.08 -0.06 (-0,27, 0.15) 0.99
Digit Span -0.27 -0.37 (-0.66, -0.07) -0.99
Recall -0.91 0.04 (-0.28, 0.36) 0.29
11.3.1.3 Videoed motor tests 
Table 11.6 Videoed motor tests
Test/
predictor
Linear 
regression 
rate (An3)
Linear mixed model 
rate (95% Cl)
Correlation
coefficient
Eye mvmts 0.25 0.27 (0.10, 0.44) 0.87
Finger nose 0.58 0.11 (-0.18, 0.41) 0.03
Rapid alternate 1.17 0.27 (-0.13, 0.68) -0.21
Sequ Index 0.24 0.39 (-0.04, 0.82) 0.55
Sequ Opposit 1.07 0.08 (-0 .21 ,0 .37) 1
Prim Reflexes 0.11 -0.05 (-0.26, 0.17) 1
One Min Obs 0.49 0.06 (-0.11, 0.23) 1
Walk-gait -0.03 -0.03 (-0.10, 0.05) -1
Walk-overall 1.41 0.04 (-0.16, 0.23) 0.30
Heel toe 0.66 -0.79 (-1 .27 ,-0 .32) -1
Rombergs -0.62 -0.24 (-0.45, -0.04) -1
Neuro exam 0.20 -0.03 (-0.22, 0.16) 1
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11.3.1.4 Videoed overall scores
Table 11.7 Videoed overall scores
Test/
predictor
Linear 
regression 
rate (An3)
Linear mixed model 
rate (95% Cl)
Correlation
coefficient
C opes tasks 0.06 -0.08 (-0 .41,0 .25) -0.55
Attention Cone -0.38 -0.39 (-0.76, -0.01) -0.51
Cooperative -0.09 0.008 (-0.32, 0.33) -1
Cog impair -0.05 0.17 (-0.16, 0.37) -1
Extrapyramidal 0.16 0.11 (-0.28, 0.50) 0.17
Pyramidal 0.08 -0.12 (-0.50, 0.27) -0.72
Cerebellar 0.66 0.003 (-0.31, 0.32) 1
Generally rates o f change calculated by linear regression were larger (further from 0) 
than those calculated within the linear mixed model.
11.3.2 Analvsis o f  rates o f chari2e in clinical tests
11.3.2.1 Non-videoed score rate o f  change
The figures in the tables above are explained with the following examples: On average 
9.24 MMSE points were lost per year when linear regressions were used or 2.48 MMSE 
points per year using the linear mixed model. On average 6.6 ADAS-COG points were 
gained per year when linear regressions were used or 7.65 points per year using the 
linear mixed model.
The correlation coefficient was highest for MMSE and ADAS-COG (GCS was 
discarded due to findings on scatterplots). Thus, those starting with the scores nearest 
normal declined at the highest rates. This may represent the fact that in this cohort of 
patients those initially near normal declined most during the trial, whereas those already 
impaired declined less in these two tests.
11.3.2.2 Videoed cognitive score rates o f  change
Changes in test scores for memory, calculation, miming, copying gestures, frontal lobe 
sequencing, words beginning with, proverbs and digit span all best mirrored rates o f 
atrophy as correlation coefficients were 1 or -1. Again rates o f decline were smaller in 
the linear mixed model than in the linear regression rate.
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11.3.2.3 Videoed motor score rates o f  change
Tests with correlation coefficients o f 1 or - I were sequential opposition, primitive 
reflexes, one minute observation, walking-gait, heel toe, Rombergs and the neurological 
exam. This was an interesting change from the pattern o f significant baseline predictor 
tests, whieh were sequential index finger tapping and walking overall.
11.3.2.4 Videoed overall score
Changes in the video summary scores (Table 11.7) were much smaller than in other 
tests indicating that these scores changed little over the course o f the study. Cerebellar 
impairment changed most at 0.66 points/yr (but only 0.03/yr using LMM).
Cognitive impairment and cerebellar impairment rates had correlation coefficients o f 1 
or -1. Cooperativeness scores were not considered after viewing data distribution on 
scatterplots.
11.3.3 Univariate linear re2ressions o f  rate o f  clinical score chanse 
asainst rate o f  whole brain atrophv usins analvses 1-3 and the linear 
mixed model.
A linear regression where atrophy rate (analyses 1-3) was the outcome and rate of 
clinical score change was the predictor was performed. 
bysort patientid: regress mmse tot intervalyears 
regress atrophyrate (1-3) mmserate
In Table 11.8 univariate linear regression results are shown for each clinical score. P 
values were coloured orange if  P<0.05 (significant) and yellow if  P>0.05 and <0.1 
(suggesting a trend). If  P values were <0.1 then the coefficient and the 95% confidence 
interval were also recorded.
Regression within the linear mixed model was also performed (final column). 
xtmixed mmse tot intervalyears \\ patientid: intervalyears, cov(un) 
matrix B=e(b)
predict random slope random intercept, reffects 
replace random_slope=random slopedB[1,1] 
drop if  patientid===patientid[_n-l] 
reg atrophy rate random slope
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Table 11.8 Univariate linear regressions o f rate o f change o f clinical scores against rate o f whole brain atrophy
using analyses 1-3 and the LMM
(a) Rate o f change o f non-videoed score asainst rate o f atrophy
Test/
predictor
An 1 
P value An 1 coeff (Cl)
An 2 
P value An 2 coeff (Cl)
An 3 
P value An 3 coeff (Cl)
Linmix 
P Value Linmix Coeff (Cl)
MMSE <0.001 -0.08 (-0.11,-0.05) <0.001 -0.08 (-0.11,-0.05) 0.03 -0.02 (-0.04, -0.003) 0.05 -0.32 (-0.64, 0.002)
Barthel 0.07 -0.12 (-0.24, 0.008) 0.10 0.09 -0.36 (-0.08, 0.006) 0.02 -0.74 (-0.13,-0.02)
GIC Dr 0.05 0.87 (-0.007, 1.74) 0.04 0.90 (0.03, 1.77) 0.04 0.31 (0.02, 0.60) 0.001 2 .2 0 (1 .01 ,3 .40 )
GIC nurse 0.05 0.87 (-0.002, 1.74) 0.04 0.90 (0.03, 1.76) 0.04 0.31 (0.02, 0.60) 0.001 2.06 (0.98, 3.13)
CDR 0.04 0.36 (0.02, 0.69) 0.05 0.34 (0 .001,0 .68) 0.02 0.13(0 .03 , 0.24) 0.01 0.38(0 .10 , 0.67)
Rankin 0.03 1.35 (0 .15,2 .55) 0.02 1.40 (0 .21,2 .59) 0.02 ' 0.50 (0 .11,0 .89) 0.001 1.94 (0 .93,2 .95)
ADAS-COG 0.02 0.09 (0.14, 0.17) 0.02 0.10(0 .02 , 0.17) 0.07 0.04 (-0.003, 0.09) 0.09 0.05 (-0 .11,0.11)
GCS 0.33 0.33 0.07 -0.18 (-0.38, 0.02) 0.12
(b) Rate o f change o f videoed cognitive score against rate o f atrophy
Test/
predictor
An 1 
P value An 1 coeff (Cl)
An 2 
P value An 2 coeff (Cl)
An 3 
P value An 3 coeff (Cl)
Linmix 
P Value Linmix Coeff (Cl)
Memory 0.38 0.34 0.50 0.001 30.6 (14.7, 46.5)
Letter cancel 0.001 -0.14 (-0.23, 0.06) 0.001 -0.15 (-0.23, -0.07) 0.07 -0.04 (-0.08, 0.004) 0.50
Line drawing 0.001 -0.09 (-0.14, 0.05) <0.001 -0.09 (-0.14, -0.05) 0.07 -0.02 (-0.05, 0.002) 0.07 -0.65 (-1.34, 0.05)
Reading <0.001 0.31 (0.20, 0.42) <0.001 0.32 (0 .21,0 .43) 0.02 0.08 (0 .01 ,0 .15) 0.02 1.03 (0.17, 1.86)
Spelling 0.03 0.39 (0.32, 0.75) 0.04 0.39 (0.03, 0.74) 0.36 0.73
Fragm letters <0.001 -0.45 (-0.64, -0.27) <0.001 -0.46 (-0.64, -0.28) 0.02 -0.12 (-0.23, -0.02) 0.14
Frag Objects 0.95 0.51 0.95 0.52
Calculation <0.001 -0.32 (-0.43, -0.21) <0.001 -0.32 (-0.43, 0.22) 0.02 -0.09 (-0.15, -0.02) 0.34
Miming 0.002 -0.70 (-1 .11 ,-2 .49 ) 0.002 -0.71 (-1 .12 ,-0 .31 ) 0.10 -0.17 (-0.38, 0.03) 0.24
Copy Gestures 0.03 -0.36 (-0.68, -0.04) 0.03 -0.36 (-0.68, -0.05) 0.22 0.35
Frontal L Sequ 0.002 0.56 (0.23, 0.89) 0.001 0.58 (0.26, 0.90) 0.04 0 .17(0 .008, 0.33) 0.07 2.30 (-0.24, 4.85)
Words begin 0.05 -0.06 (-0.12, 0.00) 0.006 -0.08 (-0.13, 0.02) 0.12 0.44
Proverbs 0.18 0.18 0.47 0.62
Digit Span 0.02 -0.40 (-0.72, -0.07) 0.005 -0.46 (-0.76, -0.16) 0.19 0.47
Recall 0.64 0.53 0.86 0.40
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(c) Rate o f change o f motor score against rate o f atrophy
Test/
predictor
An 1 
P value An 1 coeff (Cl)
An 2 
P value An 2 coeff (Cl)
An 3 
P value An 3 coeff (01)
Linmix 
P Value Linmix Coeff (Cl)
Eye mvmts 0.69 0.65 (-2.69, 3.99) 0.59 0.12 <0.001 8.2 (4.54, 11.86)
Finger nose 0.10 0.41 (-0.81, 0.91) 0.09 0.41 (-0.07, 0.90) 0.39 0.47
Rapid alternate <0.001 0.41 (0 .21,0 .61) <0.001 0.42 (0.23, 0.62) 0.08 0.10 (-0.01, 0.21) 0.98 0.02 (-1.41, 1.44)
Sequ Index 0.41 0.60 0.20 0.01 0.79 (0.18, 1.39)
Sequ Opposit 0.06 0.32 (-0.01,0.66) 0.09 0.30 (-0.04, 0.64) 0.23 0.06 2.62 (-0.07, 5.32)
Prim Reflexes 0.23 0.22 0.41 0.06 10.4 (-0.36, 21.24)
One Min Obs 0.38 0.76 0.39 0.01 4 .55(1 .02 , 8.09)
Walk-qait 0.26 0.27 0.32 0.13
Walk-overall 0.001 0.53 (0.25, 0.80) <0.001 0.54 (0.28, 0.81) 0.03 0.16(0 .02 , 0.29) 0.001 11.0 (4.98, 17.08)
Heel toe 0.01 0.45 (0 .11,0 .79) 0.02 0.45 (0 .11 ,0 .79) 0.01 0.23 (0.06, 0.40) 0.20
Rombergs 0.15 0.22 0.11 0.91
Neuro exam 0.26 0.27 0.44 0.07 6 .3(1 .91 , 10.71)
(d) Rate o f change o f overall video score against rate o f atrophy
Test/
predictor
An 1 
P value An 1 coeff (Cl)
An 2 
P value An 2 coeff (Cl)
An 3 
P value An 3 coeff (Cl)
Linmix 
P Value Linmix Coeff (Cl)
Copes tasks 0.83 0.81 0.74 0.55
Attention Cone 0.29 0.26 0.08 -0.52 (-1.11,0.07) 0.04 -0.84 (-1.62,-0.55)
Cooperative 0.73 0.60 0.46 0.59
Cog impair 0.41 0.23 0.47 0.03 -16.5 (-31.8, -1.33)
Extrapyramidal 0.04 0.84 (0.02, 1.66) 0.01 1.04 (0.27, 1.82) 0.07 0.25 (-0.03, 0.54) <0.001 4.87 (2 .71,7 .02)
Pyramidal 0.41 0.41 0.42 0.21
Cerebellar 0.04 0.53 (0.02, 1.04) 0.09 0.45 (-0.08, 0.98) 0.10 0.02 83.2(15 .1 , 151.2)
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11.3.3.1 Rate o f change o f non-videoed score predictors 
Similar to the baseline clinical score regressions, rates of change in some simple clinical 
scores are predictors of rate of atrophy e.g. GIC and Rankin, but now the more complex 
measures of cognition, the MMSE and the ADAS-COG became significant. Analyses 1 and 
2 had almost identical P values and coefficients. When Analysis 3 and the LMM were 
compared, the coefficients for the LMM were much larger, the P values for the simple tests 
such as Barthel, Rankin and CDR had smaller P values, and the P values for the MMSE and 
ADAS-COG were higher. Using the LMM thus strengthened the association between rate 
of change in test and atrophy in simple tests, and slightly reduced the association for 
MMSE and ADAS-COG, taking their P values to trend, rather than significant levels.
The set of patients in whom baseline clinical measures were not best suited to predict 
atrophy rate was those who declined rapidly (and atrophied rapidly) over a short time 
period. Rates of clinical score change could better identify those atrophying rapidly, 
particularly the variant and sporadic cases.
The MMSE rates of change in analyses 1-3 are strongly significantly associated with rate of 
atrophy (P<0.001, <0.001, 0.03) whereas there is a borderline significant association with 
the linear mixed model for MMSE (0.05). This can be explained in the scatterplots in 
Figure 11.7. An outlier was identified from the scatterplots using Analysis 3 but not in rates 
of decline generated in the linear mixed model. This method gives less weight to such 
outliers.
i
MMSE change per year
Figure 11.7 MMSE rate o f change scatterplots in Analysis 3 and the LMM
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Non-significant P values were obtained in analyses 1-3 for the Barthel score (0.07, 0.10, 
0.09), but the P value was significant in the LMM (0.02). Higher value outliers are seen in 
the scatter plots in Figure 11.8 below in analysis 3 than in the LMM (note different x axes 
values).
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Figure 11.8 Barthel rate o f change scatterplots in Analysis 3 and the LMM
Rate of ADAS-COG change became a less significant predictor in the LMM (0.09) than 
Analyses 1 -3 (0.02, 0.02, 0.07). Scatterplots show two patients with rapid decline in 
ADAS-COG and rate of atrophy in analysis 3, and one in the LMM.
Scatterplots for ADAS-COG rate of decline v whole brain rate of atrophy in 
analysis 3 (left) and linear mixed model (right).
30 40
Figure 11.9 ADAS-COG rate o f change scatterplots in Analysis 3 and the LMM
11.3.3.2 Rate o f change o f videoed cognitive score predictors 
All coefficients were of the appropriate sign (negative or positive) according to clinical 
context. The only exception was Spelling where coefficients appeared to improve (as the
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coefficients were positive) as atrophy worsened. It is possible that performance improved 
with practice (the same 6 spelling words were used at each test).
The fragmented objects, proverb interpretation and recall tasks were non significant in all 
analyses.
Different patterns of significant predictors are found in the four different analyses. Memory 
was a strongly significant predictor, but only in the linear mixed model (see Figure 11.10 
below).
Figure 11.10 Memory rate o f change scatterplot using the LMM
Letter cancelling and fragmented letters had some outliers in the LMM that meant there 
was no significance, unlike in the other 3 analyses.
Tests showing significance or trend in at least three analyses included Line drawing, 
Reading Passage, Fragmented letters. Calculation and Frontal lobe sequencing.
11.3.3.3 Rate o f change o f videoed motor score predictors 
Rate of change in walking overall was the best predictor o f rate of atrophy. Significantly 
predictive tests from baseline (sequential index finger tapping and one minute observation) 
were significant predictors as rate of change only in the LMM.
Rate of change in eye movements became a significant predictor in the LMM (see Figure 
11.11 below).
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Eye movement change per year
Figure 11.11 Eye movement rate o f change scatterplot using the LMM
Rate of change in rapid alternating movements was significant in analyses 1 -3 and the 
presence of outliers in the LMM (see below) meant that significance was lost. Rapid 
alternating movements change is a good predictor of rate of atrophy.
Rapid Allemallng mvmts change per year
Figure 11.12 Rapidly alternating movements rate of change scatterplots in Analysis 3 and 
the LMM
Several tests showed on scatterplots a large group with very little change and a small group 
showing larger rates of change that tended to influence their significance as predictors. 
Scatterplots are shown below of Sequential index finger tapping, sequential opposition, 
walking gait and Rombergs. P values for these tests differed from those seen in Analyses 1 - 
3. This demonstrates the difficulties of trying to treat CJD patients as a homogenous group.
217
Sequantot index Unger tapping change per year Sequential opposWort change per year
W aking gall ch s ig e  per year Rombergs change per year
Figure 11.13 Scatterplots showing outlying groups
11.3.3.4 Rate o f change of videoed overall score predictors 
In the overall video scores cognitive impairment for the first time became a predictor 
(P=0.03) using the LMM. Likewise extrapyramidal impairment became a predictor, most 
significantly so in the LMM (<0.001). The difference in the scatterplots for Analysis 3 
(P=0.07) and the LMM (P<0.001) is demonstrated in the scatterplots below. This was the 
only overall motor score that was a significant predictor of atrophy rate.
extrapyamldel Jmpalrmenl change per year
Figure 11.14 Extrapyramidal impairment rate of change scatterplot in Analysis 3 and the 
LMM
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Cerebellar impairment here becomes a significant predictor of rate of whole brain atrophy 
(LMM P=0.02). The same association, but with cerebellar rate of atrophy is performed 
below. If the association becomes more significant when cerebellar atrophy rather than 
whole brain atrophy is the outcome measure, then this may indicate that it is the cerebellar 
atrophy within the whole brain that is having this effect.
11.3.4 Multivariate resression
On multivariate regression, MMSE in Analysis 1 maintained significance when regressed 
by ADAS-COG (MMSE coefficient P value=0.015) and ADAS-COG and Rankin (MMSE 
coefficient P value= (0.016)). No other clinical score rate predictors maintained 
significance on multivariate regression in any combination. It is possible that ADAS-COG 
and Rankin are confounders, only associated with MMSE and not with rate of atrophy. 
Analyses 2 and 3 were non significant on multivariate regression in any combination.
11.3.5 R squared values
Finally, it is possible to look at the R squared values for the linear regressions in Analysis 
3. This quantifies how much o f the variation in the slopes is captured by variation in rate of 
change of clinical score. All scores which predicted univariably to a significance of P<0.05 
were included.
An example showing non-videoed scores is shown.
R squared value for Analysis 3:
Change in clinical score ranking:Rankin>CDR>MMSE>ADASCOG>GIC(n)>GIC(d) 
Corresponding R squared value: 0.251>0.250>0.234>0.194>0.189>0.187
Change in Rankin and CDR are the best predictors (CDR also being best for baseline 
predictor overall). The more complex cognitive measures of MMSE and ADAS-COG are 
the next best predictors followed by GIC.
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11.3.6 Does rate o f chanse in cerebellar impairment predict rate of 
cerebellar atrophy?
The same univariate regression was performed with rate of cerebellar impairment from the 
video tests as predictor against cerebellar atrophy rate as outcome. (Linear mixed 
scatterplot can be seen in Appendix T, final scatterplot).
Table 11.9 Univariate linear regressions o f rate o f change in cerebellar impairment rate 
o f cerebellar atrophy using analyses 1-3 and the LMM
An 1 An 3 Linmi Linmix
An1 coeff An2 An 2 coeff An3 coeff X Coeff
predictor P val (Cl) P val (Cl) P val (Cl) P val (Cl)
cerebellar
impairment 0.03
0.80
(0.09, 1.5) 0.03
0.83
(0.10, 1.56) 0.73 0.008
0.53
(0.16, 0.91)
Decline in cerebellar function does predict rate of cerebellar atrophy, when analysis 1, 2 or 
the linear mixed model is used. The result for analysis 3 was unexpected in view of the 
results from the other analyses. When the scatterplots for Analysis 3 (left) and the LMM 
(right) are reviewed, the differences can be seen.
Scatterplots for Cerebellar impairment rate of decline v cerebellar rate of atrophy in 
analysis 3 (left) and linear mixed model (right).
. I
cerebellar impairmert change per year cerebellar Impatrmert change per year
Figure 11.15 Cerebellar impairment rate o f change scatterplot in Analysis 3 and the LMM
The association in the linear mixed model is stronger when cerebellar atrophy (0.008) 
rather than whole brain atrophy (0.03) is the outcome. This may imply that more of the 
association is due to the cerebellar atrophy in whole brains than the non cerebellar tissue.
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NB Regression within a simple linear model was attempted, however, due to the small 
numbers involved the robust Standard Errors could not be applied and results were the 
same as for the linear regressions, 
e.g. Simple linear model:
bysort patientid: regress mmse tot intervalyears, cluster(patientid)
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11.4 Crossover patients: Determining overall atrophy in patients who were 
scanned in both pilot and full trial
Different scanners were used in the pilot and full phases of the PRION-1 trial. Eight 
patients crossed over from the pilot to the full phase. In the analysis thus far, the data from 
each patient has been analysed separately in the two phases. It is possible to calculate the 
rate of atrophy across the entire time interval of scanning. If we assume that subjects are 
losing a constant % per year, it is equally valid either to calculate the percentage (or 
proportion) lost between any pair of scans, all we need to know is the time interval between 
the scans and the logarithm of the ratio of the volume at the second time point to the first. 
The volume at the second time point is taken to be the volume at the first time point minus 
the BSI value. (NB a positive BSI indicates volume loss, hence it is subtracted in the 
formula).
y=log((WBvolscanl- WBBSI)/WBvolscan 1)
The same methods were used as above in Analysis 2 and 3 to generate an overall rate of 
atrophy across pilot and full phases.
Rates of whole brain atrophy In crossover patients
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Figure 11.16 Rates o f whole brain atrophy in crossover patients
Scatter plot above and below show pilot rates of atrophy in dark blue, full trial in light blue 
and crossover rates in green. Patient A is asymptomatic, the rest are symptomatic.
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Rates of cerebellar atrophy In crossover patients
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Figure 11.17 Rates o f cerebellar atrophy in crossover patients
If rates of brain atrophy accelerated in the symptomatic CJD patient (i.e. were non linear), 
one might expect the atrophy rates in the full trial to be significantly more than in the pilot 
trial. This might also occur if a presymptomatic patient became symptomatic 
ttest pilotrate=-fulltrialrate
Table 11.10 Paired T test ofpilot and full trial whole brain atrophy rates
paired I  
test Ani An2 An3
P value 0.2 0.5 0.5
There was no significant difference in the means of the pilot rates and full trial rates in the 
crossover patients. Thus, (despite only having a small sample of eight crossover patients) 
there is no evidence for acceleration in rate of atrophy and assumption of a linear rate of 
atrophy is justified.
Further analyses with these calculated overall rates of atrophy will not be performed. 
However, the demonstration that this method works could be utilised in future trials where 
different scanners are used (e.g. mixture of MRI at local hospital and specialist hospital).
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CASE DESCRIPTIONS
Case Reports
1) A patient with symptomatic P102L disease with high rates of cerebellar atrophy
2) A rapidly progressing sporadic patient
3) A patient with symptomatic 6-OPRI disease with high global rates o f atrophy
4) An iatrogenically acquired case of variant CJD
12.1 A patient with symptomatic P102L disease with high rates o f cerebellar 
atrophy
A man in his fifties presented with a two year history of progressive speech and balance 
problems. Two first degree relatives had tested positive for the P102L mutation. At first 
assessment he complained of diplopia and examination demonstrated jerky visual pursuit 
eye movements and dysarthria. Tendon reflexes were reduced in the lower limb and there 
was marked gait ataxia. He scored 26/30 on MMSE with mild dyscalculia. He had donated 
blood prior to the discovery of the P102L mutation in his family.
Cerebellar symptoms progressed over the next three years until he was wheelchair bound 
and profoundly dysarthric. Cognitive function remained stable until two months before his 
death, six years from first symptoms.
Volumetric analysis of this patient’s cerebellum and whole brain over 18 months revealed 
that the rate of cerebellar atrophy was almost five times that of the whole brain (2.3%/year 
V 0.5 %/year).
Figures 12.1-12.3 demonstrate this cerebellar atrophy.
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Figure 12.1 Serial cerebellar change from baseline. Red = atrophy, green = apparent gain. 
(A) Baseline (B) 6 months (C) 9 months (D) 12 months(E) 14 months(F) 18 months.
Figure 12.2 Cerebellar atrophy in situ. (A) Baseline whole 
brain mask (B) Baseline whole brain mask with baseline 
cerebellum highlighted (C) Baseline whole brain and 
cerebellar mask with atrophied cerebellum highlighted.
B
Figure 12.3 3D image o f cerebellum at baseline (A) and 
after 18 months (B) (Anterior view).
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12.2 A rapidly progressing sporadic patient
A man in his fifties presented with an eight month history of a progressive neuropsychiatrie 
disorder characterised by personality change and aggression, followed by 6 month history 
o f progressive cerebellar syndrome and 2 month history of myoclonus. The prion gene was 
heterozygous at codon 129 MA^ with no mutations detected and no family history of 
dementia. The EEG was non-specifically slow, with no periodic sharp wave complexes. 
MRI showed high signal in cortical ribbon on DWI, with high signal in caudate, putamen 
and pulvinar nuclei, but did not reach the diagnostic criteria for a pulvinar sign as the 
pulvinar hyperintensity was no more than that in the caudate and putamen. CSF showed a 
mildly raised 14-3-3. Due to the diagnostic uncertainty between sporadic and variant 
disease a tonsil biopsy was performed. Immunohistochemistry was negative for abnormal 
prion protein and Western blot was negative. The patient and family declined a brain 
biopsy. A diagnosis of sporadic CJD was made after exclusion of other potential causes.
On examination at presentation he was alert and responsive with an MMSE of 27/30, this 
fell to 22/30 a month later, and 10/30 a further month later. Frontal dysfunction was 
prominent at presentation with progressive rapid cognitive difficulties and ataxia. A 
radiologically inserted gastrostomy tube was placed eight months after presentation.
Whole brain atrophy rates were 3.3%/year with a cerebellar atrophy rate of 1.2%. Figure
12.4 (A and B) demonstrate cortical loss.
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Figure 12.4 3D Whole brain reconstructions (A, B) Sporadic patient demonstrating atrophy 
with widening o f sulci over a 2 month period. (C, D) Symptomatic 6-OPRl patient showing 
cortical loss over a 9 month period.
12,3 A patient with symptomatic 6-OPRI disease with high global rates o f atrophy
A woman in her thirties presented with an eighteen month history of increasing 
forgetfulness, poor concentration and attention. She had been involved in several minor car 
accidents over the same period. She had had to give up work and was having anxiety 
attacks and frequent loss of temper. Three first degree relatives had tested positive for a 6- 
octapeptide repeat insertion in the prion protein gene. Neurological examination was 
normal apart from mild impairment of rapidly alternating movements. She had a normal 
gait and walked independently. Cognitive impairment was significant, with a MMSE of 
15/30, dyscalculia and impaired frontal testing.
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Over the next five years there was progression o f cognitive impairment, such that the 
severely affected protocol had to be used for assessment. The patient remained 
independently mobile for a further three years during this cognitive decline. For the last 
year the patient has become mute, unable to follow simple commands, although is still able 
to mobilise.
Figure 12.4 (C and D) demonstrate cortical loss. Whole brain atrophy rates were 2.7%/year 
with a cerebellar atrophy rate of 3.0%/year.
12.4 An iatrogenically acquired case o f variant CJD
A man in his thirties presented with a 6-month history of progressive balance difficulties 
and impaired concentration. He had incapacitating leg pains and increasing difficulty 
walking. The patient had suffered from ulcerative colitis requiring a colectomy and 
ileostomy nine years before. A year later the ileostomy had been converted to an ileoanal J- 
pouch. Complications in the immediate postoperative period included pelvic bleeding, for 
which he was transfused 22 units of red cells, 15 units of fresh frozen plasma, and three 
platelet doses. He required a further laparotomy and intensive care management. He then 
made a good recovery. One of the donors of the non-leucodepleted red cells received by the 
patient developed vCJD 20 months after donating this blood.
Six years after the vCJD-implicated transfusion the patient had presented to his family 
doctor with a short history o f fluctuating exertional fatigue and impaired concentration. At 
around this time the patient and his doctor were notified of his exposure to a vCJD- 
implicated transfusion, and that he was considered to be at risk of vCJD.
Neurological examination, including clinical cognitive assessment, was normal and no 
biological symptoms of depressive illness were noted. Routine electroencephalogram and 
MR neuroimaging were normal (Figure 12.5 A,B). Eighteen months later, over seven years 
after the vCJD-implicated transfusion, progressive neurological symptoms led to referral to 
the National Prion Clinic. The patient reported a sense of imbalance on turning with a 
tendency to stagger. Memory problems were becoming more prominent and he reported 
difficulties in recalling details of events in the preceding few days. He described a sense of 
tremor in his hands with reduced manual dexterity. Within a few weeks he reported
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severely incapacitating leg pains as an unvarying “searing pain” worsened by activity and 
eased by rest.
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Figure 12.5 Axial MRI in iatrogenically acquired vCJD. Initial T2 (A) and FLAIR (B), no 
pulvinar sign visible. Eighteen months later T2(C) and FLAIR (D) showing the pulvinar 
sign.
Examination six months after the onset of progressive neurological symptoms showed an 
MMSE score of 30/30, digit recall of 6 forward and 5 backwards, with no evidence of 
dyspraxia or visuospatial dysfunction. The patient could walk unaided but preferred to use a 
stick to ease his leg pains. Other than minimal first-degree gaze-evoked nystagmus, cranial 
nerve and other neurological examination was normal.
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Neurological decline continued with more prominent cognitive impairment. 6 weeks later, 
the patient’s MMSE scored 22/30 (with errors in orientation for time, delayed recall, and 
serial subtraction). He was increasingly unsteady. Caregivers reported several falls, and the 
patient indicated that limb pains were less severe. Results of routine haematological and 
biochemical investigations, infection screen, and nerve conduction studies were normal. At 
this stage, MR neuroimaging showed symmetrical abnormal increased T2 and fluid 
attenuation inversion recovery (FLAIR) high signal within the posteromedial thalamus, 
consistent with the pulvinar sign (Figure 12.5 C,D). Non-specific changes were evident on 
EEG. PRNP genotyping excluded genetic mutations and showed codon 129 methionine 
homozygosity. Tonsil biopsy was declined. The patient continued to decline with 
progressive cognitive impairment, ataxia, and dysarthria. He became bed-bound and poorly 
responsive before admission for hospice care. In line with the expressed wishes of the 
patient and his family, medical intervention was kept to a minimum and neither 
gastrostomy nor nasogastric feeding was instituted. The patient died eight years and eight 
months after the vCJD implicated transfusion and an autopsy was done. 
Immunohistochemical analysis of brain and tonsil showed widespread deposition of 
abnormal PrP with characteristic neuropathological changes.
Volumetric analysis revealed a whole brain atrophy rate of 2.3%/year and a cerebellar 
atrophy rate of 1.2%/year.
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DISCUSSION
13.1 Summary o f  findings in this thesis
13.1.1 Brain atrophy in CJD
This study showed that rates of brain atrophy and cerebellar atrophy were significantly 
higher in symptomatic CJD patients than in control patients. Mean whole brain atrophy 
rates were 1.3%/year higher than controls. A threshold at which symptomatic disease might 
be expected would be 1.5%/year or above (as the rate of whole brain atrophy in controls 
was 0.17%/year). It was not possible to match ranges of rates of atrophy to clinical severity 
due to crossover between groups.
Whole brains did not atrophy at a significantly different rate than cerebelli. Atrophy rates 
were not significantly different according to presence of symptoms, sex, disease type or 
inherited disease type in this set of patients.
No asymptomatic patients were deemed to have become symptomatic during the study. 
Rates of atrophy in these patients were not as low as those of the control population, 
suggesting that rate of atrophy may be a prognostic indicator of onset of symptoms. This 
has similarities with neuropsychiatrie signs reported in CJD that are evident on examination 
prior to symptoms being noticed by the patient (Cordery).
13.1.2 Brain volume as a biomarker o f clinical disease
The main assumption if brain volume is used as a biomarker of clinical disease is that rate 
of brain atrophy correlates with disease severity. This assumption was proven in this study 
as several tests across a wide range of the clinical spectrum were significant predictors of 
atrophy rate.
Baseline values of simple tests such as Barthel, GIG, Rankin and CDR were predictors of 
atrophy. An important negative was that baseline brain volume was not a predictor of 
atrophy. Cerebellar impairment at baseline predicted cerebellar atrophy.
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Rates of change of both simple and complex tests such as MMSE and ADAS-COG were 
predictors of whole brain atrophy. Decline in cerebellar function predicted rate of cerebellar 
atrophy.
I suspect from the experience gained in assessing and scanning patients with CJD that 
patients have periods of high rates of atrophy, usually at symptom onset (similar to the 
MRS changes seen in Waldman 2006), at acceleration of symptom severity and when new 
areas of disability start e.g. when P102L patients with cerebellar symptoms start to develop 
cognitive disability late in disease course. Alternative patterns of brain atrophy might be 
seen. For example patients whose clinical course ‘accelerates’ prior to death might be 
expected to be atrophying at a high or accelerating rate, whereas those whose disease 
course has been slow but relentless may reach a ‘plateau’ phase where atrophy rates are low 
and clinical function is severely affected but stable.
13.1.3 Best method for measurins change in volume
BSI was confirmed as being a more accurate means of calculating rate of atrophy than raw 
volumes alone as there was no segmentation error (Analysis 4). CJD volumetry thus 
concurred with all available volumetry evidence in the literature in other dementias.
13.1.4 Best method for determining rate o f atrophy
The majority of the subjects in this study (and all o f the pilot patients) were inherited 
patients. The linear mixed model was the most useful method for determining rate of 
atrophy within the structure o f this study. This may not be true for sporadic or variant 
disease where there is greater variability in rates between patients and a linear regression 
approach may be more appropriate.
13.1.5 SAP
The SAP was a novel technique developed to try and achieve a gradation of function within 
the severe spectrum of CJD. No existing scales for severe dementia adequately fitted the 
clinical spectrum in CJD. The SAP did not prove to be a workable system for assessment of 
the severely affected CJD patients. Further suggestions for a better protocol, in the light of 
the knowledge and experience gained from this study are given later in this discussion.
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13.2 Findings in the context o f  other work
13.2.1 Videoed examination
The use of the videoed examination with later independent scoring, blinded to patient 
details was a novel one with much potential in CJD. It was a technique mostly pioneered 
for the movement disorders, particularly Parkinson’s disease. Within CJD, the use of video 
in the recording and assessment of Kuru in Papua New Guinea played an essential part in 
cataloguing the clinical features of this unique form of human prion disease and provided 
inspiration for the technique.
Patients had consented to the use of their videos for research and teaching purposes so a 
useful library of signs has been collected over the time of the PRION-1 trial which will help 
in educating and informing staff, and recording the clinical features of this disease visually.
13.2.2 Brain volume measurement
This study used a well validated technique to measure brain atrophy in a new population.
No modifications in technique were required for the CJD population, other than a robust 
quality control process due to the common finding of movement artefact. There are no 
reports in the literature from other investigators of the rate of atrophy in CJD.
Rates of atrophy in control patients (0.17%/year) matched those of previous studies such as 
Scahill 2003 at 0.32%/year and rates of global atrophy of 0.2% a year at age 30-50 and of 
0.4% at age 70-80 in very healthy subjects in Fox 2000, Jack 2000 and Jack 2004.
Rates of atrophy found in CJD patients can be compared to AD. In AD atrophy rates of 2- 
3%/year are seen (Fox 1997b) which are not linear throughout the disease. Chan showed 
that rates increase gradually over several years prior to symptom development and 
accelerate as AD progresses. In AD mean presymptomatic atrophy was 0.3%/year and over 
2%/year once MMSE was 23/30 or below. There are clear correlations here with the CJD 
patterns found in this study.
To date in CJD there has been no obvious candidate area designated as a region of interest, 
unlike the hippocampus/amygdala/entorhinal cortex in AD, the caudate and putamen in HD
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and the superior cerebellar peduncle in PSP. The cerebellum has been the first region of 
interest to have volumetric studies in CJD.
Knowledge of the profile of volume loss in CJD adds to the body of knowledge o f brain 
atrophy in dementia, aiding sensitivity and specificity. The particular challenge with CJD, 
is recruiting sufficient numbers of patients into clinical trials to detect differences and 
patterns specific to CJD types.
13.2.3 Identification o f anatomical patterns o f atrophy 
Identification of patterns of atrophy in different dementias started out with observations at 
post-mortem, with areas such as the hippocampus in AD being noted as smaller than 
expected. A similar situation was true in this study, where repeated viewing of CJD 
segmentations revealed a pattern of cerebellar atrophy not seen in other dementias.
Whole brain atrophy rates at best highlight diseases that cause atrophy and at worst mask 
the actual area of atrophy. Now that atrophy has been quantified and identified in CJD 
questions to resolve include whether rates of atrophy reflect a global atrophy affecting all 
glial cells in all brain areas, a cortical process in some patients, or a predominantly 
cerebellar process in others.
Different neuropathological processes or rapidity of neuropathological change may be 
occurring in different mutations, explaining why A117V patients have higher rates of 
atrophy than other mutations. Understanding the neuropathological basis of MRI changes, 
as well as the neuropathological changes that represent whole brain atrophy will be 
important, and studies are currently under way at the Prion Unit comparing 
neuropathological and MRI change.
Non-volumetric MRI sequences can identify changes in anatomical patterns of disease. For 
example basal ganglia change in sporadic patients seen on DWI may disappear late in the 
disease course (Wroe, Oppenheim, Matoba, Ukisu). A combination of MRI sequences 
tailored to CJD type and stage o f disease may be required to provide optimal information.
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If early identification of high atrophy rates could be made on MRI, there is potential for 
atrophy rate being a prognostic indicator in CJD. Earlier diagnosis in rapidly progressing 
patients such as sporadic or variant patients may catch the early stages of the disease and 
presymptomatic vCJD exposed blood transfusion recipients may provide a fascinating 
population within which to test this theory.
Obtaining scans in end stage disease is often impractical. Overcoming the practical 
problems of getting a severely ill, bedbound and mute patient to travel to a hospital for an 
MRI scan is difficult. Consideration must also be given to the ethical issues of the Mental 
Capacity Act of whether on balance the MRI would have any beneficial effect, rather than a 
potential risk for the patient unable to give their own consent.
13.2.4 Outcome measures in clinical trials 
One of the most difficult aspects to determine in a clinical drug trial is how to measure 
differences in outcome between groups. Volumetric MRI has been proven to be a validated 
outcome measure for Alzheimer’s disease. In dementia as a whole a set of validated tests 
have emerged such as the MMSE, ADAS-COG and Rankin scale that provide reliable and 
reproducible results. The challenge in this study was to find a set o f tests which produced 
reliable outcome measures across the huge range of clinical severity and range of 
symptoms seen in CJD. In some ways, the simplest tests bore out the best, with Rankin, 
CDR and GIC being useful predictors of atrophy.
There are interesting correlates with other diseases such as Huntington disease (HD). A 
quote from a paper on outcome measures in HD by Wild and Tabrizi rings very true for 
CJD:
‘HD progresses slowly and our current clinical assessments are inadequately 
sensitive to detect change reliably, even over several years, and cannot distinguish 
between symptomatic benefit and disease modification. There are no established 
methods to assess disease progression in preclinical gene carriers. Therapies in 
mutation carriers early in the disease will probably have slight benefits and be 
associated with adverse effects. The pool of potential participants in HD is finite, 
and trials using current outcome measures would require thousands o f participants 
over long periods. These limitations might restrict the number o f interventions 
that can be assessed, introduce potentially harmful therapies on inadequate 
grounds, or lead to decades of delay in making useful treatments available.’
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Trials such as PREDICT-HD (Paulsen) aiming to identify reliable markers of symptom 
onset in presymptomatic HD patients have parallels with the asymptomatic, mutation 
positive inherited CJD population. Preliminary results from this trial show the volume of 
the caudate and putamen decreased significantly with increasing likelihood of preclinical 
HD becoming symptomatic; corresponding cognitive, motor and neuropsychiatrie scores 
were also significantly predictive.
13.2.5 Statistics Mixed models 
Mixed models have been used to analyse results from longitudinal clinical trials and 
observational trials, for example in HD (Marder). A very similar approach to this thesis was 
used, with baseline predictors of rate of decline being investigated as well as rates of 
decline in clinical scores.
13.3 Advantages and Limitations o f this study
13.3.1 Advantases
The reproducibly good quality scans produced in the full phase of the trial on the National 
Hospital scanner were notable. Scans still had to be excluded due to motion artefacts or 
patient factors, but there were very few technical reasons to exclude scans.
A factor that improved inclusion rates considerably was the introduction of MRIs under 
general anaesthetic. Patients who had had previous scans excluded due to motion artefact 
began to produce good quality volumetric sequences again and patients with claustrophobia 
or severe myoclonus were able to tolerate the scan.
One strength of this study is that one operator (myself) segmented all whole brains and 
cerebelli. Inter-rater variability was therefore not a confounding factor in calculating 
atrophy rates.
The technique for acquisition of the video was optimal. Videoed and non-videoed 
examinations were all performed by two experienced registrars, who had learned the 
PRION-1 protocols during the pilot phase. They followed up their own cohort of patients, 
optimising accuracy o f longitudinal clinical assessment. The clinic nurses who manned the
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video cameras were likewise experienced in the practical videoing o f the examinations, 
adhering to the storyboards to achieve optimal images and sound.
Use of linear regressions meant that missing values did not have to be estimated using 
methods such as ‘last observation carried forward’ or ‘missed^fail’. These methods 
introduce their own types of bias e.g. dead patients keep scoring at the level of their last 
assessment throughout the trial. This was also particularly important as the reasons for tests 
being missed were wide and varied. Simple estimations of missing values would not have 
represented the underlying reasons for absent data.
13.3.2 Limitations
This thesis attempted to generalise all patients into a single CJD category for the purposes 
of atrophy rates and clinical performance. In reality pilot patients were all inherited patients 
and all but three pilot patients crossed over to the full phase. It would perhaps be reasonable 
to infer generalisations of rates of atrophy for symptomatic inherited patients, but to insert 
the caveat for variant, sporadic and asymptomatic inherited cases that more cases are 
required before making any generalisations.
13.3.2.1 Control Group
Ideally, the control group should have comprised an age and sex matched group, recruited 
at the same time as the PRION-1 patients and scanned contemporaneously. In order to 
control for environmental factors, non affected siblings or close family members could 
have been used.
13.3.2.2 Pilot phase
It is perhaps unfortunate for this study that the learning curve o f improvement happened 
during the pilot phase. No videos taken during the pilot phase were used due to the 
evolving protocols and number of missing values. The videos were optimised in terms of 
test content (by creating several similar versions of tests to prevent learning effects, adding 
memory tests to strengthen assessment in this area) and acquisition (by developing a two 
camera approach and adding microphones and a table tripod). The full trial however 
benefited from the experience o f the pilot phase, and produced a fuller and more accurate
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data set because of it. The pilot phase was longer than the full phase, so more longitudinal 
data could have been collected over a longer time period.
13.3.2.3 Full phase
The obvious omission in this study is a control group for the full trial patients, where both 
MRI and clinical controls would have been useful. The need for this group was not 
anticipated when planning the PRION-1 trial. The National Prion Monitoring Cohort Study 
starting in 2007 has provision for control groups from asymptomatic mutation-positive 
family members.
13.3.2.4 Spacing o f scans
A balance has to be made between scan intervals that are too long to catch longitudinal 
atrophy in rapidly progressing disease or asymptomatic to symptomatic switching, and 
intervals that are too short in stable or asymptomatic disease. Provision was made for this 
to a certain extent in PRION-1 as asymptomatic patients were scanned annually, all other 
patients were scanned at intervals according to the PRION-1 protocol.
The cohort of CJD patients investigated in this thesis often had maximum scan intervals of 
less than six months. The minimum scan interval deemed to give reliable BSIs in 
Alzheimer’s disease is six months (Schott). Due to the small number of patients it was felt 
better to analyse atrophy rates in all patients regardless of maximum scan interval. The 
limitations of the less reliable BSIs from shorter scan intervals had to be accepted and 
accuracy optimised. This was partly achieved by having a single segmentor, thus excluding 
inter-segmentor error. The CJD population tests the limits of this technique for determining 
brain volume.
Advantages of the shortest intervals of 0, 4 and 8 weeks was the inclusion of two sporadic, 
one variant, one P102L, one 6-OPRI and one A117V patient whose longest interval was 
shorter than eight weeks. These patients would otherwise have been excluded from 
analysis.
Problems with annual scanning included if there were technical problems with the scan 
(such as the patient moving) which meant that an interval of two years sometimes occurred.
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There was then the potential to lose the scan just before clinical symptoms begin. As MRI 
can be a claustrophobic and noisy environment, stable or asymptomatic patients would 
sometimes elect not to have an MRI, and ‘wait until the next visit’, with the same potential 
problems. Sometimes patients worried that symptoms might be starting would elect not to 
have an MRI for fear o f symptomatic disease stage onset being confirmed. If the index of 
worry for disease onset becomes higher during a routine visit, scans should be planned 
more frequently, at least six monthly.
13.3.2.5 Quality control process
Seventy nine out of 216 scans had to be excluded during the quality control process. This 
process was particularly necessary for the CJD population due to movement artefact. The 
crux of determining brain volume is being able to identify the brain/CSF boundary, and this 
could not be done accurately where movement existed. All scans were segmented prior to 
quality control, so segmentation was often possible despite movement. However, the error 
and therefore variability in brain volumes in this population where very small changes need 
to be detected meant that only perfect or near perfect groups of scans could be used.
An unfortunate effect of the quality control process was that 4/5 variants, 3/5 sporadic 
patients and the single iatrogenic patient were completely excluded. It was felt better to 
apply the same standards to all scans in the trial, rather than making allowanees (and 
therefore increasing error) for certain disease types.
13.3.2.6 Brain volume measurement
In order to improve accuraey repeated segmentation of whole brains and cerebellum could 
have been undertaken by the same segmentor, or by other segmentors and the inter- and 
intra-rater reproducibility calculated. Any learning effects with experience or systematic 
errors in segmentation could have been identified.
Ventricular volumes were not performed in this study due to time constraints, but would 
have been a useful method of internal control of volume change, potentially used to 
highlight any whole brain volumes that were mistakenly high or low. TIV correction was 
not performed in this thesis for a variety of reasons. Instead o f performing TIV, baseline 
variability in brain volume was instead corrected for by calculating % atrophy/year, thus
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negating the need for standardisation of the actual volume. Despite the decreased 
frequency of slice analysis required, the time taken to calculate TIV for every scan would 
have been considerable.
Regression of actual baseline volume against rate of atrophy in each patient did not show 
any significant prediction effect. In light of what we know about baseline variability, this is 
perhaps not unexpected, however, the effect of age and sex could have been removed if 
correction for TIV was done and then regressions performed. More complex analysis over 
the whole asymptomatic and symptomatic phases of disease would be required to fully 
understand rates of atrophy.
In several instances there appeared to be evidence of volume gain over time in whole brains 
and cerebellum. Although it is known that there are daily fluctuations in brain volume due 
to hydration status, volume gain seen is more likely to be due to the error in measurement 
of atrophy or voxel drift (Whitwell 2004) where fluctuations in scanners can affect brain 
volume. Voxel drift can be corrected with TIV correction which was not done in this study. 
There were no examples of very large gains, only small percentages within the expected 
standard errors of segmentation and the technique itself.
In patients with very large rates of atrophy the brain/CSF boundaries could sometimes 
move to such an extent that even the BSI was not an accurate measurement of change as a 
whole lobe could sometimes move several millimetres from its original site. This happened 
infrequently and images were discarded where this effect was large.
13.3.2.7 Videoed examination 
The set of tests videoed in PRION-1 had a lot of overlap and redundancy, but it was 
important to assess which tests worked best in CJD. Editing of the videos was a time 
consuming and laborious task, but a useful one in standardising the images assessed by the 
independent neurologist. There were often many verbal clues to diagnosis which, as far as 
possible were dubbed, or edited out, to keep the independent neurologist blinded to 
diagnosis.
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The obvious visual sign of quinacrine usage (quinacrine imparts a lemon yellow tint to the 
skin) was obliterated with the use of a yellow filter over the DVD player. Other visual clues 
to diagnosis were impossible to remove. It is not hard to guess that a small cohort of 
teenage patients might have variant disease, a cohort of middle aged patients might have 
inherited disease and an older population, bedbound, mute with myoclonus might have 
sporadic disease. These patient stereotypes do not always hold true however, and it is 
equally important to blind to the chronological sequence of follow up visits for this study.
A common reason for data to be missing was that the independent neurologist could not 
hear or interpret the response. As far as possible the recording o f sound and video was 
optimised with good quality digital video recorders and directional microphones on both 
the table and tripod cameras. Despite this, the dysphasia in many patients meant that tests 
could not be scored; equally other causes such as loud background noise, loss of sound on 
the video and extremely quiet speech had the same score outcome.
13.3.2.8 Statistical analysis 
There are three main areas of difficulty in the statistical analysis in this thesis. The first is 
that relatively small numbers of patients were involved and often a non-homogenous 
clinical phenotype was seen even within the same diagnostic category (particularly in 
sporadic cases). Secondly an assumption that data values were normally distributed was 
made. Thirdly an assumption of a linear relationship between tests was made, regardless of 
scoring structure or tendency to categorical values for scoring.
Multiple statistical comparisons have been performed in this study; the interpretation of P 
values or any corrections used must be considered in the light of this multiple testing. There 
are two aspects to consider. Firstly when multiple explanatory variables (such as different 
cognitive tests) are assessed on a single outcome (e.g. whole brain atrophy) there is a 
problem of confounding. The best way to correct for this is to fit a multivariate regression 
with variable selection (as was performed). The second aspect is where multiple outcomes 
are considered e.g. rates of atrophy in many regions. This is less of an issue in this study as 
the only outcome variables were whole brain and cerebellar atrophy rates and the only 
explanatory variable common to both was the cerebellar decline score (no other explanatory 
variables were tested with cerebellar atrophy).
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Techniques such as Bonferroni and Simes corrections can be used where multiple outcomes 
are considered. It is possible to adjust the P values to allow for multiple testing with these 
tests. Bonferroni considers a result statistically significant at the 5% level if p<0.05/no. 
tests. Simes orders the P values, then accepts as significant at the 5% level the first test if 
P<0.05/no. tests, the second test if P<0.05/(no. tests-1), the third if P<0.05/(no. tests-2) etc. 
The P values in this study have not been adjusted as it is probably more important to be 
able to understand what the P value means in the context of each test, rather than trying to 
adjust the level at which significant differences are achieved.
The majority of the statistical tests used in this study were affected to a greater extent by 
confounding than multiple outcomes. A more important problem is the small numbers of 
patients involved. P values will not be large because power is extremely low. The ability to 
identify real effects is simply very small, and there is no way to improve this without larger 
numbers.
Analysis 1 (using first and last values) was the most open of all analysis techniques to 
inaccuracy from errors in measurement of volume change in one or either scan, as this 
method assumed that both measurements were performed without error. Analysis 2 (a 
linear regression of all points) assumed a normal distribution of atrophy rates and that the 
baseline scan was the ‘gold standard’, measured without error.
The effect of the linear mixed model in Analysis 3 was to downweight the effect on the 
group mean of slopes from patients with fewer scans. The linear mixed model tended to 
draw towards the mean rate those patients at rate extremes (low in asymptomatic patients 
and high in variant and sporadic disease). The model therefore reduced the variability from 
the mean (SD), the more so the more patients with only two scans.
The combination of this effect, along with the small numbers involved meant that rates 
were largely determined by those with the greatest number of scans (i.e. the symptomatic 
inherited patients). These patients formed the majority of disease types within the trial 
patients anyway, but this method further exacerbated their effect.
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Data across both the pilot and full phase of the trial was pooled, and rates from analysis 3 
determined using the group mean of all patients. Although using all patients increased the 
numbers, it made the group mean even more dependent on rates from inherited patients as 
the seven crossover patients included one asymptomatic and six symptomatic inherited 
patients, and their rates (although differing between pilot and full trial) were included 
twice.
The ways to correct for this bias are:
a) for every patient to have the same time interval between scans and same number of 
scans, or
b) for patients to have as many scans over as long a time period as possible.
The linear mixed model is best used in a homogenous group; however this was not the case 
in the population assessed here. Large changes in atrophy over short periods of time were 
expected to be accurate in sporadic or variant disease, rather than representing a 
measurement with a lot of error due to the short time intervals involved. This method did 
not give as much weight to those patients atrophying faster over the shortest intervals. The 
only way to give these subjects’ atrophy rate more appropriate weight would be to have 
multiple scans over the short intervals,
A balance between interpreting rates of atrophy generated by analyses 1-3 is required. No 
method is ideal; all have their limitations and advantages.
13.3.2.9 Statistical methods for dealing with missing data 
Linear regressions were used as reasons for data to be missing were varied. All 
analyses of slopes made a ‘missing completely at random’ assumption, i.e. that missing 
values did not depend on any important factor. Mixed models made a ‘missing at random’ 
assumption, i.e. that missing values only depended on other things measured, but not the 
missing (unobserved) value itself. These assumptions could be questioned as sick patients 
were most likely to not have values and this is ‘missing not at random’. Use of linear 
regressions was the best solution devised to deal with these problems.
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GCS measurements were often not recorded as the patients were able to perform the 
MMSE instead. However, determination of the time when GCS became less than 15 was 
lost. Conversely almost all the walking score missing data was due to the patient being 
unable to stand, and data was missing as there were inadequate means of recording this on 
the trial forms.
Overall it was felt better not to try and estimate missing values directly due to the range of 
reasons for them to be missing, as well as the assumptions made in the methods such as 
linear regression partly used to deal with the missing values.
Disadvantages of the linear regression method were that periods o f rapid change were 
missed due to the effective averaging out of points over the timescale of the trial. Also, 
rates of change generated over very short intervals were more susceptible to error in rate of 
change estimates, and again may not have been representative of the pattern of atrophy over 
the time course o f the trial.
Some analyses regressed estimated quantities on other estimated quantities (e.g. rate of 
change in clinical score against rate of atrophy). Usually this method regresses 
observed factors on other observed factors which are assumed to be without error. Within a 
model an error for the dependent variable is fitted; the fact that the independent variables 
here were measured with error is a potential disadvantage. Other methods have been 
developed for meta-analysis which can adjust for this (meta-regression) but cannot be 
performed in conjunction with a mixed model.
13.3.2.10 Quinacrine
The small numbers of patients and the ‘patient preference’ aspect o f the trial caused large 
problems in interpretation of analysis and fundamentally questioned whether analyses were 
meaningful to perform in the first place.
The PRION-1 trial was powered to detect statistically significant differences between 
groups but assumed that the majority of patients would choose randomisation, which they 
did not. Thus any statistically significant difference found between treated and non-treated 
patient groups might reflect selection bias in each study population.
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Many factors could affect the patient’s decision of whether or not to choose quinacrine. 
These factors would also have to be involved in matching patients. Some factors can be 
measured within the trial, such as severity of disease, but other potentially significant 
factors (such as presence of an enthusiastic relative, recent media coverage or provision of 
sufficient social care) need to be taken into account which cannot or have not been formally 
measured.
The length of time that quinacrine was taken and the dosage varied sufficiently such that 
the ‘quinacrine’ group were heterogeneous, even before association with MRI and clinical 
measures were made. Ideally the same dose should have been used for the same length of 
time in all patients -  it would be difficult to justify that any effect quinacrine had on a 
clinical measure was the same whatever the dosage and length of time quinacrine was 
taken. Reasons for changing dose or stopping quinacrine were varied, but mostly 
independent o f disease stage (e.g. liver toxicity, nausea and rash, rather than inability to 
swallow or decreased level o f consciousness), so no useful information on disease stage and 
stopping quinacrine can be made.
If there were large numbers in both quinacrine and no quinacrine groups, and they were 
well matched then interaction effects could be better ascertained. Possible interaction 
effects could be qualitative (e.g. association absent on quinacrine, association present off 
quinacrine) or quantitative (e.g. association smaller on quinacrine than off quinacrine).
Most potential interactions in the context of MRI and clinical measures would be 
quantitative. The linear mixed models used are designed to allow "individual" level effects 
which can be slightly smaller or larger than the group mean. Even if there are small 
quantitative interactions between atrophy rate and clinical score which cannot be detected 
due to low power, the effect of the model is to decrease any differences in atrophy rate in a 
subgroup. Thus even if quinacrine had some demonstrable effects on the clinical scores and 
atrophy rates, the effects would have been smoothed by the model. This justifies 
extrapolation of the whole group as being representative of the described CJD population, 
rather than of a treatment and no treatment arm combined.
Many different kinds of analysis could have been performed comparing quinacrine with no 
quinacrine groups. However, any associations found would be uninterpretable, because any
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effect seen might be due to differences in the kind of patient who chooses quinacrine or not, 
(which cannot be adjusted for), and not due to quinacrine itself. Similarly, even if no 
associations are found, there might be a large quinacrine effect obscured by lack of 
comparability which again cannot be adjusted for.
As quinacrine is a stimulant, it might be predicted that clinical measures reflecting 
increased levels of attention (such as words beginning with the letter...) would not decline, 
or would improve. An obstacle in assessing this is that the baseline clinical assessment and 
scan were often done soon before the quinacrine was started which did not allow sufficient 
time to properly assess level of functioning before the treatment was commenced. Ideally at 
least two measures could have been performed before quinacrine was started with as long 
an interval as possible.
Ideally clinical data used to inform decisions on disease specific clinical severity scores 
should have come exclusively from patients not taking quinacrine, or off quinacrine for a 
suitable length o f time. However, in a small treatment group whose members are at best 
hoped to improve in the short term or cease to progress, it was felt reasonable to include all 
patients.
13.4 Future potential work - MRI
Ideas for improvements to any future clinical trials in CJD are proposed, as well as severity 
scales in CJD in light of the results produced.
13.4.1 MRI as an objective measure in future trials 
Clinical assessment in CJD is challenging due to the diverse range of symptoms and 
disease severity. Many of the cognitive and motor measures used in this thesis are affected 
by variable factors such as mood, intellectual ability, motivation or fatigue as well as 
neurological dysfunction such as apraxia or dysarthria.
Brain volume is an objective measure unaffected by such factors and unable to be altered 
intentionally by the patient. It is a tool that can be used across all types o f CJD at all stages 
of disease and is therefore potentially one of the most usefiil independent measures of 
disease progression in future clinical trials in CJD.
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13.4.2 Proposals for scan intervals in future clinical trials in CJD 
Asymptomatic patients on yearly scanning should be scanned six monthly. Variant and 
sporadic patients should be scanned every four weeks if tolerated. Careful trial protocol 
planning is required to optimise the number of scans performed in each disease type to 
sufficiently power the study.
13.4.3 Brain volume measurement
With additional time to develop segmentation protocols it would have been useful to 
segment the caudate, putamen and thalamus, to see if signal changes on MRI equate to loss 
of volume in these structures and whether these structures atrophy before clinical disease. 
VBM could be used either in a cross sectional manner to compare changes with a control 
group, or in a longitudinal manner to ascertain the anatomical patterns of atrophy in 
different CJD types. VBM may provide a diagnostic aspect to CJD volumetry to add to its 
current monitoring and outcome measure roles.
13.4.4 Cerebellar sesmentation
In theory, as the cerebellum is a relatively large structure (approximately 10% of whole 
brain volume) there should be less measurement error than in smaller, less well defined 
structures such as the amygdala and hippocampus which have measurement errors of 
around 5%.
Boundaries were defined by manual tracing of the tentorium cerebelli and the superior 
cerebellar peduncles. Improvements on this technique could be achieved by a semi 
automated method of identification of linear boundaries (such as the tentorium) and 
therefore remove some of the manual element.
The future for determining brain volumes undoubtedly involves automated techniques, 
rather than time consuming manual segmentation. Methods for automated calculation of 
whole brain volume with well defined brain/CSF boundaries exist and are being developed 
for other regions of interest such as the hippocampus and cingulate where boundaries are 
less well defined or are a mix of grey matter, white matter and CSF.
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13.4.5 Future use o f imasins in CJD diasnosis
A future area of study is the labelling of PrP using a marker visible on imaging (for 
example PET) which would be specific to prion disease and which would form the basis of 
a diagnostic test in vCJD and sCJD, without the need for biopsy.
13.4.6 Future applications o f neuroimasins
Volumetric and non-volumetric MRI both have roles in monitoring CJD progression, but 
may be stronger in combination than alone. Future research will be directed towards finding 
the earliest point in the disease course where imaging changes are evident. Quantitative 
techniques such as DWI, diffusion tensor imaging, and volumetric imaging may be o f use 
firstly in presymptomatic patients (either inherited or exposed to infectious prions) to help 
predict the onset of clinical disease, and secondly in symptomatic patients measuring the 
response to treatment in therapeutic trials. As current and future MRI sequences evolve, 
those showing the earliest changes, with the highest sensitivity and specificity should be 
prioritised in diagnostic imaging.
13.5 Future potential work -  clinical assessment
Part of the reason for assessing predictors of brain atrophy rates was to provide evidence 
for which tests were most useful in monitoring disease progression in CJD. The group of 
tests used was intentionally large; there was significant overlap and thus redundancy in the 
testing. Prioritising tests that most closely mirror rate of atrophy will make clinical 
assessment more efficient and reproducible in the future.
13.5.1 Which non-videoed tests should be used?
The non-videoed assessments such as MMSE, ADAS-COG, Rankin, Barthel, CDR and 
GIC were applicable and useful in all CJD patients. MMSE and ADAS-COG were the two 
most comprehensive cognitive tests. The decision as to which to use should be tailored to 
symptom state. The ADAS-COG was best used when trying to identify the point at which a 
patient changed from asymptomatic to symptomatic status, MMSE was a better general 
measure. Repeated measures of both tests were important to allow rate of decline to be 
measured, which was a better predictor of brain atrophy.
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Baseline MMSE and ADAS-COG scores were too widely spread to be significant 
predictors of brain atrophy. P102L patients had higher scores in both MMSE and ADAS- 
COG for longer than 6-OPRI patients as they manifested their decline more in cerebellar 
function and mobility than cognitive function. Rate of decline in MMSE and ADAS-COG 
was a significant predictor o f atrophy rate.
Activities of daily life were measured with the more complex Barthel and simpler Rankin. 
Barthel was the more superior due to greater range of activities considered and greater 
range of outcome scores. The range of scores in Rankin was low, and many patients did not 
change scores throughout. This was not necessarily a criticism as most inherited 
symptomatic patients were very stable clinically, and Barthel scores could fluctuate in these 
patients more.
The associations between rate of atrophy and Barthel and Rankin scores were almost 
identical when baseline Barthel and Rankin scores were used as predictors. Rate of Rankin 
score change had marginally better associations with rate of atrophy than rate o f Barthel 
score.
Rankin is such a quick and easy test to perform that there can be few grounds for excluding 
this test from future clinical trials. The more detailed assessment used in the Barthel index 
could be more useful in the least affected or asymptomatic patients.
CDR scores subtly different functions to the tests of activities o f daily life above and is a 
useful comparison as it may detect differences more applicable to the CJD population or a 
subgroup of it. Baseline CDR was an almost identically good predictor of atrophy rates as 
Barthel and Rankin scores. Rate of change of CDR was as good as Rankin as a predictor. 
Being sufficiently different, but just as useful, it should be included in future clinical trials.
GIC is the most subjective of the tests, as it is dependent on the rater’s opinion which may 
be affected by knowledge of disease type and length of symptoms. However, it is also free 
of the restraints of fixed determined outcome scores that the other tests have. If  the other 
tests are too rigid to detect or measure change in patient status this may be the only way of
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getting a true global picture of decline. Separate doctor and nurse GICs were scored in the 
trial; in future a consensus view should be sought and recorded.
Baseline GIC and rate of change of GIG were both significant predictors of rate of atrophy, 
thus both subjective and objective measures of disease severity were significant predictors 
of brain atrophy. That the subjective clinician’s assessment was as good a measure as 
objective tests is a testimony to the knowledge and experience of CJD that these clinicians 
had accrued over the course of the trial. If the clinicians were less experienced or if there 
were more clinicians assessing patients there might have been more variability in scores, 
thus making GIC a less significant predictor. Trial clinicians carried individual caseloads so 
they followed up their own sets of patients, and were thus in the best position to identify 
change.
The theory behind the GIC score is that it is an instrument intended to measure clinically 
meaningful change, rather than a measure of the score’s use in assessing change. GIC is not 
intended to be a sensitive measure o f small changes that are unlikely to be clinically 
meaningful. In principle, a clinician rating a subject as changed on a global change scale is 
determining clinically meaningful and distinct change. Therefore, any change recorded on a 
GIC is considered clinically significant by definition.
GIC should be included in future clinical trials as it is a simple and quick test, but with the 
proviso that a small number of experienced clinicians do the rating and that each patient is 
followed up by the same clinician. If time is limited then either the GIC or the Rankin 
should be omitted as both have very similar scales and are equally good predictors of 
atrophy.
Patient visual analogue scores are useful measures of symptom control and patient insight, 
but little consistent information is gained about disease progression. Analogue scores 
should not be used as an outcome measure in trials in CJD patients similar to PRION-1.
GCS is a very useful tool in assessment across all CJD types. Its utility was compromised 
by a high rate of missing values due to poor trial design. This test should certainly be
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performed and due to its simplicity could be reliably completed in all patients at all stages 
of disease (an uncommon virtue amongst tests).
A summary table of these findings is shown below:
Table 13.1 Which non-videoed tests should be used in a future CJD trial?
Tests to keep Area of most use Tests to discard
MMSE Global Patient visual analogue scale
Rankin
GCS
ADAS-COG Early symptomatic disease
Barthel
CDR Significant predictors of 
atrophyGIC
GCS Terminal decline
The global tests and significant predictors of atrophy should be used in all patients and tests 
best suited to early disease or terminal decline utilised in the appropriate patients.
13.5.2 Which videoed tests should be used?
13.5.2.1 Cognitive
Tests used should be tailored to disease type to maximise efficiency. Added to these 
disease-specific tests should be a core of tests that demonstrate more general change. A 
combination of tests that change as asymptomatic disease becomes symptomatic, as well as 
tests whose longitudinal changes mirror brain atrophy should be used. Currently the 
videoed examination is too long, patients tire quickly and tests at the end of the assessment 
may suffer. Evidence based streamlining is required and is demonstrated here.
In all disease types WC (words beginning with...) was a test that declined with disease 
severity. WC scores in sporadic, variant, asymptomatic inherited and symptomatic inherited 
patients all mirrored clinical decline, and showed pre-terminal decline. This test 
encompasses the full spectrum of CJD and should be included in future testing. It was not a
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test that consistently predicted atrophy, however its good profile of change warrants its 
inclusion.
Memory (ME) is the only test included in the severely affected protocol. It should be 
included to aid comparison between patients.
Spelling (SP) was particularly useful in early symptomatic disease as a sensitive measure of 
decline. Unfortunately SP was not a predictor o f atrophy rates, but its utility may lie more 
in showing a tipping effect from asymptomatic to symptomatic disease, than longitudinal 
mirroring of decline. SP should be included in asymptomatic or mildly affected patients. 
Patients in this early symptomatic phase are a group likely to show learning effects of tests. 
In some ways this can be avoided by producing different versions of picture tests, but 
learning of the method as seen in LC (letter cancelling) and WC cannot be avoided, and 
should be expected in the relatively well and stable patient.
Calculation (CA) was useful in demonstrating rapid decline in sporadic and variant patients 
and should be included.
The reading passage and recall tests (RP, RC) were the least well completed tests. However 
RP was a significant predictor of atrophy rates in those who performed the test. If time 
allows this test should be included. Recall was not significant, and added nothing to the test 
spectrum. It was difficult to standardise scoring of response and was dependent on good 
reading and speech ability.
Fragmented letters (FL) was a much more significant predictor of atrophy than the similar 
test Fragmented objects (FO). FO should be dropped. Proverbs added little to the 
information gained in the video, being unrelated to atrophy and not representing a 
demonstrable stage of decline. Interpretation of patients’ answers was also difficult to 
standardise. Miming and copying gestures similarly added little overall, apart from apraxia, 
which could be better assessed in motor tests.
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Frontal lobe sequencing (PS) was a significant predictor o f atrophy and the best 
representation of frontal lobe function, which can often be impaired, particularly in 
inherited patients with 6-OPRI.
Digit span (DS) is a well validated test in many types of dementia, and was found to be a 
significant predictor in CJD. Tests best showing terminal decline included LD (line 
drawing), LC (letter cancelling) and WC.
A summary table of tests is shown below;
Table 13.2 Which videoed cognitive tests should be used in a future CJD trial?
Tests to keep Area of most use Tests to discard
Words beginning with Global Recall
Memory Fragmented Objects
Spelling Early symptomatic disease Proverbs
Calculation Miming
Reading Passage Significant predictors of 
atrophy
Copying Gestures
Fragmented letters
Digit span
Frontal lobe sequencing
Letter cancelling Terminal decline
Line drawing
The global tests and significant predictors of atrophy should be used in all patients and tests 
best suited to early disease or terminal decline utilised in the appropriate patients.
13.5.2.2 Motor
There was less ‘redundancy’ or overlap of test areas in the motor section than in the 
cognitive section. Scatterplots in motor scores often showed the majority of patients with 
little change, and a cohort of patients who had larger change. Matching disease type to test 
is therefore important.
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Walking was a good overall indicator of severity of disease. Heel toe tests were useful if 
walking was normal, or near normal, but should only have been attempted if the patient 
could walk unaided. Heel toe and finger nose tests were most useful in the disease types 
with cerebellar manifestations such as P102L and vCJD. The Rombergs test added little to 
the test profile.
Tests demonstrating apraxia such as SO (sequential opposition) and RA (rapid alternating 
movements) are useful for 6-OPRI, variant and sporadic patients. SI (sequential index 
finger tapping) is predictive at baseline and at rate of change, so this is a useful global 
score.
P102L patients lose their reflexes during the course of their disease, so this aspect of the 
neurological examination is particularly useful here.
Presence of myoclonus is not a marker of disease severity, but is a useful confirmation that 
CJD is a likely diagnosis in patients who have not met diagnostic criteria or undergone a 
brain or tonsil biopsy in sporadic or variant CJD. The one minute observation for 
movement disorder should therefore be included.
Eye movement examination was useful in adding to the knowledge of the types of eye 
movement disorder seen in CJD and rate of change in eye movements was significant in the 
LMM, however this is probably not a good candidate for monitoring change. There are 
interesting correlates with presymptomatic changes in eye movements in Huntington 
disease that could be compared with the CJD population (Golding).
Primitive reflex was the test least likely to show a change in any disease type. The one 
caveat to this was the highly performing sporadic patient whose only change was the 
presence of one reflex in their last assessment. This alone was insufficient to warrant the 
inclusion of the test for all. The palmomental reflex was not a useful test in CJD; pout and 
glabellar reflexes were easier to perform and video and were more likely to be present.
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A summary table of tests is shown below:
Table 13.3 Which videoed motor tests should be used in a future CJD trial?
Tests to keep Area of most use Tests to discard
Walking Global Eye movements
Neurological examination Pr Reflex, esp palmomental
Sequential index finger Rombergs
Sequential opposition 6-OPRI
Rapid alternating mvmts
Finger nose test P102L
Heel toe test
Neuro exam - reflexes
Rapid alternating mvmts vCJD/sCJD
Finger nose test
Heel toe test
One minute observation
As there is a lot of crossover of useful tests between disease types, all tests except the 
discarded ones above should be used in all patients.
13.5.2.3 Overall assessments 
Did the overall assessments from the cognitive and motor sections of the video provide any 
more enlightenment than the sections themselves? With one exception, the answer is no.
Extrapyramidal impairment change was a significant predictor, an aspect that could not 
easily be analysed from individual test scores. There was confirmation that rate of change 
in cognitive impairment and cerebellar impairment were significant predictors, but these 
results could have been gleaned from individual tests. Tests such as cooperativeness did not 
differentiate adequately between patients (as only two patients scored differently from the 
rest), and the attention/concentration and coping with task questions were non-significant 
throughout.
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13.5.3. Su22ested future use o f ratins scales in severely affected patients 
The Severely Affected Protocol was an unsatisfactory method for measuring function and 
disability in the PRION-1 trial. Further thought on how to assess these patients is required, 
particularly as increasingly CJD patients are surviving for months and sometimes years in 
end stage disease. This is particularly true of variant CJD; improved nursing, nutrition via 
gastrostomy tube and high vigilance for infection mean the average life expectancy in this 
young group o f patients is probably higher than the quoted six months in the literature.
There is a need for a comprehensive scale that can be applied to all patients, but which does 
not have the ‘flooring’ problems of losing the ability to differentiate between the final few 
levels of function. Delineation of these symptoms is important, particularly in trials in CJD 
where the aim to date has been to halt progression of disease, rather than make 
improvement. If the level of severe impairment at baseline cannot be adequately measured, 
there is no hope of detecting a treatment effect.
A potential comprehensive rating scale is the Disability Rating Scale (DRS) which was 
designed to assess improvement in moderate and severe patients with traumatic brain 
injury. It is mixture o f the Barthel measure of ADL and GCS with additions. Areas covered 
include: Eye opening. Communication ability. Motor response. Feeding, Toileting, 
Grooming, Level of functioning and Employability. It aims to cover the full range of 
abilities from ‘coma to community’. The DRS is however not particularly sensitive at the 
lower end of the scale, so although an improvement on the current severely affected 
protocol, additional tests to delineate these patients would be desirable (see Coma/Near 
Coma Score below).
Disadvantages of comprehensive scales such as this are also that the subtle early signs in 
previously asymptomatic patients are often not detected. A solution might be to incorporate 
aspects of different scales, such that detection of change is focussed on areas significant in 
the patient’s CJD type and stage, for example doing a full ADAS-COG and MMSE on all 
asymptomatic patients at each visit.
Another comprehensive rating scale is the Total Functional Capacity score (TFC) which is 
used to grade progression of symptoms in HD (Shoulson) (Table 13.4).
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Table 13.4 Total Functional Capacity Scale
Total Functional Capacity (TFC) Scale
Engagement
in
occupation
Stage I (TFC 
11-13)(0-8 
years)
Stage II 
(TFC 7-10) 
(3-13 y)
Stage III 
(TFC 3-6) 
(5-16 y)
Stage IV 
(TFC 1-2) 
(9-21 y)
Stage V 
(TFC 0)(11- 
26 y)
Lower level
Marginal
Unable
Unable
Capacity to 
handle 
financial 
affairs
Usual level Full
Requires
slight
assistance
Requires
major
assistance
Unable
Unable
Capacity to 
manage 
domestic 
responsibilities daily living
Capacity to C arecanbe
per o m  provided
activities of at...
Full
Full
Impaired
Unable
Unable
Full
Full
Mildly
impaired
Moderately
impaired
Severely
impaired
Home
Home
Home
Home or 
extended 
care facility
Total care 
facility only
This scale details level of function in the domains of workplace, finances, domestic chores, 
activities of daily living and requirements for unskilled or skilled care. It has the benefit of 
being in regular use and validated in HD, a disease with a similar profile of asymptomatic 
through to severe disease. The additional measurement of where care is provided is a useful 
measure not covered in other scores. In CJD access to care at home or hospice is available 
to all due to funding from the National Care Package, so is not dependent on income.
Several scales have been developed for the severely affected group of patients with 
dementia. The Level of Cognitive Functioning Scale (LCFS) has potential use as it covers 
the spectrum from normal to severely affected but better delineates the later stages. It is an 
eight point scale gradating the presence and appropriateness of response to general external 
stimuli. It is effectively an extension of the GCS, but more tailored to a declining patient 
with dementia:
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1 -No response
2-Generalised response
3-Localised response
4-Confnsed, agitated response
5-Confused, inappropriate, non-agitated response
6-Confused, appropriate response
7-Automatic, appropriate response
8-Purposeful, appropriate response
This would be a useful scale to use in all variant and sporadic patients from the first 
assessment, in order to catch the point at which less than full scores are obtained and to 
provide an overall measure of decline. An indication of appropriate score could be gained 
from carers and relatives, particularly if there is fluctuation in severity. One of the 
drawbacks of the PRION-1 assessments was that a brief snapshot of function was gained 
and rated, which may not have been representative of current level of functioning. Carers’ 
assessments were not always possible to include. The LCFS should be piloted before future 
trials to ascertain its effectiveness as it seems a useful and practical test in end stage CJD.
The Severe Impairment Battery (SIB) is another alternative to the SAP, however it has too 
many shortfalls that are similar to the SAP such as ‘flooring’ of scores, so would perhaps 
add little.
Two potential tests in pre-terminal stages are the Coma Recovery Scale (CRS) and the 
Coma/Near-Coma (CNC) Scores. Pre-terminal patients in PRION-1 who had few videos 
(and usually no MRIs) often had abnormal patterns of respiration or were mute and 
unresponsive. Current assessment did not include measurement of pre-terminal markers, yet 
progression in these patients was often visible on follow up assessments.
The Coma Recovery Scale was initially described by Giacino in 1991 and revised in 2004.
It was designed to assess patients with disorders of consciousness. The scale has 23 items 
in six subscales covering auditory, visual, motor, oromotor, communication and arousal 
functions. The subscales are organised into hierarchical brain stem, subcortical and cortical 
processes. The lowest score on each subscale represents reflex activity while the highest 
scores represent cognitively mediated behaviours.
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The CNC expands the levels of the Disability Rating Scale (DRS) to include the vegetative 
categories. It was developed to measure small clinical changes in patients with severe brain 
injuries. The CNC has five levels, based on 11 items that can be scored to indicate severity 
of sensory, perceptual, and primitive response deficits.
The 11 items are:
Auditory: Bell ringing
Command Responsivity: Request patient to open or close eyes
Visual: Light flashes
Visual: Tracking
Threat: Eye blink to threat
Olfactory: Ammonia capsule
Tactile: Shoulder tap
Tactile: Nasal swab
Pain: Firm pinch on finger tip
Pain: Robust ear pinch/pull x3
Vocalisation: Best response.
The total score is calculated as a mean response from the 11 items.
Use of the DRS combined with the CNC for patients in the lowest band of scores for the 
DRS should be piloted. This would extend the spectrum of disease that could be measured 
to include more severely affected patients. Due to its all encompassing nature, it may 
obviate the need for the other separate scores.
There are many scales that could be used in the CJD population that have been used in 
other dementias. Revisiting which scales should be used in which patients, or alternatively 
choosing comprehensive scales to apply to all patients at all stages of disease would be a 
useful exercise, as there are several easily applicable alternatives.
13.6 How should disease severity in CJD be measured?
PRION-1 used a wide range of clinical tests on a CJD population in order to assess which 
tests best represented decline or change. There is currently no classification of disease 
severity in CJD, like that found in Alzheimer’s disease (McKhann). AD is a better studied
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disease with more patients in whom to assess and validate markers of severity.
Development of a ‘Global Severity Score in CJD’ comprising various aspects of clinical 
tests, that could perhaps be tailored to clinical scenario would be advantageous as a clinical 
tool.
Markers of change between asymptomatic and symptomatic disease would be useful both 
for inherited patients, as well as the cohort of patients exposed to variant CJD via infected 
blood transfusion. These markers could be used in the future when a new exposure of a 
group to infectious prions through an iatrogenic medium occurs, be it blood transfusion, 
infected surgical instruments or endoscopes. A sensitive and specific marker is required. 
The ftiture cohorts of those with iatrogenically acquired CJD may prove to be the 
population that validates these markers of severity.
No patients officially turned from asymptomatic to symptomatic during the course of this 
study. A group of five asymptomatic patients are being followed up (and will continue to be 
followed up after PRJON-1 within the auspices of the National Prion Monitoring Cohort). 
Experience gained from when these two P102L, one E200K, one A117V and one D178N 
patients become symptomatic will be invaluable in informing clinicians in the pattern of 
change. Unfortunately there are currently no 6-OPRJ asymptomatic patients being followed 
up.
The correlation coefficients of the regressions of rate of change o f clinical score and rate of 
atrophy showed that MMSE, ADAS-COG, cognitive impairment and cerebellar impairment 
rates were the tests that mirrored rates of brain atrophy most closely. This also provides 
some justification for my reasoning in segmenting cerebellums as well as whole brains in 
this thesis.
Using the information gained in the PRION-1 trial the following clinical severity markers 
are suggested in different disease types:
P102L:
Typical disease course includes early cerebellar signs followed by loss of lower limb 
reflexes and confinement to wheelchair, with later cognitive decline and reduced GCS.
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Stage 0: Asymptomatic, normal cerebellar and cognitive function.
Stage 1: Presence of one or more cerebellar signs on consecutive assessments (Finger nose 
testing, gait if wide based, heel shin test, nystagmus on eye movements) or not normal on 
videoed cerebellar impairment score.
Stage 2: Loss of lower limb reflexes
Stage 3: Confined to wheelchair for most daily tasks
Stage 4: MMSE <28 or ADAS-COG >10
Stage 5: GCS <10
6-OPRI:
Typical disease course includes early cognitive decline, demonstrated first on ADAS-COG, 
severity of cognitive symptoms increases such that Barthel score falls below half, MMSE 
falls to a third and finally GCS drops.
Stage 0: Asymptomatic, normal cognitive function
Stage 1 : Score of >5 on the ADAS-COG on consecutive assessments
Stage 2: Score of >10 on the ADAS-COG on consecutive assessments
Stage 3: Barthel <10
Stage 4: MMSE <10
Stage 5: GCS <10
Sporadic:
A simpler scale is required in sporadic patients due to the later presentation to specialist 
services and rapid progression of symptoms
Stage 0: Asymptomatic, normal cognitive, cerebellar and psychiatric features
Stage 1 : Able to attempt all questions in MMSE
Stage 2: Barthel <10
Stage 3: GCS <10
Stage 4: Bedbound and mute
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Variant:
The need to identify symptomatic disease exists due to the cohort of infected blood 
recipients.
Stage 0: Asymptomatic, normal cognitive, cerebellar and psychiatric features
Stage 1 : Mild social withdrawal, depression, uncharacteristic behaviour
Stage 2: MMSE < 28 or ADAS-COG > 10
Stage 3 : Barthel < 10 or MMSE <10
Stage 4: GCS <10
Stage 5: Bedbound and mute
Overall:
An overall scale that would generalise across all types of CJD is described below:
Stage 0: Asymptomatic, normal cognitive, cerebellar and psychiatric features
Stage 1 : Score o f 5 or more on ADAS-COG or cerebellar symptoms
Stage 2: Barthel <10
Stage 3: GCS <10
Stage 4: Bedbound and mute
Myoclonus, although typical o f variant and sporadic disease is not present consistently 
enough to warrant it being a disease severity marker, more a confirmatory sign that a 
diagnosis of CJD is likely to be correct.
In future trials rates of brain atrophy could be correlated with stage of disease to assess the 
prognostic use of brain atrophy rate. Finding the right combination o f markers o f disease 
severity in each disease type will make disease staging and therefore prognostic 
information more robust. It will also allow easier assessment o f change in treatment trials if 
disease severity has been delineated.
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13,7 Future trial design
Patient recruitment is a crucial factor in achieving sufficient power in comparisons between 
groups. Matching or balancing numbers of controls, asymptomatic and symptomatic 
patients is important. For example, comparisons of the pilot rates of atrophy with controls 
confirmed that patients with inherited CJD had an average rate of atrophy 1.3% higher than 
a normal population. One out of the twelve pilot patients was asymptomatic. Ideally 12 
asymptomatic patients would have been compared to 12 matched controls and 12 (or more) 
symptomatic patients. It might be expected that the asymptomatic patients would have 
acceleration in atrophy rate prior to symptom development, similar to the MRS changes 
reported by Waldman (2006) in two asymptomatic P102L patients. With one asymptomatic 
patient this could not be tested or detected.
For every inherited CJD patient diagnosed, there is a normal control population (first 
degree relatives without the mutation) and a population who could be followed up regularly 
to check for symptom onset (mutation positive relatives or those not yet tested). My thesis 
suffers due to a lack of a control population in the full trial patients, both in MRIs and 
clinical scores. Future studies should include a much larger and potentially age and sex 
matched (and environmentally matched in family members) control population. It is 
unlikely that many patients with CJD are missed by the National Prion Clinic or CJD 
Surveillance Unit due to a National referral agreement, and the heightened awareness of 
CJD this has generated in neurologists and GPs. Further steps could be taken to improve 
enrolment success by auditing reasons for patients turning down the trial and seeing if there 
are any solvable issues. Full training for staff in the best manner and technique to broach 
the subject of the trial and recruitment into it should be mandatory.
The fact remains that CJD is a rare, progressive and fatal disease in which patients and 
relatives may be unwilling to enter trials, particularly if they may be randomised to non­
treatment arms of randomised therapeutic studies (Brewin). The emphasis for future trials 
must be to recruit as many patients as possible and to including normal controls as well as 
presymptomatic inherited patients and high risk presymptomatic vCJD exposed patients. 
Recruitment number aims should be realistic within the timeframe of the trial to answer the 
questions posed.
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The National Prion Monitoring Cohort study starting in 2008 addresses some of these 
issues, particularly in aiming to recruit more patients who might provide natural history 
control data. As no drug is being trialled a further opportunity to describe the clinical and 
MRI features in CJD will be provided. If or until a new putative prion active drug is ready 
for trials in humans, it is essential that as much experience can be gained in CJD to 
establish solid baseline characteristics and reproducible tests in order that treatment effects 
can be detected.
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CONCLUSION
14.1 Achievement o f aims
The range and pattern of cognitive and motor test performance in patients with CJD, and 
how these change with time have been described. The rates of whole brain and cerebellar 
atrophy have been quantified and compared to a normal control group, the first time this 
has been done in a population with CJD. Associations between clinical score and rate of 
atrophy were assessed, using baseline clinical and rate of clinical decline measurement.
14.2 Hypothesis
I have shown in this thesis that whole brain atrophy rate is a biomarker o f disease severity 
in CJD and that cerebellar atrophy is a biomarker of cerebellar symptoms in CJD.
With the additional use of suggested severity scales in different CJD types, rate of atrophy 
could be used as a prognostic indicator. Brain atrophy has the potential to be an outcome 
measure in future clinical trials in CJD.
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15.1 Contents
A: Patient Information Sheet: PRION-1 MRI scans
B: Ethics Committee Approval and Consent Form for Control Patients
C: PRION-1 MRI Scan Protocol
D; PRION-1 Schedule for Follow Up
E: Standard Operating Procedure for MRI scans under General Anaesthesia in the
PRION-1 trial 
F: Prion-1 Trial MRI Proforma
G: Neurological Examination PRION-1 Form
H: Cognitive Picture Tests
I: Independent Neurologist Score sheet
J: MMSE (Mini Mental State Examination)
K: CDR (Clinician’s Dementia Rating Scale)
L: ADAS-COG
M: GCS (Glasgow Coma Score)
N: Barthel scale and Patient’s visual analogue score
O: GIC (Global Impression of Change)
P: Scatterplots of whole brain BSI against time-PRION-1 patients
Q: Scatterplots of whole brain BSI against time-Control patients
R: Histograms showing normal distribution of atrophy rates
S: Scatterplots of baseline clinical values and whole brain atrophy rate
T: Scatterplots of rate of clinical score change with rate of whole brain atrophy
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Appendix A Patient Information Sheets:
PRION-1: Clinical investigations
{Form to be on local headed paper)
Version: 2.0 Date: 12 January 2006
PRION-1: MRI 
What is MRI?
MRI stands for Magnetic Resonance Imaging. This is a scanning procedure that uses a combination o f a 
strong magnet, radiowaves and a computer to produce very detailed pictures o f your body. The scan will not 
hurt and has no long-term effect on your body once it is over.
What does an MRI scan show?
An MRI scan provides pictures o f the inside o f your body. Whereas an ordinary x-ray produces very good 
pictures o f the bones, an MRI scan can show details o f the brain, muscles, nerves, cartilage and other internal 
organs.
Preparation for an MRI scan
As the MRI scanner uses a very strong magnet, there are some safety guidelines that must be followed. Let 
the staff in the scanning department know as soon as possible if any o f the following applies to you: 
you have a pacemaker 
you have an artificial heart valve 
you have ever had surgery on your head or spine 
you have any metallic implants, for example joint replacement 
you have ever had metal in your eyes, for example from welding or metalwork 
you may be pregnant
In some of these eases you may need to have an X-ray to make sure that it is safe for you to have an MRI 
scan. The staff in the MRI Department will discuss this with you. You will also be asked to remove personal 
belongings such as your watch, jewellery, keys, credit cards and coins. This is because if  you go into the scan 
room with loose metal objects in your pockets they may be pulled out by the strong magnetic field and fly 
into the scanner. If  you wear your watch into the scanner it may not work when you come out and if  you have 
credit cards in your pocket the information held on the magnetic strip will be wiped off. Metal fastenings on 
your clothes are all right because the magnetic field is not strong enough to pull them off. However, if they 
are close to the part o f your body you are having scanned they may interfere with the pictures and you may be 
asked to change into a gown.
Involuntary movements such as muscle jerking, which is common in prion disease, can interfere with the MRI 
scan. If this is likely to be a problem with your scan, the study doctor will discuss with you about having 
sedation before the scan. This sedation may either be taken in tablet form or as a general anaesthetic. If the 
MRI scan were to be performed under a general anaesthetic it carries the usual risks associated with receiving 
general anaesthetic.
What happens during the scan?
You will be asked to lie on the scanner couch where you will be made as comfortable as possible. The 
position will vary depending on the part o f the body that is being scanned. For example, for a scan o f the head
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you will be asked to lie with your neck or head in a specially shaped support. You should tell the staff if you 
are not comfortable as you will need to keep very still during the scan which may take up to 45 minutes to 
complete. There will be an intercom in the scanning room or some other means o f communicating with the 
staff during the scan. Once you are ready to start you will be moved into the scanner. The scanner is a long 
tube, and the part o f your body being scanned must be completely inside this tube. Although the staff will be 
able to reassure you during the scan, some people do find this unpleasant and slightly frightening.
Each set o f pictures takes about five minutes and while the pictures are being taken you will hear a knocking 
sound. This noise means the scanner is collecting information to produce the pictures and therefore you must 
keep very still. If  you move while the pictures are being taken they will be blurred and the scan may need to 
be repeated. Several sets o f pictures may be taken during each examination and there will be a short pause 
between them. The scanner will go quiet between pictures; during this time the staff will be setting up ready 
to start the next set.
Will I  need an injection?
When certain areas o f the body are scanned, you may need an injection o f a special dye known as a contrast 
agent that helps to see more detail on the pictures. If you need an injection it will be given into a vein in your 
arm by a radiologist or one of the radiographers trained to give injections. Sometimes several scans will be 
taken before the dye is injected and then further scans are taken after the injection. If your scan is being 
performed under general anaesthetic, you would be assessed by an anaesthetist who would give you an 
injection as part o f this procedure.
Can anyone be with me during the scan?
As there are no harmful rays, a friend or relative can stay in the room with you during the scan. Anyone 
coming into the scan will also be asked questions about pacemakers and metal objects in their body, and will 
be asked to remove all metallic objects such as watches and jewellery.
What happens after the scan?
There are no after effects from the scan so you can carry on with your normal activities immediately.
When will I  receive the results o f the scan?
For each scan as many as 50 images may be produced which need to be carefully studied by the radiologists. 
The radiologists will produce a detailed report that will be sent to your specialist, usually within 7 to 14 days. 
More complicated analyses comparing information from different scans over long periods o f time will only be 
carried out at the end o f the trial, so the results will not be available to you for example, at your routine clinic 
visits.
This information sheet has been adapted from an information sheet prepared by the Brain and Spine
Foundation. Their permission to reproduce this is gratefully acknowledged.
www.brainandspine.org
268
Appendix B
THE NATIONAL HOSPITAL FOR NEUROLOGY
AND NEUROSURGERY
Queen Loodon W C IN  3 0 0  
T«kphoo«:017l » 7  3 « |1  
F»x: 0171 *291737
IFM/JK
REF: 
22nd April 1998
Dr M N Rossor 
Consultant Neurologist 
NHNN
Dear Dr Rossor
ALZHEIMER'S DISEASE: LONGITUDINAL NEUROIMAGING, CUNICAL AND 
BIOCHEMICAL STUDIES
I am pleased to inform you that the Joint Medical Ethics Committee approved the 
part of the study as modified in your letter to me dated 11th March 1998 at its 
meeting on 9th Aprii 1998.
The Committee require copies of tiie following documents regarding this application: 
1)
2)
A brief final report on completion of the study and a copy of any published 
results.
immediate notification of any prot)lems which may be identified during the 
study.
3) Notification that the project has been at>orted should this be the case.
Would you kindiy ensure that the points raised by the Joint Medical Ethics 
Committee are addressed before the commencement of this trial. Please send 
confirmation of copies of any amended correspondence to Ms Jayne Kavanagh, 
Secretary to the Joint Medical Ethics Committee, Patient Services Department
I would like to remind you that you must also have approval from the Research and 
Development Office before commencing with this project, therefore, please 
complete the R & D Registration form if this fias not already been done.
continued ...
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22nd April 1998 
Dr Rossor (continued) 
REF; 
1 would be grateful if you could ensure that the appropriate forms enclosed are 
completed.
Please quote above reference on future correspondence relating to this project.
W ith b e s t  w ish es .
Your sincerely
Or I F Moseley 
Chairman
Joint Medical Ethics Committee
Encs.
Ethksriett 99S/2nd/060797
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CONSENT FORM - Confldcntial 
Stady: LongUudinal Research into Alzheimer*s Disease and Other Dementias
Investigator: Professor Rossor 020 7829 8773
I. Have you read the information sheet? Yes No
2. Have you had an opportunity to ask questions? Yes No
3. Have you received satisfactory answers to your Yes No
questions?
4. Which doctor have you spoken to about this study? Dr..........................
5. Do you understand that you are tree to withdraw
from this study
at any time Yes No
without giving a reason for withdrawing Yes No
without affecting your future medical care? Yes No
6. Do you agree to take part in this study? Yes No
Signed Date
Name in BLOCK LETTERS
P*tient/Par«nt/GuArdian - please delete as appropriate
Doctor
signed name in BLOCK. LETTERS
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Appendix C PRION-1 Trial: MRI Scan Protocol
1. MRI Bookings
1.1 Trial Research Fellow to ensure that PRION-1 trial Investigations Consent form has 
been completed before each MRI is booked and carried out (Consent form does not 
need to be seen by MRI department).
1.2 Trial Nurse to book all MRI scans with Neuroradiology Department nurse at least 
48hrs prior to scan being required.
1.3 Booking phone number and contact person : Trial Nurse XXXX
1.4 Request form and safety questionnaire to be completed before patient attends MRI 
appointment and given to MRI department by Trial Nurse at least 48 hours in 
advance.
1.5 MRI request forms and safety questionnaires to be available at National Prion 
Clinic.
1.6 Trial MRI scans to be carried out during the following times:
Inpatients: Tuesday pm, Wednesday am
Outpatients: Friday midday
1.7.1 At the time of making the booking the Radiographer should complete the PRION-1
Trial MRI Proforma with the aid of the Trial Nurse. A provisional decision as to
how many sequences to attempt should be made by the Radiographer in the light of
the proforma information.
1.8 If requested in advance, a Trial Research Fellow or Trial Nurse will 
accompany patient to MRI scan and stay with the patient until the scan is 
complete.
1.9 Inpatients will be transported from the ward by hospital porters who will also return 
them to the ward as per hospital protocol.
Outpatients will, depending on level of mobility and function, either attend alone, 
with a relative/carer or, if requested in advance, with the Trial Nurse. This will be 
confirmed at the time of booking.
1.10 The number of sequences actually performed will be at the discretion of the 
Radiologist or Radiographer depending on patient compliance and movement.
1.11 The NHS scanner at The National Hospital will be the onlv MRI scanner used.
1.12 The Radiographer will be responsible for checking the quality of the scan and re­
scanning if necessary, as time permits.
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1.13 The Neuroradiology Department must be notified immediately of any 
cancellations to MRI bookings.
2. Patient Preparation
2.1 MRI staff to ensure safety questionnaire has been filled in adequately and check 
there have been no changes since the form was signed. They should enquire about 
previous MRIs the patient may have had done, if none, then explain the 
procedure. Ask if the patient or their carer have any questions and answer them.
2.2 Establish whether oral sedation has been given, if required.
2.3 If any queries should arise contact the Trial Nurse for advice (see above).
3. MRI Scan Protocol
The MRI protocol will be programmed into the scanner and performed in the order 
of sequences below, as patient compliance permits:
Sequencing prioritv
1. Volumetric scan
2. Diffusion/ADC
3. DTI
4. FLAIR
5. MT
6. Spectroscopy
4. MRI Scan Data Collection, Analysis and Backup
4.1 Scans will be archived in the MRI Department as per standard protocol and also 
saved onto a designated ‘PRION-1 Trial’ optical disc to be provided, and replaced 
as necessary, by the Trial Research Fellow.
4.2 If requested by a Trial Research Fellow (and providing the network connection is 
open), scans will be ‘pushed’ onto the network by MRI staff.
4.3 After scanning the PRION-1 Trial MRI Proforma should be completed by the 
Radiographer showing which sequences were actually performed.
4.4 The Trial Research Fellow will take the completed forms to the National Prion 
Clinic for storage.
4.5 A hard copy of relevant sequences (eg FLAIR) will be produced and sent to 
Professor Yousry. Should any problems be identified the clinical team will be 
contacted. Prion-1 scans will not be reported routinely by the MRI Department.
4.6 A Trial Research Fellow will be responsible for collecting the PRION-1 Trial 
optical disc and downloading scans for analysis as necessary.
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Appendix DV^OH-X  Schedule for follow-up
Evaluation
(month)
Screen
-ing*
Entr
y
(0)*
1 2* 3 4 5 6* 7.5 9* 10.5 12*
Local assessment® X X X X
Informed Consent X (X)
Screen for 
eligibility X
Complete general 
medical history 
and physical exam
X
Brief history and 
physical exam X
X X X X X X
Full blood count*’ X X X X X X X X X X X X
Biochemistry*’ X X X X X X X X X X X X
Clinical 
examination 
(digital visual
X X X X X X X
CIBIC-plus, BPRS X X X X X X X
Other neurological 
assessments X X X X X X X
Specimen storage** X X X X X X X
Plasma drug 
levels®
X X X X X X
repeat
3
monthly
13.5 1 5 *
X
X
X X
X X
X
X
X
X
X
Quina-
crine
discont-
inuatio
n
X
X
X
X
X
X
X
OPTIONAL INVESTIGATIONS^
CSF exam® X X X X X X
Tonsil biopsy 
(vCJD only) X
■ ■
MRI X X X X X X X X
EEC X X X X X X X X
* full blood count and biochemistry perform ed locally and a copy o f results s en t to  th e  National Prion Clinic
haemoglobin, w hite cells, neutrophils, lym phocytes and  platelets 
‘ sodium, potassium , urea, creatinine, AST or ALT, alkaline phosphatase , bilirubin, GGT, am ylase 
At least 30ml, and w herever possible 50ml, EDTA blood for plasm a sto rage  and 24-hour urine sam ple 
'  10ml blood for plasm a sto re  for quinacrine assay
'  consen t for th e se  optional research  investigations is not required for en try  into PRION-1, and will be  re-confirm ed a t each  tim epoint
 ^ cell count, protein, glucose, 14-3-3 im m unostaining, NSE, S-lOOb.
if no t previously perform ed and  no t contra-indicated.
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Appendix E
STANDARD OPERATING PROCEDURE FOR MRI SCANS DONE UNDER 
GENERAL ANAESTHESIA (GA) AT THE NATIONAL HOSPITAL FOR 
NEUROLOGY AND NEUROSURGERY (NHNN) FOR THE NATIONAL PRION
CLINIC (N P g
1. Patients with different forms of prion disease will be scanned under general 
anaesthetic, where patient movement would otherwise prevent scans of adequate 
quality being obtained.
2. The procedure will be discussed with patients, or their next of kin (in cases where 
patients are cognitively impaired and lack capacity to consent), as far as possible in 
advance by one of the trial fellows or the trial nurse. Information about the 
procedure will be provided and intended benefits and risks explained. In addition, in 
cognitively impaired patients, written assent will be obtained from next of kin in 
advance of the scan appointment. This procedure will be repeated at follow-up trial 
visits. The next of kin may be referred to Dr. Sally Wilson, consultant anaesthetist, 
NHNN (email: sallv.wilson@uclh.org or extension 8711 at NHNN) if they request a 
detailed discussion directly with the anaesthetist.
3. Dr. Sally Wilson (email: sallv.wilson@uclh.org or extension 8711 at NHNN or air 
call through NHNN switchboard) and Caroline Andrews, superintendent 
radiographer, MRI Department, NHNN (email: caroiine.andrews@uclh.org or 
extension 3638 at NHNN) will be informed (where possible) two weeks in advance 
by one of the trial nurses (Christopher Rhymes, email:
christopher.rhvmes@uclh.org or Suzanne Walker, email: suzanne.walker@ucIh.org 
or phone 02074052882).
4. MRI scans will be done under GA on Wednesday afternoons at 2:30 pm. Patients 
will usually be admitted for planned assessments on Tuesday to the Nuffield Ward 
at NHNN and stay for 2 nights. Dr. Sally Wilson will consent those patients on the 
ward who are able to give consent themselves. She will be assisted by one of the 
trial or clinical research fellows (Dr. D. Siddique, email:
d.siddique@prion.ucl.ac.uk. Dr Tom Webb, email: t.webb@prion.ucl.ac.uk. Dr. H. 
Hyare, email: harpreet.hvare@uclh.org or phone: 02074052882) or by one of the 
trial nurses (see above).
5. Patients will be kept overnight after MRI scan under GA has been performed. Out 
of hours neurology cover will be provided by the on-call neurology SHO and SpR, 
and anaesthetic cover will be provided by the on-call anaesthetic SpR (bleep 8131). 
Dr Sally Wilson will be available out of hours through switchboard in case of an 
emergency.
6. All patients having MRI scan under GA will be resuscitated in the event of a 
cardiorespiratory arrest during or after the procedure.
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Appendix F Prion-1 Trial MRI Proforma
To be completed for each scan for every trial patient with aid of Prion-1 Trial Nurse 
(contact on 020 7405 0755 (Prion Office) or pager 08700555500 #H4757 (Prion Nurse 
specialist) if any queries arise)
Name:
Date of scan: / /
Sequencing priority Anticipated sequences 
possible
Actual sequences 
performed
Volumetric scan (10 mins)
Diffusion/ADC ( 1 min)
DTI (10 mins)
FLAIR (4 mins)
MT (12 mins)
Spectroscopy
Hard copy generated? Yes / No
Archived onto Prion-1 Trial Optical Disc? Yes / No
Radiographer signature................................................ Date.
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Appendix G
FORM 7
PRION-1 TRIAL
Neurological Examination •sSr®MRC pfuoN-1
Dab form completed 
Date of birth
Par»' Monlti[üm
m m
h o | o Male O
1 ' 9 1 1
n r n
PRION-1 S tu d y  
N um ber
Video ID 
number Visit w eek  num ber
Initials | | | | S oundex
Hospital N um ber [
0 4 8 16 24 36 4a 60 72 84 96 Extra
NEUROLOGICAL EXAMINATION
1. Is the neurological examination being digitally recorded?.........................................................  Yes □  NoO Full video □
2. Cognitive Function (For all tests: Tick if oornect, cross if incorrect, leave blank if not tested. U if unable to quantify)
Severely affected protocol *□
No. Task Standard Question Workings Number Correct
1.* Memory “What is your name? What is your age? Which month is 
your birthday in?'
name ! agem onth 13
2. Letter cancelling “Can you show me all the letter A / B / E s?" /12
3. Line drawings “Can you tell me what these drawings are?"
sœrpionMricydW spadw  ow</ vblin/ hjppor ladybird/ p eg  aqu ra li padlock 
b a td W lro llay ^  rvwr/oockarabguita'/canial/butterfly/nail/goaUdoor handle 
crab.'ikatoboaidf beakeUduck/haripAangaroortpldar/tafetv pinWaheepfkev
/10
4. Reading passage “Can you read this passage out for me? 1 will ask 
you some questions about it later’
dysphasia /  poor fluency / neologism norm.1nild'mod.''sev
5. Spelling "Can you spell the word...as in...' aunt / eye / build / humour / neighbour ! autumn /6
6. Fragmented letters "Can you see any letters here?" E . ' N / K  L / M / P  A . ' C / W / 3
7.
Fragmented objects “Can you see any objects here?"
teapot / shoe / chair / guitar or violin 
pig /cake/boot/car 
fish / boat / plane / dog
/4
8. Calculation “I’d like you to do some sums for me. What is..." 5+4(9), 7+5(12), 13+8(21), 17+25(42) .'4
9. Miming “Show me how you.' brush teeth / comb hair / use a screwdriver ,■'3
10. Copying gestures "Can you copy these shapes for me with your 
hand?’
‘ring’ / horns’ /  three prongs' /3
11. Frontal lobe sequencing “Can you copy this for me?' - norm.'tnild^ mod/sov
12. Words beginning with 
the letter....
"Can you give me as many words beginning with the 
letter F / A / S »  possible?' (Choose one only)
13. Proverbs "Can you tell me what these sayings mean?' strike v/hile the iron / too many cooks 12
14. Digit span “Can you repeat these numbers after me?" 5-8-2, e - 4 -3 -9 .  4-2-7-3-1, 6-1-9-4-7-3, 5-9-1-74-2-8 /5
15. Recall “Tell me everything you can remember about the 
passage you read out to me’
norm.tnild'mod/sev
Motor Function
No. Task Standard question Right j Left Example
16.* Eye movements ‘Keep your head  still and follow my finger with your norm .' nystagmus ; failure of upgaze other
17.
Finger-nose testing
Put your index finger on your no6e....lhen on my 
finger...and keep going backwards and forwards 
between the two* ...and now wHh the other trand*
nonm .■ mild ! mod sev norm ; mild ; mod ! sev
18. Rapid alternating 
tiand movements
‘Can you copy this for me?. ..and with the other 
hand ' norm.' mild mod ; sev norm ; mild ; mod .' sev
19. Sequential index 
finoer taooina
‘Can you do  this for me?^ 
‘And with th e  other hand" norm mild ; mod sev norm ; mild ; mod.' sev
20. Sequential opposition ‘Can you do this for m eT  •And with the  other hand" norm ! mi l dmod ; sev norm ! mild mod.' sev
21.*
Primitive reflexes
‘Could you look straight a head tor me ? 1 am just 
going to tap on yo ir forehead...and now on your 
lip...and look a t the camera «tiile 1 stroke your
norm :
glabellar : pout ! palmomental.' grasp present
22.* One minute 
hand observation
‘Could you put y o u  hands on your knees and relax 
for a minute while we watch your hands?* norm ! myoclonus ; chorea ; tremor ; other
23.
Walking ‘Could you walk to . .. .and back again for m e? '
go it : norm.' ataxic ,• a praxic / cerebe liar
impairment; norm • mild ; mod ; sev .• wheelchair bed bound
scale: 0 ! 1 i 2; 2>; 4 ; 5 ! 6
24. Heel toev/alking ‘Can you put one foot i n front of the other like this?" norm .' mild : mod : sev ! wheelchair ! bed bound
25. Rombergs ‘Can you stand with your feet together... and now shut y o u  ev es ' norm .' abnormal
26 .* Neurological exam Ton* Power? Reflexes (esp  plantar) norm tone i  pow ! ref a bnormal tone ! pow i ref
norm tone ! pow i ref 
abnormal tone i pow i ref
Overall assessment
Yes No Fluctuates
Is patient able to cope with task demands?
Is overall level of attention and concentration satisfactc'ry?
Is the potient cooperative?
Overall impression of impairment in this patient was:
None Mild Moderate Severe Cannot assess
Cognitive Impairment
Extrapyramidal Impairment
Pyramidal Impairment
Cerebellar Impairment
Signature Print name Date v'ideo Identification Number
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Appendix H  Cognitive picture tests 
Line drawings test:
Lot' 
n
Fragmented letters task:
•J
■  I
VC T,
I I  K f
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Fragmented objects task:
/ / i
/ r
} ,
Letter cancelling task:
B C E A D E C B
B E B D C A E A
C E D B E C A E
E D C B D C E B
A E D E A E D A
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Reading passage task:
J o h n  G i f f o r d  w a s  t h e  k i n d  o f  p e r s o n  w h o  w o u l d  g o  o f f  s a i l i n g  i n  h i s  
y a c h t  t h e  ‘N e v a ’ a r o u n d  t h e  i s l a n d  o f  S c o r b a  w h e n e v e r  t h e r e  w e r e  
s i g n s  o f  c h a o s  a t  w o r k .  H e  h a d  a  t h o r o u g h  k n o w l e d g e  o f  t h i s  a r e a  
a s  h e  h a d  g r o w n  u p  t h e r e  i n  h i s  c h i l d h o o d ,  a n d  t h i s  w a s  h o w  h e  
a l w a y s  s o u g h t  r e l a x a t i o n  f r o m  t h e  b u s y  r o u t i n e  o f  o f f i c e  l i f e  a t  
B e r g e s s ,  C h a l l i c e  &  C o .  H e  w o u l d  s i t  o n  d e c k  s i p p i n g  h i s  
c h a m p a g n e ,  a s  t h e  b r e e z e  t a n g l e d  h i s  n o r m a l l y  i m m a c u l a t e l y  
c o m b e d  h a i r .  G r a d u a l l y  h i s  b u s i n e s s  w o r r i e s  w o u l d  r e c e d e .  
D r e s s e d  i n  h i s  o l d ,  b a g g y  s w e a t e r ,  d e c r e p i t  s u e d e  b o o t s  a n d  w i t h  
h i s  s t u b b l y  b e a r d  h e  f e l t  q u i t e  t h e  p a r t  o f  a n  a n c i e n t  m a r i n e r .
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Appendix I
FORM 7A
PRION-1 TRIAL
In d epen d en t  Neu ro lo g ist  
Neurological  Examination (Video  As s e s s m e n t ) MRC PRION-1
PRION-1 Study Number Video IdentificationNumber
Normal Protocol Severely Affected Protocol
NEUROLOGICAL EXAMINATION (VIDEO A SSESSM EN T)
Cognitive Function
No. Label T a sk Workings
(Tick If correct, cross if incorrect, leave blank if not tested)
Number Correct
(U if unable to quantify)
Level of function Example
Normal Impaired
1. ME Memory name / age / married / 3
2 LC Letter cancelling A / B / E / 1 2
3. LD Line drawings
scorpion/ tricycle/ spade/ owl/ violin/ hippo/ ladybird/ peg/ squirrel/ padlock 
beetle/trolley/spanner/cockerei/guitar/camel/butterfly/nail/goat/door handle 
crab/skateboard/basket/duck/harp/ksngaroo/spider/safety pins/sheep/key
/1 0
4. RP Reading passage John / Richard / Jill dysphasia / poor fluency / neologism norm / mild / mod / sev
5. SP Spelling aunt / eye / build / humour / neighbour / autumn 16
6. FL Fragmented letters E / N / K  L / M / P  A / C / W / 3
7. FO Fragmented object
teapot / shoe / chair / guitar or violin 
pig / cake / boot / car 
fish / boat / plane / dog
/ 4
8. GA Calculation 5+4(9), 7+5(12), 13+8(21), 17+25(42) / 4
9. Ml Miming brush teeth / comb hair / use screwdriver / 3
10. CG Copying gestures 1st/2nd/3rd / 3
11. FS Frontal lobe sequen - norm / mild / mod / sev
12. WC Words begin with F / A / S
13. PV Proverbs Strike while the iron / too many cooks 12
14. DS Digit span 5-8-2, e-4-3-9,4-2-7-3-1, 6-1-9-4-7-3, 5-9-1-7-4-2-8 / 5
15. RC Recall norm / mild / mod / sev
T o ta l:
CRF Version 2.0. September 2005
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Motor Function
No. Label Task Right j Left Normal impaired Example
16. EM Eye movements nystagmus / failure of upgaze / other
17. FN Finger-nose testing norm / mild / mod / sev norm / mild / mod / sev
18. RA Rapid alternating hand mvmts norm / mild / mod / sev norm / mild / mod / sev
19. SI Sequential index finger tapping norm / mild / mod / sev norm / mild / mod /  sev
20 SO Sequential opposition norm / mild / mod / sev norm / mild / mod / sev
21. PR Primitive reflexes glabellar / pout /  palmomental / grasp present
22. CM One minute hand observation myoclonus / chorea / tremor / other
23. WA Walking gait: norm / ataxic / apraxic / cerebellar
impairment: norm /  mild /  mod / sev /  wheelchair / bed bound
scale: 0 / 1 / 2 / 3 / 4 / 5 / 6
24. HT Heel toe walking norm /  mild /  mod /  sev /  wheelchair / bed bound
25 RH Rombergs -
26 NE Neurological examination UL tone / pow /  ref UL tone / pow / ref
(tick normal, cross abnormal) LL lone / pow / ref LL tone / pow / ref
Total:
Overall assessment
Yes No Fluctuates
Is patient able to cope with task demands?
Is overall level of attention and concentration satisfactory?
Is the patient cooperative?
Overall Impression of impairment In this patient was:
None Mild Moderate Severe Cannot assess
Cognitive Impairment
Extrapyramidal Impairment
Pyramidal Impairment
Cerebellar Impairment
Signature Print name Date 1 Confirm Video Identification Number
CRF Version 2 0, S ep tem ber 2005
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Appendix J
FORM 6
PRION-1 TRIAL
MMSE
Date test performed | | | | | | 2|«|0l
Date of birth I 1 II 1 1 1 |g| 1
PRION-1 Study N um ber | | |
Male O  Fem ale O  Initials
MRC PRION-1
Soundex
Inpatient □  O u laa tlen tD  H o m e D
Visit month number
1 2 4 6  9 12 15 18 21 24 E xtra
MINI MENTAL STATE EXAMINATION (MMSE)
S co re  e a c h  correct a n s w e r  o r a c tio n  a s  sh o w n  in italics. A p p ro ach  th e  p a tie n t with r e s p e c t  a n d  e n c o u ra g e m e n t. A sk
IXi you have any trouble with your m em ory?   Yes □  No O
May I a sk  you som e questions abou t your m em ory?  Yes □  No □
Time
orientation
Place
orientation
Word
registration
Attention and 
calculation
What is the
W here a re  we now ? W hat is the
iSiC?
w a s o n ?
month ot the year? 
d a te?
d ay  of the w eek?
m
(1}
(1)n>
(1}
country?   <i)
county?    (If
town or city? (1}
bulidinq? (1)
floor of the buiWinq? d)
Listen ca re fJiy . i am  going to say  3 w ords. You say  them  back to me after I stop. Ready?
Here they a re  ... LEMON (wait 1 second). KEY (wait l second),
BALL (wait 1 second). W hat w ere those w ords?    (if
______________________  (If
(If
(Repeat the words unfi tne paSen:iearns ail mreef
Subtract 7 from 100 an d  continue to subtract 7 from each  subsequen t rem ainder
until i teii you to stop . W hat is  too  ta k e  awav 7 ? ____________________
K eep going ____________________
P lease spell WORLD for m e? Then a sk  him her to spell it backwards;
Word recall
Naming
Repetition
What were those  3 w ords 1 asked  you to rem em ber?
What is t t is  (Show Dend;<7 _____________________
(Show watch)?
Now 1 am going to a sk  you to  repea t w hat 1 say. R e a d y ... ?  No its. ands. or buts, 
rqow you say  that.
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
(tf
Comprehension Listen carefJIy  b e c a u se  1 am going to ask  you to  do  something. Take this paper
Reading
Writing
Drawing
Score
Total
Total L
T otal \_
T otal [
(for the best 
performed task)
Total
Total [
T otal [
in your riaht hand N o o Y e s D (tf
fold it in M lf No d Y e s D (tf
and put it on th e  floor No □ Y e s D (tf Total
P lease read  the  following and  do wtnat it says, but do not say  it aloud
(Give the patient the sheet with Close your eyes' on itf No d Y e s G It) Total
P lease write a  sen ten ce .
(If the patient do e s  oof respond say Write about the w eather) No □ Y e s D (tf Total
P lease  copy this design.
B(Hand m e sheet with the design to the patient! No d Y e s u (tf TotalTotal Score (sum) =
D octor s  s ig n a tu re Print n a m e D ate
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Appendix K
FO R M  11
PR IO N -1 TRIAL
CDR
Date lesi performed | | |
1 1
2 | 0 | 0 |
Date of birth | | |
1 1 1 | 9 |  1
PRION-1 S tudy N um ber | 1
Male o  Female o  Initiais
inpatient □  Outpatient □  Home □  N ^ ^ ^e r
MRC PRION-1
Soundex
Visit month numtier
0 1 2 4 6 9 12 IS  18 21 24 Extra
CLINICIAN’S DEMENTIA RATING (COR)
Each of the 6 domains should be rated by circling the number by the term that best describes the patient's current 
capabilities. Rate each domain a s  independently a s  possible, a s  it is not unusual for patients to have varying 
degrees of impairment across domains. Only assign scores greater than 0 if impairment is due to cognitive loss.
Memory No memoiy loss or slight inconstant lorgelfulness
Mid consistent torgetlulness; partial recollection of events; laenign" forgetfulness 
Moderate memory loss; m ore marked for recent eirents: defect interferes with everyday activities 
Severe memory loss; only highly learned material retained; newly material rapidly lost 
Severe memory loss; only fragments remain
Orientation Fuly orientated
Fuly orientated except for slight difficulty with time relationships
Moderate difficulty with time relationships: orientated for place at examination, but may have 
geography disassociation elsew here
S evere difficulty with time relationships: usualy  disorientated in time, often ii place 
Orientated to person only
Solves everyday problem s well; judgem ent good In relation to past performance 
Only s igh t im parm ent in solving problems, simlarities. differences
Moderate difficuiy ii h and ing  problems, similarities, differences: social judgem ent usually maintained 
Severely in paired in handling problems, similarities, differences; social judgem ent usually impaired 
Unable to make judgem ents or solve problems
Independently functions a t usual level in job. shopping, business and financial affairs, volunteer and  
social groups
Slight Impairment in these activities
Unable to function independently at th ese  activities a lhough may still be engaged In some; appears 
normal to casua l inspection
f ^  pretence of independent function outside home; appears well enough to be taken to functions 
outside family hom e
f ^  pretence of independent function outside home; appears too ill to b e  taken outside famly home
Life at home, hobbies, intellectual interests w el maintained 
Life at home, hobbles. Intellectual interests w el sightly impaired
Mid but definite impairment of function at home; m oredrflcu l chores abandoned; more com p k ated  
hobbies and interests abandoned
Only simple chores preserved; very restricted interests, poorly sustained 
No significant function at home
Personal care Fuly capable of self care 
f^eeds prompting
Fteqiires assistance in dressing, hygiene, keeping of personal effects 
Flequires substantial help with personal care; frequently incontinent
Judgement and 
problem solving
Community
affairs
Home and 
hobbles
0
0.5
1
2
3
0
0.5
1
2
3
0
0.5
1
2
3
0
0.5
1
2
3
0
0.5
1
2
3
0
1
2
3
Score
□
C = ]
Total Score (sum) = | |
Doctor's signature Print name Date
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Appendix L
FO RM  10
PRION-1 TRIAL
ADAS-COG MRC PRION-1
Date te st performed [ | ] 
Date of birth [ | |
n Nioioi
rii'N 1
PRION-1 S tudy N um ber | 1 1
Male o  Female o  Initials Soundex
Inpatient □  Ouljatlent □  Home □
Visit month number 0 1 2 4 6 9 12 15 18 21 24 Extra
ALZHEIMER’S DISEASE ASSESSMENT SCALE (ADAS-COG)
S c o re  e a c h  Incorrect a n s w e r  o r ac tio n  in e a c h  of th e  11 d o m a in s  below .
1. Word recall
I a m  go ing  to  show  you  s o m e  w o rd s , o n e  a t a  tim e. P le a s e  re a d  e a c h  w ord ou t loud  a n d  try to  re m e m b e r  it. b e c a u s e  
la te r  I will a s k  you to  try  to  re m e m b e r  all of th e  w o rd s  I h a v e  show n  you. (The patient reads dou d  10 words exposed  
for 2  seconds each. The patient then recalls the words aloud. Three trials of readina and recallina are aiven.l
Recalled Not recalled Recalled Not recalled Recalled Not recalled
Butter □  □  Pole □  □  Shore □  □
Arm □  □  Letter □  □  Letter □  □
Shore □  □  Butter □  □  Arm □  □
Letter □  □  Queen □  □  Cabin □  □
Queen □  □  Arm □  □  Pole □  □
Cabin □  □  Shore □  □  Ticket □  □
Pole □  □  G rass □  □  Engine □  □
Ticket □  □  Cabin □  □  G rass □  □
Grass □  □  Ticket □  □  Butter □  □
Engine □  □  Engine □  □  Queen □  □
Total DOÎ recalled | |  Total n o i recalled  | | Total not recalled | 1
Score = m ean num ber of w o rd s not recalled on 3 tria ls (maximum = 10) = | |
2. Naming ob lec ts  and fingers
I am going to show you som e objects. What is this called? or What is the name of this thing? (If the patient does not 
respond, give the cue listed bdow. If the patient still does not respond or makes an error go onto the next object).
Correct Incorrect
Objects Standard clue that can be used to assist those patients having difficulties (or not named)
Flower - grows in the garden ............................................................................................... □  □
Bed - used for sleeping ...................................................................................................  □  □
Whistle - makes a  sound when you blow i t ......................................................................... □  □
Pencil - used for writing...........................................................................    □  □
Rattle - a baby’s to y .............................................................................................................  □  □
Mask - hides your f a c e ........................................................................................................ □  □
Scissors -cu ts  p a p e r ................................................................................................................ □  □
Comb - used on h a i r ................................................................................................  □  □
Wallet - holds your money ..................................................................................................  □  □
Harmonica - a musical instrum ent..............................................................................................  □  □
Stethoscope - doctor uses it to listen to your h e a r t..................................................................... □  □
Tweezers - used to pick up th in g s ............................................................................................  □  □
Now can you nam e the fingers on your left right (dominarrt) hand? □  □
Thumb    □  □
Index     □  □
Middle    □  □
Ring   □  □
Little    □  □
Total Incorrect | |
Score .0=0-2 Incorrect: 1=3-5 Incorrect;2=6-8 Incorrect;3=9-111ncorrect; 4=12-14 incorrect: 5=15-17 Incorrect;. = j |
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Correct Incorrect
(or not performed)
□ □
□ □
□ □
□ □
□ □
3. Commands
1 a m  go in g  to  a s k  y ou  to  d o  s o m e  a c tio n s . (Each c o m m a n d  should be read once. If the patient does not respond, or 
makes an error, ^ e  the command one more 6me. Then go onto the next command. M  commands should be given.) 
C o m m an d
(Each underlirTed element represents a single step Each commartd is scored as a whole)
M ake a | i § l ..................................................................................................................................................
P oin t to  th e  ce iling  a n d  th e n  to  th e  floor ......................................................................................
Line up a pencil, watch, and card, in that order, on a table in front of the patient
P u t th e  p enc il o n  to o  of th e  c a rd  a n d  th e n  o u t it b a c h  ..................................................... ....
P u t th e  w a tc h  o n  th e  o th e r  s id e  of th e  p enc il a n d  th e n  tu rn  o v e r  th e  c a rd  .................
T a p  e a c h  s h o u ld e r  tw ic e , w ith  tw o f in g e rs , k e e p in g  y o u r g y g â j M ..............................
Score = number of Jflcorreciiy performed commands (minimum 0, maximum 5) 
4. Constructional praxis
O n th is  p a p e r  is  a  s h a p e .  Try to  d raw  a n o th e r  o n e  th a t lo o k s  ju s t like th is , s o m e w h e re  o n  th e  p a g e .
(Allow 2 attempts for each shape, then go onto the next shape. A drawing should be scored as correct if the patient 
has reproduced all the essential geometric features of the orignal. Changes in size do not count as errors. Small 
gaps between lines do not indicate an error, as long as the shape has been reproduced.)
C orrect
S h a p e
C  ircle (a dosed  curved figure)...........................................      □
Tw o o v e rla p p in g  r e c t a n g le s ...............................................  □
(forms must be 4~sidecl. and overtap must be simtar to presertted term Changes In sae  are not scored. )
Corr»c«
Incorrect 
(or not drawn)
□
□
Incorrect
c
Diamond
(Figure must be 4-stded onentedwth pants atthe top ana bottom, and the sides are approximately eoual tengfh.) 
Correct A  / \  Incorrect
0  ~ ~  0  a
Cube  ....................................................................................................................................................
(The fam  k  3-dimensK>nal. with Kort face tn the carect cnertaBon. internal lines drawn correctly between co rners 
Opposite Sides a! faces should be  approximately para!el. )
C o rrec t/)  7 |  f \  | \  Incorrect
□
□
□
□
\ \
\ \
Total I I correct
Score = number of jQCorrectly drawn figures <score=5 if only scribbles, parts  of sh ap es , or words) = |
5. Ideational praxis
I want you to pretend that you have written yourself a letter. Take this piece of paper, fold it so  that it will fit into the 
envelope, and then put it into the envelope. Then seal the envelope, address the envelope to vourself. and show me 
where the stamp goes. (If the patient forgets part of the task, or is  having difficulty, repeat the instruction for the 
component of the task where the patient is has/ing difficulty.)
Command Correct
Fold a  le tte r  .................................................................................................................   □
Put the letter in an e n v e lo p e .................................................................................................................... □
Seal the envelope ......................................................................................................................................  □
Address the en v e lo p e ...............................................................................................................................  □
Indicate where the stamp g o e s ................................................................................................................ □
Score = number of Jncorrectly performed commands = [
6. Orientation
Ensure that no dodrs. watches, or calendars are visible.
Incorrect 
(or not performed)
□
□
□
□
□
Correct Incorrect 
(or not answered)
Correct Incorrect 
(or not answered)
Full nam e (iratmlie»t) □ □ Year □ □
Day □ □ Season (mUWtlwtetUufxxmtgorlitmeikMalfretriousmator!) □ □
Date (i 1 day) □ □ Time of day rs / hour) □ □
Month □ □ Place (partial or full name of site) □ □
7. Word recognition
Score = number of jncorrect answers = [
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FORM 10
PRION-1 TRIAL
ADAS-COG MRC PRION-1
I am  going to  show  you som e w ords printed on ca rds. I want you to read  each  word out loud and  try to rem em ber It. lif m e patient 
cannot react a word say  m e word out loud. However, it is important for me patient to actually look at eacn word and try to read it i 
Now I'm going to  show  you an o th er se t of words. Som e of the  words w ere on the list I just show ed you, and o the rs  a re  new. For 
each  word. I w ant you to tell m e w tiether It Is one of tfie w ords I just show ed you. Is th is  o n e  of the  w ords I show ed you before, 
yes or no?  (or Did I show  you th is word befo re?; (Ttie same instruction is given before me second test word For the remaining 
test wads say How abou t this o n e?  ; df m e patient does not rem em ber m e task (eg reads m e w ad  ratna man responding Yes ' 
a  No') men repeat a  re p h ra se  m e  entire question and make a note mat m e  patient bad to be reminded i
Yes No»' 
Shown New
Nurse O
Magazine □ 
Wizard □
Van
Leopard
Sale
Sea
Train
Coin
Ship
Institution □
Map
Axe
Board
Carrot
Milk
Volume
Faest
Anchor
Gem
Cat
Fund
Edge
Cake
O
o
□
o
o
o
o
□
□
o
□
o
o
□
o
o
o
o
□
o
o
o
□
o
□
□
o
□
□
□
□
o
o
□
o
□
□
Remind
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
□
Board
Turnip 
Gem
Institution 
Coin
Master 
Magazine □ 
Van 
Anchor
Lumber 
Servant 
Pond 
Military 
Hospitd 
Sea 
Jungle 
Nail 
Wizard 
Leopard 
Train 
Editorial 
Bread 
Fund 
Trade
Yes No Remind Yes No Remi
Shown New Shown New
□ O □ Coin □ O □
O □ □ Plank O □ □
□ o □ War 0 □ □
□ o □ Porch o □ □
□ o □ Toast 0 □ □
O □ □ Rope o □ □
o □ Anchor □ O □
□ o □ Board □ O □
□ o □ Leopard □ O □
O □ □ Judge o □ □
o □ □ Magazine □ O □
0 □ □ Camp o □ □
o □ □ Sea □ O □
o □ □ Institution □ o □
□ o □ Tack 0 □ □
0 □ □ Emerald o □ □
o □ □ Van □ o □
□ o □ Globe 0 □ □
□ o □ Train □ o □
□ o □ Fund □ o □
o □ □ Coast 0 □ □
o □ □ Gem □ o □
□ o □ Wizard □ o □
o □ □ Kitten o □ □
Total circles ticked Total circles ticked Total circles ticked
(incorrect response) (incorrect response) (incorrect response)
S core  = mean number of iijcorrect words on 3 trials (max=12; score 12 if average more than 12 Incorrect responses) = [
8. Remembering test Instructions
Evduate the patient's atxiity to remember the recfuirements of the word recognition tadc above.
0  did not need  any extra rem inders of Instructions
1 very mild -  forgot once
2  mild -  rem inded twice
3 m oderate  -  rem inded 3 or 4 tim es
4 m oderately sev ere  -  rem inded 5 or 6  tim es
5 se-vere -  rem inded 7 or m ore times
d. Spoken language ability
Provide a global rating of the quality of speech, ie clarity, difficulty in making oneself understood.
0  D2, instance w here It is difficult to understand  the  patient
1 very mild -  one Instance of lack of understandabillty
2  m M  -  patient h a s  difficulty le ss  than 25%  of time
3 m oderate  -  patient h a s  difficulty 25-509. of time
4 m oderately sev ere  -  patient h a s  difficulty m ore than 50%  of time
5 sev e re  -  one or two w oid utterance: fluent, but em pty speech ; m ute
Score = [
Score % [
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10. Word-finding difficulty In spontaneous speech
Rûte the patient's difficulty in finding desired words, e.g.. droumlocutions.
0 02. evidence of word-finding difficulty in spontaneous speech
1 very mild -  I or 2 instances, not ciinlcaliy significant
2 mil2 -  notlceaPle circumlocution or synonym substitution
3 moderate -  loss of words without compensation on occasion
4 moderately severe -  frequent loss of words without compensation
5 severe -  nearly total loss of content words: speech sounds empty; 1-2 words utterances
Score = [
11. Comprehension
Rate the patient’s ability to understand speech. Do not include responses to commands.
0 D2 evidence of poor comprehension
1 very mild -  f-2 instances of misunderstanding
2 mild -  3-5 instances of misunderstanding
3 moderate -  requires several repetitions and rephrasing
4 moderately severe -  patient only occasionaily responds correctly; e.g., yesno questions
5 severe -  patient rarely responds to questions appropriately, not due to poverty of speech
Score = [
12. Concentration distractlblllty
Rate the frequency with which the patient is distracted by irrelevant stimuli and or must be reoriented to the ongoing 
task because the patient has lost hi& her train of thought or appears to be caught up in his her own thoughts.
0 no evidence of poor concentration or distractibiiity
1 very mild -  one instance of poor concentration
2 mild -  2-3 instances of poor concentration.distractibiiity; signs of restlessness and inattentiveness
3 moderate - 4 - 5  instances during intervie>;v
4 moderately severe -  poor concentration distractibiiity throughout much of interview
5 severe -  extreme difficulty in concentration and extremely distractibie, unable to complete tasks
Score = i
SCORE SUMMARY
Copy the sc o res in each  domain from the grey boxes, then total.
5 Ideational praxis1 Word recall
(max 10}
2 Naming objects and 
fingers (max
3 Com m ands
4 Constructional praxis
(max S)
□
l  5) I I
□ □
(max 5)
Total score
(m ax 7S)\
(max 5
6 Orientation
7 Word recognition
(max s i
8 Remembering test 
instructions (max
□ 
□
□
<ax 5;j I
(max 12
9 Spoken language ability
(max 5)\
10 Word-finding difficulty in 
spontaneous speech fmax 5}\
11 C om prehension
(max 5t
12 Concentration.
distractability (max 5l\
□□□□
Doctor’s  signature Print name Date
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Appendix M
FO R M  13
PR IO N -1 TRIAL
Glasgow Coma Score
Date test performed | [ | 
Dale of birth | | |
3
H
2 | o|o|
' h i  1
PRION-1 S tudy N um ber | 1
Male Q  Fem ale o  Initials
MRC PRION-1
Soundex
Inpatient □  O u |5 a tlen tD  H o m e O  Q j
0 1 2 4 6 9 12 15 18 21 24  E xtra
Visit month number
GLASGOW COMA SCORE
Each of the 3 responses should be rated on scales. 
Circle the number headed by the term that best describes the patient’s current response.
E y e s  o p e n
Verbal response
S pon tan eo u sly  4
To sp e e c h  3
To pain 2
N one 1
O rien ta ted  5
C onfused  (se n te n c e s)  4
Inappropriate  w ords 3
Incom prehensib le  so u n d s  2
N one 1
B e s t m o to r  r e s p o n s e  O b ey s co m m an d s 6
(record  b e s t arm ) Localise pain 5
Normal flexion (w ithdraw s from pain) 4
A bnorm al flexion 3
E xtension  to  pain 2
N one 1
Score
Total Score (sum) = | |
D octor 's  s ig n a l m e P rin t n a m e D ate
290
Appendix N
FO R M  9
P R IO N -1 TRIAL
BARTHEL ADL MRC PRION-1
Dale test perfonmed ^  
Date of birth
□  m 
i m
2|o |o | 1
l|9 | I |i
PRION-1 S tudy  N um ber 1 1
Male o  Fem ale o  initials Soundex
I Inpadent □  Outpatient □  Home □
Visit month numljer
0 1 2 4 6 9 12 15 18 21 24 Extta
MODIFIED BARTHEL ACTIVITIES OF DAILY LIVING (ADL)
S co rn  = [A) Bow els
0: Incontinent o r needs enem a 
1: Occasional accident 
2: Continent
D) Toilet u s e  S c o re  =| |
0: Dependent 
1: N eeds som e help 
2; Fully independent
S c o re  = [G) Mobility
0: lmmoi3ie 
1; W heelchair-independent 
2: Walk with help d o n e  person 
3: Independent
J )  B ath ing  S c o re  =| |
0: Dependent 
1; Independent
B) B ladder S c o re  =|  |
0: Incontinent or catheterised 
1: Occasional accident 
2; Continent for > 7 days
S c o re  =1 IE) F eed ing
0: Unable 
1: N eeds help 
2: Independent
H) D ressin g  S c o re  =( |
0: Dependent 
1: N eeds help 
2: Independent
0 )  G room ing  S c o re  = | |
0: N eeds help with personal care  
1: Independent with a ids if necessary
F) T ra n sfe rs  S c o re  = | |
0: Unable, no sitting balance
1: Major help (one or Wo people, physical).
can sit
2; Minor help (veitxal or physical)
3: Independent
I) S ta irs
0: Unable 
1; N eeds help 
2: Independent
S c o re  = 1 I
Total S c o re  (sum , m ax 20) = |_ _ J
Instructions:
This is an example for an answer to the question Tlow well do you feel today? "as shown:
Excellent, 
very well -X-
Very unwell
The answer at the cross on the line means that in this example that you are feeling "weir txjt not 
"very we// '.
Put a mark on the line at the point that best describes HOW YOU FEEL TODAY
Best I have 
ever felt
Worst I have 
ever felt
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Appendix O
FO R M  12
PRION-1 TRIAL
Global Impression of Change MRC PRION-1
Date te st performed j | | 2|o |o|
Dale of birth | | | 1 1 '1 4  1
PRION-1 S tudy N u m t» r  | 1
Male o  Female o  Initials Soundex
Inpatient□  O u$)atien tO  H o m e O
Visit month num ber 0 1 2 4 6 9 12 15  18 21 24  Extra
RATING O F  G L O B A L SEV ER ITY
E ach  ra te r  sh o u ld  s e le c t th e  o n e  d e s c r ip to r  w hich  b e s t  c h a ra c te r is e s  your g lobal im p ressio n  of t h e  p a t ie n t 's  c u r r e n t  
condition. Y our ra ting  s h o u ld  b e  ca rr ied  o u t in d e p en d en tly , b u t b e  b a s e d  o n  inform ation  d e riv ed  from  rev iew  of 
pa tien t re c o rd s  a n d  o th e r  s tu d y  a s s e s s m e n t s  an d  m ay  n o te  inform ation e licited  from  o th e r s tu d y  p e r s o n n e l (CIBIC- 
plus).
1 Normal, not III a t all 
4 Moderately III
2 Borderline mentally III 
S Markedly III
Day Mof
3 Mildly ill 
6  Severely ill
D o c to r
N u rse
D ate of Rating 
D ate of Rating
I2 » 0
2 0 0
R ating  | |
R ating  | [
7 Amongst the m ost ill
R a te r s  Initials | |
R a te r 's  Initials \
RATING o f  C H A N G E  fro m  B A SE L IN E
S e le c t th e  o n e  d e sc r ip to r  w hich  b e s t c h a ra c te r is e s  your g lobal im pression  of th e  p a tie n t 's  c u r r e n t  cond ition  re la tive  to  
th e  p a t ie n t 's  cond ition  a t  b a s e l in e  (trial/study entry). Your rating  shou ld  b e  ca rried  ou t in d ep en d en tly , a n d  b e  b a s e d  
o n ly  on  infonm ation d e riv ed  from  your In te rv ie w s  w ith  b o th  th e  p a t ie n t  a n d  th e  c a re g iv e r ,  with re fe re n c e  to  your 
n o te s  from  th e  b a s e l in e  interview  (CIBIC-plus).
1 Markedly improved 4 Unchanged 5 Minimally w orse
2 Moderately improved 6 Moderately w orse
3 Minimally im proved 7 Markedly w orse
Note: mild m eans there should b e  a  "d é tec tab le” change In the patient; m oderate that the degree of change should b e  c learly  apparen t" ;
and m arlied that the d eg ree  of change should t*  considered d ram atic” .
D o c to r  Dale of Rating | | | | | | 1 2 0 0 R ating  | | R a te r’s  Initials | | | |
N u rs e  Date of Rating | | | | | | 1 2 0 0 R ating  | | R a te r ’s  Initials | | | |
RATING Of C H A N G E fro m  LA ST A S S E S S M E N T
This following section should be completed bv the doctor completing the sections above
U sing th e  s a m e  sca le , s e le c t th e  o n e  descrip to r w hich  b e s t c h a ra c te r is e s  th e  c o m p o s ite  g lobal im p ressio n  of all th e  
clinical an d  nursing  staff of th e  p a tie n t 's  c u r r e n t  condition  relative to  th e  p a tie n t’s  condition a t th e  l a s t  a s s e s s m e n t
Month Year
O v e ra ll  Date of Rating | | | | | | 1 2 0 0 R ating  | j R a te r ’s  Initials | | | |
D a e  ot n a i n ,  1 | | | | | F 0 0 R ating  | j R a te r ’s  Initials | | | |
M o to r s k i l l s  Date of Rating 1 | | j j | 12 0 0 R ating  | | R a te r ’s  Initials | | | |
Date of Rating 1 | | [  |  | | 2 0 0 R ating  | | R a te r ’s  Initials | | | |
D o c to r 's  s ig n a tu re Print n a m e D ate
N u rse 's  s ig n a tu re Print n a m e D ate
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Appendix P (Ughl blue horizontal lines represent gradations o f  BSl values over the range fo r that patient; th ey  axis scale is the
same for all patients)
A{ipendix P
PR IO N -I p a tw n li 
ScattorpltJls o f  wiiolo hrain IÎSI 
ugaiiMi time
Li««3i- rcgmKHi u*in|! AjulysU 2
S catferp lo l P lo t P atien t 3 
W hole brain BSl v s  interval y ea rs
S catterp lo t Pilot P atien t 6 
'Whole brain BSl v s  interval y ea rs
S catterp lo t PSot P atien t 9  
'Whole brain BSl v s  interval y ea rs
S catterp lo t Pilot P atien t 12 
W hole brain BSl v s  interval y ea rs
S catterp lo t Full P atien t 3 
'Whole brain BSl v s  interval y ea rs
S catterp lo t Pilot P atien t 1 
W tid e  brain BSl vs interval y ea rs
S catterp lo t Pilot P atien t 4 
W hole brain BSl v s interval y ea rs
Scatterplot Pilot P atien t 7 
W hole brain BSl v s interval years
S ca tte rp lo t Pilot P atien t 10 
V/hole brain BSl vs interval y ea rs
S catterp lo t Full P a tien t 1 
W hole brain BSl vs interval y ea rs
S catterp lo t Full P a tien t 4 
W hole brain BSl v s interval y ea rs
- 3. .  "
Scatterp lo t Pilot P atien t 2 
‘W hole brain BSl v s interval y ea rs
S catterp lo t Pilot P atien t 5 
'Whole brain BSl v s  interval y e a rs
S ca tte ip lo t Pilot P atien t 8 
W hole brain BSl v s  interval y e a rs
S catterp lo t Pilot P a tien t 11 
W ho le  brain BSl v s  interval y ea rs
S catterp lo t Full P atien t 2 
'.Vhole brain BSl v s  interval y e a rs
i ! /
S catterp lo t Full P atien t 5 
'W hole brain BSl v s  interval y ea rs
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S catterp lo t Full P atien t 6  
W hole brain BSl v s  interval y ea rs
S catterp lo t Full P atien t 12 
'Whole brain BSl v s  interval y ea rs
S catterp lo t Full P atien t 18 
'Whole brain BSl v s  interval y e a rs
S catterp lo t Full P a tien t 7 
W hole brain  BSl vs interval y ea rs
S catterp lo t Full P atien t 9 
W hole brain BSl v s  interval y ea rs
Scatterp lo t Full Patien t 10 
W hole brain BSl vs interval y ea rs
Scatterp lo t Full Patien t 13 
W hole brain BSl vs interval y ea rs
S e a  
W hole 1
!
tterplot Full P atien t 15 
jra in  BSl v s  interval y e a rs
S catterp lo t Full P atien t 16 
W hole brain  BSl vs interval y ea rs
k /
S catterp lo t Full P atien t 19 
W hole brain BSl vs interval yea rs
S e a  
W hole 1
I
tterplot Full P atien t 21 
jra in  BSl v s  interval y e a rs
S catterp lo t Full P atien t 22 
W hole brain BSl vs interval y ea rs
Sc< 
W hole I
I
ii
itterp lo t Full P atien t 8 
x a in  BSl v s  interval y ea rs
/
" ---------
S catterp lo t Full P atien t 11 
W hole brain  BSl v s  interval y ea rs
TTT
S ca tte rp lo t Full P atien t 14 
'W hole brain  BSl v s  interval y ea rs
S e a  
W hole I
j
h
tterp lo t Full P a tien t 17 
x a in  BSl v s  interval y ea rs
•
B S È S s s a
S ca tte rp lo t Full P atien t 20 
'W hole brain  BSl v s  interval y e a rs
: «■--- r
S ca tte rp lo t Full P a tien t 23
W hole brain  BSl v s  interval y ea rs
i ----------
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Appendix Q (Ught blue horizontal lines represent gradations o f  BSl values over the range fo r  that patient; the y  axis scale is the
same for all patients)
A |ip o id ix  0
C ontro l P atien ts 
S c a tte rp lo lso f  w lto k  bi;uiii ÜSI 
against lim e
Lincjr n q trsw i u*i«; analyiii 2
S catterp lo t C ontro l 6 
W hole bra in BSl vs interval jv a rs
S ca tte rp lo t C ontro l 4 
W hole b rain BSl vs interval y ears
S catterp lo t C ontro l 12 
W hole brain BSl vs interval years
S catterplot Contro l I 
W lxile brain BSl vs interval vears
s
W hole 1 
!,
c a tte rp k 't  C ontro l .1 
ira  in BSl vs interval y ears
Scatterplot Cvvitrol 4 
WIvole brain BSl vs interval vears
Scatterplot C ontrol 7 
W liole brain BSl vs interval years
Scatterplot C ontrol 10 
W hole brain BSl vs interval years
S ca tte rp lo t C ontro l 2 
W hole  brain BSl vs interval years
S ca tte rp lo t C ontro l 5 
W hWe brain  BSl vs interval y ears
S ca tte rp lo t C ontro l » 
W h U e brain  B S l vs interval y ears
S ca tte rp lo t C ontro l 11 
W hole  brain B S l vs interval y ears
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Appendix R
A ppendix  R
Hi&(oyrams show ing luvnial 
d istribution  o f  alro|.Ttiy ra tes  
P ilot patients
Wkole Brain A«alyse»l-3
P ilo t  W h o le  B ra in  A n a ly s is  3
H istogram s show ing norm al 
distribution  o f  atropliy ra tes 
Full trial patients
Cerehelluni Antlysnl-3
P ilo t \VIh >Io  H ra in  A n a ly s is  I
H istogram s show ing ixirmal 
distribution o f  a trophy  rates 
Full trial patients
^lialc Briin Anilysnl-J
Full Trial W hole Brain A nalysis Full Trial W hole Brain A nalysis 3
P ilo t (  e re h e llu m  A naly  s is  1
iwl ■ ;
'till T ria l (  e re h e l lu m  A n a ly s is
P ilo t W h o le  H ra in  A n a ly s is  2
Full Tr 
f
iai W lxde Brain A nalysis 1 
1
H istogram s sliow ing normal 
d istribu tion  o f  atropliy rates 
Pilot patien ts
Cerebellum Analy<e>l O
P ilo t C e re b e llu m  A n a ly s is  2 P ilo t (  e re h e l lu m  A n a ly s is .!
1 4 .
Tull T r ia l  C e re b e llu m  .A n a ly sis  I 1 F u ll T r ia l  (  e re b c l lu m  .A n aly sis  2 1
J kf
1
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Appendix S
A|Tpondi\ S
S catterpk iis  o f  baseliiie  clin ical 
values and vvW e brain a tro p h y  rate 
(An .I)
GIC Df
Rankin
:
i
----- ,----- »----- r- •
Age at visit
Letter Cancelling
Spelling
I
-
!- r-------1— *—r
MMSE
;
 ^ —A»- '  *
Fragm ented Letters
Barthel
i, Z
*■ - :
GIC Nurse
:
. • !
CDR
r
ADAS-COG 
. .3
* »
GCS
Duration symptoms 
•• .
* ' ---- -  ^ *
Memory
Line Drawing
;
:
1
Reading P a ss a g e
Fr
>'
agm ented  Objects
Î
: Î
1 1 J I 1
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Calculation
:
:
T   r
Miming
r
I
Fror
I
ital lobe sequencing
I „ 1 1
Digit Span
I ■ : • . •
,,
Finger nose test
Sequential opposition
Rapid alternating movem ents
Primitive reflexes
r
Walking gait
:
1 ;
r -  K % A !
Copying G estu res
c: :
W ords beginning with Proverbs
j
:
!
Recall
Î
»• ♦ ,
------- 1— --------- r
Eye M ovements
Sequential index finger tapping
O ne m inute observation
Walking Overall
y
f ■ ', .L  ’ *'
Heel toe test
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Attent ion and  Concentration
i1
i
Cooperative
1
:
!
■ J 1 ^1  .  i
Cc)gnitive impairment
: ; :
: ; :1
Extrapyramidal impairment
r
- -----’ ,----- Î
Pyiramidal impairment 
.
Cerebellar impairment 
:
1;
^ ■' .U  ' '
1Baseline Volume
» *■
• /
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Appendix T
\p)iendi\ T
Scaiterp lo ts o f  rale  o f  clin ical score  
change w ith ra te  o f  w hole  brain 
atroph>
I linear m ixed m odel 1
M M S i;  A U a illio l A
( IK  1)1 A ( i l l  N u ts c  A ( ’I ) R a
Î
• - *
• % ■
: «
K aiik in  A
I r
r
ag m c n itf ii  ( Ib jc c ts  A
A [)A S -C (K  I A
f a i c a ia t i i » i  A
( i t s  A
r
1 • /
'
M om orx  A I .c tte i C a n c e ll in g  A
i
I
: •  '  ••
!
1
■
'  '  „ , i — L -  ’ ‘
R e a d in g  P a ssa g e  A S}x-lling A
i {i
• .
’ ’ • .  /
l in e  D ra w in g  A
M im in g  A
1 r a g m c in e d  I d le r s  A
I'
1
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C’of>> in g  ( ie s t i i r e s  A 1 ro n ta l l .o l ie  S e q u e n c in g  A W o rd s  b e g in n in g  u i i h  A
1
! .
iz
•
j
}
P ro \e r lrx  A
.
) * s
• •
■ •• — l u . -  » *
D ig it S p an  A
1
1
R e c a ll  A 
.  ■
f • •
1
. '  ■ . '
E-iye M o x e in e n t A
1- * A »
1 • t
V  . '
S e q u e n t
1
ia i in d e x  l in g e r  ta p p in g  A 
1
( ) i ic  itiiiiu to  o b s c r \a l io n  A
I Ictfl t()tf A
l in g e r  n o s e  A
\
S cq u ciiliiil A
W a lk in g  g a it A
RonilK Tgs A
R a p id  A lte rn a tin g  M rncM iientN A
P r im it iv e  r e l l e x e s  A
}
1
!
--- CTV—1-----
W a lk in g  o v e ra l l  A
. * *■
t *
1 . "
N e u ro lo g ic a l  e x a m in a tio n  A
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C crc lv lla i 111^ x11 n iicn t A
AllcnluMi and  ConcciUiaciiHi A ('<Ki|x;rative A
,
I - r
1 1f i1
1
(  erebellar aliophy t s  
cerebellar im |)airn)enl A
l.x iiai
1-
lyraniidal !n i|\iirinc iit A
I '
t  .
y  *
pNiainiUal iitim in n c iil A
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PUBLICATIONS
This section documents peer-review papers produced as a result of work on this thesis or on 
the PRION-1 trial. My contributions to these papers are stated below.
Macfarlane RG, Wroe SJ, Collinge J, Yousry TA, Jager R. A review of the neuroimaging 
findings in human prion disease. J Neurol Neurosurg Psychiatry. Published Online First: 29 
November 2006. doi:10.1136/jnnp.2006.094821
/  researched and wrote this review. Rolf Jager reviewed the manuscript and assisted in 
finding suitable images for the MRI figures. Steve Wroe, John Collinge and Tarek Yousry 
reviewed the manuscript.
Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane RG, Joiner S, Linehan JM, Brandner S, 
Wadsworth J, Hewitt P, Collinge J. Clinical presentation and pre-mortem diagnosis of 
blood transfusion associated variant CJD. Lancet 2006;368:2061-7.
/  assisted Harpreet Hyare in producing the MRI figure, advised on the MRI CJD literature 
used and reviewed the manuscript.
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